

# 2026 PRIOR AUTHORIZATION CRITERIA

## TABLE OF CONTENTS

|                                                              |     |
|--------------------------------------------------------------|-----|
| Abilify .....                                                | 51  |
| Abilify Mycite Maintenance Kit .....                         | 51  |
| Abilify Mycite Starter Kit .....                             | 51  |
| Abiraterone Acetate .....                                    | 557 |
| Abirtega .....                                               | 557 |
| Abrilada .....                                               | 88  |
| Absorica .....                                               | 354 |
| Absorica Ld .....                                            | 21  |
| Accutane .....                                               | 354 |
| Actemra .....                                                | 90  |
| Actemra Actpen .....                                         | 90  |
| Acthar .....                                                 | 22  |
| Actimmune .....                                              | 24  |
| Acyclovir .....                                              | 25  |
| Adalimumab-Aacf .....                                        | 113 |
| Adalimumab-Aacf Starter Pack/Cd/Uc/Hs (6 Pen) .....          | 113 |
| Adalimumab-Aacf Starter Pack/Psoriasis/Uveitis (4 Pen) ..... | 113 |
| Adalimumab-Aaty Cd/Uc/Hs Starter .....                       | 168 |
| Adalimumab-Aaty Kit .....                                    | 168 |
| Adalimumab-Adaz .....                                        | 111 |
| Adalimumab-Fkjp .....                                        | 107 |
| Adapalene .....                                              | 610 |
| Adapalene Pump .....                                         | 610 |
| Adbry .....                                                  | 26  |
| Adcirca .....                                                | 514 |
| Adempas .....                                                | 500 |
| Afinitor .....                                               | 557 |
| Afinitor Disperz .....                                       | 557 |
| Agamree .....                                                | 27  |
| Aimovig .....                                                | 28  |
| Ajovy .....                                                  | 29  |
| Akeega .....                                                 | 557 |
| Aklief .....                                                 | 613 |
| Alcohol Swabs .....                                          | 30  |
| Alecensa .....                                               | 557 |
| Alosetron Hcl .....                                          | 31  |
| Altreno .....                                                | 612 |
| Alunbrig .....                                               | 557 |
| Alvaiz .....                                                 | 35  |
| Alyftrek .....                                               | 37  |
| Alyq .....                                                   | 514 |

|                                        |     |
|----------------------------------------|-----|
| Ambrisentan.....                       | 502 |
| Amjevita .....                         | 92  |
| Amnesteem .....                        | 354 |
| Ampyra .....                           | 228 |
| Ancobon .....                          | 279 |
| Andembry .....                         | 314 |
| Anzupgo .....                          | 53  |
| Apokyn .....                           | 54  |
| Apomorphine Hcl .....                  | 54  |
| Aptensio Xr.....                       | 55  |
| Aqneursa .....                         | 56  |
| Aralast Np.....                        | 32  |
| Aranesp Albumin Free .....             | 258 |
| Arazlo .....                           | 611 |
| Arcalyst.....                          | 57  |
| Arikayce.....                          | 58  |
| Aripiprazole .....                     | 51  |
| Aripiprazole Odt .....                 | 51  |
| Armodafinil .....                      | 59  |
| Ascomp/Codeine.....                    | 336 |
| Asenapine Maleate Sl.....              | 51  |
| Ativan .....                           | 77  |
| Atovaquone.....                        | 63  |
| Atralin.....                           | 612 |
| Attruby .....                          | 64  |
| Aubagio .....                          | 414 |
| Augtyro.....                           | 557 |
| Austedo .....                          | 65  |
| Austedo Xr.....                        | 65  |
| Austedo Xr Patient Titration Kit ..... | 65  |
| Aveed .....                            | 40  |
| Avmapki Fakzynja Co-Pack.....          | 557 |
| Avonex .....                           | 401 |
| Avonex Pen .....                       | 401 |
| Ayvakit.....                           | 557 |
| Azmiro .....                           | 41  |
| Azstarys .....                         | 66  |
| Bafiertam .....                        | 402 |
| Balversa.....                          | 557 |
| Belbuca.....                           | 445 |
| Belsomra .....                         | 67  |
| Benlysta SC.....                       | 69  |
| Berinert .....                         | 316 |
| Besremi .....                          | 557 |
| Betaseron.....                         | 403 |
| Bethkis.....                           | 80  |
| Bexarotene Capsules.....               | 557 |
| Bexarotene Gel .....                   | 81  |

|                                                |     |
|------------------------------------------------|-----|
| Bildyos .....                                  | 83  |
| Bilprevda .....                                | 86  |
| Bimzelx .....                                  | 94  |
| Bivigam .....                                  | 174 |
| Bomyntra .....                                 | 176 |
| Bonjesta .....                                 | 336 |
| Bonsity .....                                  | 599 |
| Bosentan .....                                 | 504 |
| Bosulif .....                                  | 557 |
| Braftovi.....                                  | 557 |
| Brekiya .....                                  | 178 |
| Brinsupri.....                                 | 179 |
| Brukinsa .....                                 | 557 |
| Budesonide Dr (Entocort) .....                 | 180 |
| Budesonide Er (Uceris).....                    | 181 |
| Buphenyl .....                                 | 630 |
| Buprenorphine .....                            | 445 |
| Butalbital/Acetaminophen/Caffeine/Codeine..... | 336 |
| Butalbital/Aspirin/Caffeine/Codeine .....      | 336 |
| Butrans .....                                  | 445 |
| Bylvay .....                                   | 183 |
| Bylvay (Pellets) .....                         | 183 |
| Cabometyx .....                                | 557 |
| Calquence.....                                 | 557 |
| Camzyos .....                                  | 184 |
| Caprelsa.....                                  | 557 |
| Carbaglu .....                                 | 185 |
| Carbinoxamine Maleate.....                     | 336 |
| Carbinoxamine Maleate Er .....                 | 336 |
| Carbzah .....                                  | 336 |
| Carglumic Acid .....                           | 185 |
| Cayston .....                                  | 186 |
| Cequa .....                                    | 441 |
| Cerdelga .....                                 | 588 |
| Cerezyme .....                                 | 286 |
| Chenodal .....                                 | 187 |
| Chlordiazepoxide Hcl .....                     | 70  |
| Chlordiazepoxide/Amitriptyline.....            | 71  |
| Chlorpromazine Hcl.....                        | 51  |
| Chorionic Gonadotropin .....                   | 188 |
| Cialis .....                                   | 68  |
| Cibinqo .....                                  | 189 |
| Cimzia.....                                    | 96  |
| Cimzia Starter Kit.....                        | 96  |
| Cinacalcet Hcl.....                            | 190 |
| Cinqair .....                                  | 191 |
| Cinryze.....                                   | 318 |
| Cladribine Pak .....                           | 408 |

|                                                        |     |
|--------------------------------------------------------|-----|
| Claravis .....                                         | 354 |
| Clemastine Fumarate .....                              | 336 |
| Clemsza .....                                          | 336 |
| Clobazam .....                                         | 72  |
| Clorazepate Dipotassium .....                          | 73  |
| Clozapine .....                                        | 51  |
| Clozapine Odt .....                                    | 51  |
| Clozaril .....                                         | 51  |
| Cobenfy .....                                          | 192 |
| Cobenfy Starter Pack .....                             | 192 |
| Cometriq .....                                         | 557 |
| Concerta .....                                         | 211 |
| Conexxence .....                                       | 194 |
| Conzip .....                                           | 461 |
| Copaxone .....                                         | 406 |
| Copiktra .....                                         | 557 |
| Corlanor .....                                         | 212 |
| Cortrophin .....                                       | 213 |
| Cosentyx .....                                         | 98  |
| Cosentyx Sensoready Pen .....                          | 98  |
| Cosentyx Unoready .....                                | 98  |
| Cotellic .....                                         | 557 |
| Cotempla Xr-Odt .....                                  | 215 |
| Crenessity .....                                       | 216 |
| Cresemba .....                                         | 217 |
| Crinone .....                                          | 218 |
| Crotan .....                                           | 219 |
| Crysvita .....                                         | 220 |
| Cutaquig .....                                         | 222 |
| Cuvrior .....                                          | 223 |
| Cyltezo .....                                          | 100 |
| Cyltezo Starter Package For Crohns Disease/Uc/Hs ..... | 100 |
| Cyltezo Starter Package For Psoriasis .....            | 100 |
| Cyltezo Starter Package For Psoriasis/Uveitis .....    | 100 |
| Cyproheptadine Hcl .....                               | 336 |
| Cystadrops .....                                       | 224 |
| Cystagon .....                                         | 226 |
| Cystaran .....                                         | 225 |
| Dalfampridine Er .....                                 | 228 |
| Daliresp .....                                         | 553 |
| Danazol .....                                          | 39  |
| Danziten .....                                         | 557 |
| Daraprim .....                                         | 526 |
| Dasatinib .....                                        | 557 |
| Daurismo .....                                         | 557 |
| Dawnzera .....                                         | 320 |
| Daybue .....                                           | 229 |
| Daytrana .....                                         | 394 |

|                                             |     |
|---------------------------------------------|-----|
| Dayvigo.....                                | 230 |
| Deferasirox (Exjade).....                   | 352 |
| Deferasirox (Jadenu).....                   | 353 |
| Deferiprone.....                            | 231 |
| Deflazacort.....                            | 232 |
| Depo-Testosterone.....                      | 43  |
| Dexmethylphenidate Hcl (Focalin).....       | 280 |
| Dexmethylphenidate Hcl Er (Focalin Xr)..... | 281 |
| Diazepam.....                               | 74  |
| Diazepam Intensol.....                      | 74  |
| Dichlorphenamide.....                       | 233 |
| Diclegis.....                               | 336 |
| Diclofenac Epolamine.....                   | 607 |
| Diclofenac Sodium (Pennsaid).....           | 609 |
| Diclofenac Sodium Gel 3%.....               | 605 |
| Dicyclomine Hcl.....                        | 336 |
| Differin.....                               | 610 |
| Dihydroergotamine Mesylate Spray.....       | 397 |
| Dimethyl Fumarate.....                      | 404 |
| Dimethyl Fumarate Starterpack.....          | 404 |
| Diphenoxylate/Atropine.....                 | 336 |
| Doptelet Cap.....                           | 234 |
| Doptelet Tab.....                           | 235 |
| Doxepin Hcl.....                            | 606 |
| Doxylamine Succinate/Pyridoxine Hcl.....    | 336 |
| Droxidopa.....                              | 237 |
| Dupixent.....                               | 238 |
| Duvyzat.....                                | 241 |
| Ebglyss.....                                | 242 |
| Edaravone.....                              | 243 |
| Ekterly.....                                | 322 |
| ElELYso.....                                | 287 |
| Elidel.....                                 | 61  |
| Eligard.....                                | 368 |
| Elmiron.....                                | 244 |
| Eltrombopag.....                            | 498 |
| Emflaza.....                                | 232 |
| Emgality.....                               | 245 |
| Empaveli.....                               | 246 |
| Emsam.....                                  | 248 |
| Enbrel.....                                 | 102 |
| Enbrel Mini.....                            | 102 |
| Enbrel Sureclick.....                       | 102 |
| Endari.....                                 | 369 |
| Enoby.....                                  | 250 |
| Ensacove.....                               | 557 |
| Enspryng.....                               | 253 |
| Entyvio Pen.....                            | 104 |

|                                         |     |
|-----------------------------------------|-----|
| Eohilia.....                            | 254 |
| Epclusa .....                           | 255 |
| Epidiolex.....                          | 256 |
| Epogen .....                            | 259 |
| Ergomar.....                            | 257 |
| Erivedge .....                          | 557 |
| Erleada .....                           | 557 |
| Erlotinib Hcl.....                      | 557 |
| Esbriet .....                           | 490 |
| Estazolam .....                         | 75  |
| Eucrisa .....                           | 60  |
| Evenity.....                            | 264 |
| Everolimus.....                         | 557 |
| Evkeeza .....                           | 266 |
| Evrysdi.....                            | 268 |
| Exenatide .....                         | 182 |
| Exjade .....                            | 352 |
| Eysuvis.....                            | 269 |
| Fabhalta .....                          | 270 |
| Fabior .....                            | 611 |
| Fanapt .....                            | 51  |
| Fanapt Pack A.....                      | 51  |
| Fanapt Pack C.....                      | 51  |
| Fasenra.....                            | 272 |
| Fasenra Pen.....                        | 272 |
| Fentanyl Citrate Oral Transmucosal..... | 274 |
| Fentanyl Patch .....                    | 447 |
| Ferriprox.....                          | 231 |
| Ferriprox Twice-A-Day .....             | 231 |
| Filspari.....                           | 275 |
| Filsuvez.....                           | 276 |
| Fingolimod Hcl .....                    | 405 |
| Fintepla .....                          | 277 |
| Fioricet/Codeine .....                  | 336 |
| Firazyr.....                            | 326 |
| Firdapse.....                           | 278 |
| Firmagon .....                          | 346 |
| Flector .....                           | 607 |
| Flucytosine .....                       | 279 |
| Fluphenazine Decanoate .....            | 51  |
| Fluphenazine Hcl.....                   | 51  |
| Flurazepam Hcl.....                     | 76  |
| Focalin .....                           | 280 |
| Focalin Xr.....                         | 281 |
| Forteo.....                             | 599 |
| Fotivda .....                           | 557 |
| Fruzaqla.....                           | 557 |
| Fulphila.....                           | 197 |

|                                            |     |
|--------------------------------------------|-----|
| Fylintra .....                             | 198 |
| Gabapentin Once-Daily .....                | 290 |
| Galafold .....                             | 282 |
| Gammagard Liquid .....                     | 283 |
| Gammagard Liquid Erc .....                 | 283 |
| Gammagard S/D Iga Less Than 1Mcg/MI .....  | 174 |
| Gammaked .....                             | 283 |
| Gammaplex .....                            | 174 |
| Gamunex-C .....                            | 283 |
| Gattex .....                               | 285 |
| Gauze Pads .....                           | 289 |
| Gavreto .....                              | 557 |
| Gefitinib .....                            | 557 |
| Genotropin .....                           | 291 |
| Genotropin Miniquick .....                 | 291 |
| Geodon .....                               | 51  |
| Gilenya .....                              | 405 |
| Gilotrif .....                             | 557 |
| Glassia .....                              | 33  |
| Glatiramer Acetate .....                   | 406 |
| Glatopa .....                              | 406 |
| Gleevec .....                              | 557 |
| Glycerol Phenylbutyrate .....              | 629 |
| Gocovri .....                              | 38  |
| Gomekli .....                              | 557 |
| Gralise .....                              | 290 |
| Granix .....                               | 199 |
| Grastek .....                              | 465 |
| Hadlima .....                              | 105 |
| Hadlima Pushtouch .....                    | 105 |
| Haegarda .....                             | 324 |
| Haldol Decanoate 100 .....                 | 51  |
| Haloperidol .....                          | 51  |
| Haloperidol Decanoate .....                | 51  |
| Haloperidol Lactate .....                  | 51  |
| Harvoni .....                              | 334 |
| Hernexeos .....                            | 557 |
| Hetlioz .....                              | 596 |
| Hetlioz Lq .....                           | 335 |
| Horizant .....                             | 340 |
| Hulio .....                                | 107 |
| Humatrope .....                            | 294 |
| Humira .....                               | 109 |
| Humira Pen .....                           | 109 |
| Humira Pen-Cd/Uc/Hs Starter .....          | 109 |
| Humira Pen-Pediatric Uc Starter Pack ..... | 109 |
| Humira Pen-Ps/UV Starter .....             | 109 |
| Hydrocodone Bitartrate Er .....            | 449 |

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| Hydromorphone Hcl Er .....                                      | 451 |
| Hydroxyzine Hcl .....                                           | 336 |
| Hydroxyzine Pamoate .....                                       | 336 |
| Hyftor .....                                                    | 341 |
| Hyrmoz .....                                                    | 111 |
| Hyrmoz Crohn's Disease And Ulcerative Colitis Starter Pack..... | 111 |
| Hyrmoz Pediatric Crohn's Disease Starter Pack .....             | 111 |
| Hyrmoz Plaque Psoriasis/Uveitis Starter Pack .....              | 111 |
| Hyrmoz Sensoready Pens.....                                     | 111 |
| Hyrnuo .....                                                    | 557 |
| Hysingla Er.....                                                | 449 |
| Ibrance .....                                                   | 557 |
| Ibtrozi .....                                                   | 557 |
| Icatibant Acetate.....                                          | 326 |
| Iclusig .....                                                   | 558 |
| Idacio.....                                                     | 113 |
| Idacio Starter Package For Crohns Disease .....                 | 113 |
| Idacio Starter Package For Plaque Psoriasis .....               | 113 |
| Idhifa .....                                                    | 558 |
| Ilumya.....                                                     | 115 |
| Imatinib Mesylate .....                                         | 558 |
| Imbruvica .....                                                 | 558 |
| Imiquimod Cream 3.75% (Zyclara).....                            | 689 |
| Imiquimod Cream 5% .....                                        | 343 |
| Imiquimod Pump.....                                             | 689 |
| Imkeldi.....                                                    | 558 |
| Imuldosa.....                                                   | 116 |
| Inbrija .....                                                   | 344 |
| Ingrezza .....                                                  | 345 |
| Inluriyo .....                                                  | 558 |
| Inlyta .....                                                    | 558 |
| Inqovi .....                                                    | 558 |
| Inrebic .....                                                   | 558 |
| Insulin Pen Needle .....                                        | 347 |
| Insulin Syringe/Needle .....                                    | 348 |
| Intrarosa.....                                                  | 349 |
| Invega.....                                                     | 51  |
| Iqirvo .....                                                    | 350 |
| Iressa .....                                                    | 558 |
| Isotretinoin .....                                              | 354 |
| Isturisa.....                                                   | 355 |
| Itovebi .....                                                   | 558 |
| Ivabradine Hcl .....                                            | 212 |
| Ivermectin Cream.....                                           | 356 |
| Ivermectin Tablet .....                                         | 357 |
| Iwilfin.....                                                    | 558 |
| Jadenu .....                                                    | 353 |
| Jadenu Sprinkle .....                                           | 353 |



|                             |     |
|-----------------------------|-----|
| Jakafi .....                | 558 |
| Jascayd .....               | 358 |
| Jatenzo .....               | 359 |
| Javygtor .....              | 556 |
| Jaypirca .....              | 558 |
| Jaythari .....              | 232 |
| Joenja .....                | 360 |
| Jornay Pm.....              | 361 |
| Jubbonti .....              | 362 |
| Juxtapid .....              | 338 |
| Jynarque .....              | 365 |
| Kalydeco .....              | 366 |
| Karbinal Er .....           | 336 |
| Kerendia .....              | 367 |
| Kesimpta .....              | 407 |
| Keveyis .....               | 233 |
| Kevzara .....               | 118 |
| Kineret.....                | 120 |
| Kisqali .....               | 558 |
| Kisqali Femara .....        | 558 |
| Kitabis Pak .....           | 604 |
| Komzifti .....              | 558 |
| Korlym .....                | 396 |
| Koselugo .....              | 558 |
| Krazati .....               | 558 |
| Kuvan .....                 | 556 |
| Kymbee .....                | 232 |
| Lapatinib Ditosylate .....  | 558 |
| Latuda .....                | 51  |
| Lazcluze .....              | 558 |
| Ledipasvir/Sofosbuvir ..... | 334 |
| Lenalidomide.....           | 558 |
| Lenvima .....               | 558 |
| Leqselvi.....               | 122 |
| Letairis.....               | 502 |
| Leukine .....               | 200 |
| Leuprolide Acetate .....    | 368 |
| L-glutamine .....           | 369 |
| Licart.....                 | 608 |
| Lidocaine Ointment.....     | 370 |
| Lidocaine Patch .....       | 371 |
| Lidocaine Solution.....     | 372 |
| Lidocaine/Prilocaine.....   | 373 |
| Lidocan .....               | 371 |
| Linezolid .....             | 375 |
| Liraglutide .....           | 377 |
| Litfulo .....               | 123 |
| Livdelzi.....               | 378 |

|                                            |     |
|--------------------------------------------|-----|
| Livmarli.....                              | 380 |
| Lomotil .....                              | 336 |
| Lonsurf .....                              | 558 |
| Lorazepam.....                             | 77  |
| Lorazepam Intensol.....                    | 77  |
| Lorbrena .....                             | 558 |
| Loreev Xr .....                            | 77  |
| Lotronex .....                             | 31  |
| Loxapine .....                             | 51  |
| Lumakras .....                             | 558 |
| Lumryz.....                                | 381 |
| Lumryz Starter Pack .....                  | 381 |
| Lupkynis .....                             | 383 |
| Lupron Depot .....                         | 368 |
| Lupron Depot-Ped.....                      | 368 |
| Lurasidone Hcl.....                        | 51  |
| Lutrate Depot .....                        | 368 |
| Lybalvi .....                              | 51  |
| Lynkuet.....                               | 384 |
| Lynparza .....                             | 558 |
| Lytgobi.....                               | 558 |
| Matulane .....                             | 558 |
| Mavenclad.....                             | 408 |
| Mavyret.....                               | 385 |
| Mayzent .....                              | 409 |
| Mayzent Starter Pack.....                  | 409 |
| Mekinist .....                             | 558 |
| Mektovi .....                              | 558 |
| Memantine Hcl.....                         | 387 |
| Memantine Hcl Er .....                     | 386 |
| Memantine Hcl Titration Pak .....          | 387 |
| Mepron .....                               | 63  |
| Metadate Cd .....                          | 390 |
| Methamphetamine Hcl .....                  | 388 |
| Methitest .....                            | 48  |
| Methylin .....                             | 389 |
| Methylphenidate Hcl (Methylin).....        | 389 |
| Methylphenidate Hcl (Ritalin) .....        | 551 |
| Methylphenidate Hcl Cd .....               | 390 |
| Methylphenidate Hcl Chewable.....          | 391 |
| Methylphenidate Hcl Er (Aptensio Xr) ..... | 55  |
| Methylphenidate Hcl Er (Concerta) .....    | 211 |
| Methylphenidate Hcl Er (La) Capsule.....   | 393 |
| Methylphenidate Hcl Er (Relexxii).....     | 540 |
| Methylphenidate Hcl Er (Ritalin LA).....   | 550 |
| Methylphenidate Hcl Er Tablet .....        | 392 |
| Methylphenidate Patch .....                | 394 |
| Methyltestosterone .....                   | 48  |

|                           |     |
|---------------------------|-----|
| Miebo .....               | 395 |
| Mifepristone .....        | 396 |
| Miglustat .....           | 589 |
| Miplyffa .....            | 398 |
| Mircera .....             | 261 |
| Modafinil .....           | 399 |
| Modeyso .....             | 558 |
| Molindone Hcl .....       | 51  |
| Morphine Sulfate Er ..... | 453 |
| Mounjaro .....            | 400 |
| Ms Contin .....           | 453 |
| Mulpleta .....            | 417 |
| Myalept .....             | 418 |
| Mycapssa .....            | 574 |
| Myfembree .....           | 419 |
| Nemludio .....            | 420 |
| Nerlynx .....             | 558 |
| Neulasta .....            | 201 |
| Neulasta Onpro Kit .....  | 201 |
| Neupogen .....            | 202 |
| Nexavar .....             | 558 |
| Nexletol .....            | 422 |
| Nexlizet .....            | 424 |
| Ngenla .....              | 297 |
| Nilotinib .....           | 558 |
| Ninlaro .....             | 558 |
| Nivestym .....            | 203 |
| Norditropin Flexpro ..... | 298 |
| Northera .....            | 237 |
| Nourianz .....            | 426 |
| Novarel .....             | 188 |
| Noxafil .....             | 491 |
| Nubeqa .....              | 558 |
| Nucala .....              | 427 |
| Nucynta Er .....          | 459 |
| Nuedexta .....            | 429 |
| Nuplazid .....            | 430 |
| Nurtec .....              | 431 |
| Nutropin Aq Nuspin .....  | 301 |
| Nuvigil .....             | 59  |
| Nuzyra IV .....           | 433 |
| Nuzyra Tablet .....       | 434 |
| Nypozi .....              | 204 |
| Nyvepria .....            | 205 |
| Octagam .....             | 174 |
| Octreotide Acetate .....  | 575 |
| Octreotide Kit .....      | 578 |
| Odactra .....             | 466 |

|                              |     |
|------------------------------|-----|
| Odomzo.....                  | 558 |
| Ofev.....                    | 436 |
| Ogsiveo.....                 | 558 |
| Ohtuvayre .....              | 437 |
| Ojemda.....                  | 558 |
| Ojjaara.....                 | 558 |
| Olanzapine .....             | 51  |
| Olanzapine Odt .....         | 51  |
| Olanzapine/Fluoxetine.....   | 51  |
| Olpruva.....                 | 627 |
| Olumiant .....               | 124 |
| Omnipod Kit.....             | 439 |
| Omnipod Pods.....            | 439 |
| Omnitrope.....               | 304 |
| Omvox.....                   | 126 |
| Onapgo.....                  | 440 |
| Onfi.....                    | 72  |
| Onureg .....                 | 558 |
| Opipza .....                 | 51  |
| Opsumit.....                 | 506 |
| Opsynvi.....                 | 508 |
| Opzelura .....               | 463 |
| Orencia.....                 | 128 |
| Orencia Clickject.....       | 128 |
| Orenitram.....               | 510 |
| Orenitram Titration Kit..... | 510 |
| Orgovyx .....                | 558 |
| Oriahnn .....                | 467 |
| Orilissa.....                | 468 |
| Orkambi .....                | 469 |
| Orladeyo.....                | 328 |
| Ormalvi.....                 | 233 |
| Orserdu .....                | 558 |
| Osenvelt .....               | 470 |
| Osphena .....                | 472 |
| Ospomyv .....                | 473 |
| Otezla .....                 | 476 |
| Otezla Xr.....               | 478 |
| Otrexup .....                | 480 |
| Otulfu .....                 | 130 |
| Oxazepam .....               | 78  |
| Oxervate.....                | 481 |
| Oxlumo.....                  | 482 |
| Oxycodone Hcl Er .....       | 455 |
| Oxycontin .....              | 455 |
| Oxymorphone Hcl Er .....     | 457 |
| Ozempic .....                | 483 |
| Palforzia .....              | 484 |

|                                  |     |
|----------------------------------|-----|
| Paliperidone Er.....             | 51  |
| Palsonify.....                   | 577 |
| Palynziq.....                    | 485 |
| Panretin.....                    | 486 |
| Panzyga.....                     | 487 |
| Pazopanib Hcl.....               | 559 |
| Pegasys.....                     | 489 |
| Pemazyre.....                    | 559 |
| Pennsaid.....                    | 609 |
| Perphenazine.....                | 51  |
| Pheburane.....                   | 628 |
| Phyrago.....                     | 559 |
| Pimecrolimus.....                | 61  |
| Pimozide.....                    | 51  |
| Piqray.....                      | 559 |
| Pirfenidone.....                 | 490 |
| Plegridy.....                    | 410 |
| Plegridy Starter Pack.....       | 410 |
| Pomalyst.....                    | 559 |
| Ponvory.....                     | 411 |
| Ponvory 14-Day Starter Pack..... | 411 |
| Posaconazole.....                | 491 |
| Posaconazole Dr.....             | 491 |
| Praluent.....                    | 493 |
| Prednisone Tab Dr.....           | 535 |
| Pregnyl.....                     | 188 |
| Privigen.....                    | 174 |
| Procrit.....                     | 259 |
| Procysbi.....                    | 227 |
| Prolastin-C.....                 | 34  |
| Prolia.....                      | 495 |
| Promacta.....                    | 498 |
| Promethazine Hcl.....            | 336 |
| Promethazine Hcl Plain.....      | 336 |
| Promethazine Syrup.....          | 336 |
| Promethazine Vc.....             | 336 |
| Promethazine/Phenylephrine.....  | 336 |
| Promethegan.....                 | 336 |
| Provigil.....                    | 399 |
| Prudoxin.....                    | 606 |
| Pruradik Lot 10%.....            | 219 |
| Pyquvi.....                      | 232 |
| Primethamine.....                | 526 |
| Pyrukynd.....                    | 527 |
| Pyrukynd Taper Pack.....         | 527 |
| Pyzchiva.....                    | 132 |
| Qbrexza.....                     | 528 |
| Qinlock.....                     | 559 |

|                                     |     |
|-------------------------------------|-----|
| Quetiapine Fumarate .....           | 51  |
| Quetiapine Fumarate Er .....        | 51  |
| Quillichew Er .....                 | 529 |
| Quillivant Xr .....                 | 530 |
| Quinine Sulfate .....               | 531 |
| Qulipta .....                       | 532 |
| Quviviq .....                       | 533 |
| Radicava .....                      | 243 |
| Radicava Ors.....                   | 243 |
| Radicava Ors Starter Kit .....      | 243 |
| Rasuvo .....                        | 534 |
| Ravicti.....                        | 629 |
| Rayos .....                         | 535 |
| Rebif .....                         | 412 |
| Rebif Rebidose .....                | 412 |
| Rebif Rebidose Titration Pack ..... | 412 |
| Rebif Titration Pack.....           | 412 |
| Reblozyl .....                      | 536 |
| Recorlev .....                      | 538 |
| Redemplo .....                      | 539 |
| Releuko .....                       | 206 |
| Relexxii .....                      | 540 |
| Relistor Injection .....            | 541 |
| Relistor Tablet .....               | 542 |
| Repatha .....                       | 543 |
| Repatha Sureclick.....              | 543 |
| Retacrit.....                       | 262 |
| Retevmo .....                       | 559 |
| Retin-A .....                       | 612 |
| Retin-A Micro .....                 | 612 |
| Retin-A Micro Pump.....             | 612 |
| Revatio .....                       | 512 |
| Revcovi .....                       | 545 |
| Revlimid .....                      | 559 |
| Revuforj.....                       | 559 |
| Rexulti .....                       | 51  |
| Reyvow .....                        | 546 |
| Rezdifra .....                      | 547 |
| Rezlidhia .....                     | 559 |
| Rezurock.....                       | 548 |
| Rhapsido .....                      | 549 |
| Rinvoq Lq.....                      | 134 |
| Rinvoq Tablet .....                 | 135 |
| Risperdal .....                     | 51  |
| Risperidone .....                   | 51  |
| Risperidone Odt .....               | 51  |
| Ritalin .....                       | 551 |
| Ritalin La.....                     | 550 |

|                                   |     |
|-----------------------------------|-----|
| Rivfloza .....                    | 552 |
| Roflumilast .....                 | 553 |
| Romvimza .....                    | 559 |
| Rozlytrek .....                   | 559 |
| Rubraca .....                     | 559 |
| Ruconest .....                    | 330 |
| Rybelsus .....                    | 554 |
| Rydapt .....                      | 559 |
| Ryvent .....                      | 336 |
| Sajazir .....                     | 326 |
| Samsca .....                      | 555 |
| Sandostatin .....                 | 575 |
| Sandostatin Lar Depot .....       | 578 |
| Saphris.....                      | 51  |
| Sapropterin Dihydrochloride ..... | 556 |
| Scemblix .....                    | 559 |
| Scopolamine.....                  | 336 |
| Secuado.....                      | 51  |
| Selarsdi.....                     | 137 |
| Sensipar.....                     | 190 |
| Sephience.....                    | 562 |
| Seroquel .....                    | 52  |
| Seroquel Xr.....                  | 52  |
| Serostim .....                    | 306 |
| Signifor .....                    | 565 |
| Signifor Lar .....                | 563 |
| Sildenafil Citrate.....           | 512 |
| Siliq.....                        | 139 |
| Simlandi.....                     | 140 |
| Simponi .....                     | 142 |
| Sivextro .....                    | 566 |
| Skyclarys.....                    | 568 |
| Skyrizi .....                     | 144 |
| Skyrizi Pen .....                 | 144 |
| Skytrofa .....                    | 307 |
| Sodium Oxybate.....               | 569 |
| Sodium Phenylbutyrate .....       | 630 |
| Sofdra .....                      | 571 |
| Sofosbuvir/Velpatasvir.....       | 255 |
| Sogroya .....                     | 309 |
| Somatuline Depot .....            | 572 |
| Somavert.....                     | 580 |
| Soolantra .....                   | 356 |
| Sorafenib.....                    | 559 |
| Sotyktu .....                     | 146 |
| Sovaldi.....                      | 581 |
| Spevigo.....                      | 582 |
| Sprycel.....                      | 559 |

|                                     |     |
|-------------------------------------|-----|
| Stelara .....                       | 147 |
| Steqeyma.....                       | 149 |
| Stimufend.....                      | 207 |
| Stivarga .....                      | 559 |
| Stoboclo .....                      | 583 |
| Strensiq .....                      | 586 |
| Stromectol.....                     | 357 |
| Sucraid.....                        | 591 |
| Sunitinib Malate.....               | 559 |
| Sunosi .....                        | 592 |
| Sutent.....                         | 559 |
| Symbyax .....                       | 52  |
| Symdeko.....                        | 593 |
| Sympazan .....                      | 79  |
| Symproic .....                      | 594 |
| Syprine .....                       | 615 |
| Tabrecta .....                      | 559 |
| Tacrolimus.....                     | 62  |
| Tadalafil 2.5Mg, 5Mg .....          | 68  |
| Tadalafil Tablet 20Mg .....         | 514 |
| Tadliq.....                         | 514 |
| Tafinlar .....                      | 559 |
| Tagrisso .....                      | 559 |
| Takhzyro .....                      | 332 |
| Taltz.....                          | 151 |
| Talzenna .....                      | 559 |
| Targretin Capsule .....             | 559 |
| Targretin Gel .....                 | 81  |
| Tarpeyo .....                       | 595 |
| Tascenso Odt.....                   | 413 |
| Tasigna .....                       | 559 |
| Tasimelteon.....                    | 596 |
| Tavalisse .....                     | 597 |
| Tavneos .....                       | 598 |
| Tazarotene .....                    | 611 |
| Tazorac.....                        | 611 |
| Tazverik .....                      | 559 |
| Tecfidera .....                     | 404 |
| Tecfidera Starter Pack .....        | 404 |
| Tepmetko .....                      | 559 |
| Teriflunomide.....                  | 414 |
| Teriparatide.....                   | 599 |
| Testim.....                         | 49  |
| Testosterone .....                  | 49  |
| Testosterone Cypionate .....        | 43  |
| Testosterone Enanthate .....        | 45  |
| Testosterone Pump.....              | 49  |
| Testosterone Topical Solution ..... | 49  |



|                                 |     |
|---------------------------------|-----|
| Tetrabenazine .....             | 601 |
| Thalomid .....                  | 559 |
| Thioridazine Hcl.....           | 52  |
| Thiothixene .....               | 52  |
| Tibsovo .....                   | 559 |
| Tlando .....                    | 602 |
| Tobi .....                      | 604 |
| Tobi Podhaler .....             | 603 |
| Tobramycin (Bethkis) .....      | 80  |
| Tobramycin Neb.....             | 604 |
| Tolvaptan (Jynarque).....       | 365 |
| Tolvaptan (Samsca).....         | 555 |
| Torpenz .....                   | 559 |
| Tracleer .....                  | 504 |
| Tramadol Hcl Er.....            | 461 |
| Transderm Scop .....            | 336 |
| Trelstar Mixject .....          | 614 |
| Tremfya .....                   | 153 |
| Tretinoin Capsule .....         | 559 |
| Tretinoin Cream, Gel.....       | 612 |
| Tretinoin Microsphere .....     | 612 |
| Tretinoin Microsphere Pump..... | 612 |
| Tridacaine Patch.....           | 371 |
| Trientine Hcl.....              | 615 |
| Trifluoperazine Hcl .....       | 52  |
| Trihexyphenidyl Hcl.....        | 336 |
| Trikafta .....                  | 616 |
| Trudhesa .....                  | 617 |
| Trulicity .....                 | 618 |
| Truqap.....                     | 559 |
| Tryngolza .....                 | 619 |
| Trypyr.....                     | 620 |
| Tryvio .....                    | 621 |
| Tukysa .....                    | 559 |
| Turalio .....                   | 559 |
| Tyenne.....                     | 155 |
| Tykerb .....                    | 559 |
| Tymlos.....                     | 622 |
| Tyrvaya.....                    | 624 |
| Tyvaso Dpi.....                 | 516 |
| Ubrelyv .....                   | 625 |
| Uceris .....                    | 181 |
| Udenyca .....                   | 208 |
| Udenyca Onbody.....             | 208 |
| Undecatrex.....                 | 626 |
| Uptravi .....                   | 519 |
| Uptravi Titration Pack .....    | 519 |
| Ustekin-Aekn.....               | 137 |

|                              |     |
|------------------------------|-----|
| Ustekin-Ttwe .....           | 132 |
| Ustekinumab .....            | 147 |
| Vabrinty .....               | 368 |
| Valchlor .....               | 631 |
| Valium .....                 | 74  |
| Vanflyta .....               | 559 |
| Vanrafia .....               | 633 |
| Velsipity.....               | 157 |
| Venclexta.....               | 559 |
| Venclexta Starting Pack..... | 559 |
| Ventavis.....                | 521 |
| Veozah.....                  | 634 |
| Verkazia.....                | 442 |
| Versacloz .....              | 52  |
| Verzenio .....               | 559 |
| Vevye.....                   | 443 |
| Vfend.....                   | 639 |
| Vfend Iv .....               | 639 |
| V-Go .....                   | 635 |
| Viberzi .....                | 636 |
| Victoza .....                | 377 |
| Vijoice.....                 | 637 |
| Vitrakvi .....               | 559 |
| Vivjoa .....                 | 638 |
| Vizimpro .....               | 559 |
| Vogelxo .....                | 49  |
| Vogelxo Pump .....           | 49  |
| Vonjo.....                   | 559 |
| Voranigo.....                | 559 |
| Voriconazole .....           | 639 |
| Vosevi .....                 | 641 |
| Votrient .....               | 560 |
| Vowst .....                  | 642 |
| Voxzogo.....                 | 643 |
| Voydeya .....                | 644 |
| Vpriv .....                  | 288 |
| Vtama .....                  | 645 |
| Vumerity .....               | 415 |
| Vykat XR .....               | 647 |
| Vyndamax .....               | 648 |
| Vyndaqel .....               | 649 |
| Vyvgart Hytrulo .....        | 650 |
| Wainua .....                 | 651 |
| Wakix.....                   | 652 |
| Wayrilz .....                | 653 |
| Wegovy .....                 | 654 |
| Welireg.....                 | 560 |
| Wezlana .....                | 158 |

|                                  |     |
|----------------------------------|-----|
| Winlevi .....                    | 656 |
| Winrevair .....                  | 523 |
| Wyost .....                      | 657 |
| Xalkori .....                    | 560 |
| Xdemvy .....                     | 659 |
| Xeljanz Solution.....            | 160 |
| Xeljanz Tablet.....              | 162 |
| Xeljanz Xr.....                  | 164 |
| Xembify .....                    | 660 |
| Xenazine.....                    | 601 |
| Xermelo.....                     | 661 |
| Xgeva.....                       | 662 |
| Xifaxan 200Mg .....              | 664 |
| Xifaxan 550Mg .....              | 665 |
| Xiidra .....                     | 444 |
| Xolair .....                     | 666 |
| Xolremdi.....                    | 669 |
| Xospata .....                    | 560 |
| Xpovio .....                     | 560 |
| Xtampza Er .....                 | 455 |
| Xtandi .....                     | 560 |
| Xtrenbo .....                    | 670 |
| Xyosted .....                    | 47  |
| Xyrem .....                      | 569 |
| Xywav .....                      | 672 |
| Yargesa.....                     | 589 |
| Yesintek.....                    | 166 |
| Yimmugo .....                    | 674 |
| Yonsa.....                       | 560 |
| Yorvipath.....                   | 676 |
| Yuflyma Cd/Uc/Hs Starter .....   | 168 |
| Yuflyma Kit .....                | 168 |
| Yusimry.....                     | 170 |
| Yutrepia.....                    | 524 |
| Zarxio.....                      | 209 |
| Zavesca.....                     | 589 |
| Zavzpret .....                   | 677 |
| Zejula.....                      | 560 |
| Zelboraf .....                   | 560 |
| Zelsuvmi .....                   | 678 |
| Zelvysia.....                    | 556 |
| Zemaira .....                    | 32  |
| Zenatane .....                   | 354 |
| Zepatier .....                   | 679 |
| Zepbound .....                   | 680 |
| Zeposia .....                    | 416 |
| Zeposia 7-Day Starter Pack ..... | 416 |
| Zeposia Starter Kit.....         | 416 |

|                            |     |
|----------------------------|-----|
| Ziextenzo .....            | 210 |
| Zilbrysq .....             | 681 |
| Ziprasidone Mesylate ..... | 52  |
| Zokinvy .....              | 682 |
| Zolinza .....              | 560 |
| Zomacton .....             | 311 |
| Zonalon .....              | 606 |
| Zoryve Cream 0.05% .....   | 683 |
| Zoryve Cream 0.15% .....   | 684 |
| Zoryve Cream 0.3% .....    | 685 |
| Zoryve Foam.....           | 686 |
| Zovirax.....               | 25  |
| Ztalmy .....               | 688 |
| Ztlido .....               | 374 |
| Zyclara .....              | 689 |
| Zyclara Pump.....          | 689 |
| Zydelig.....               | 560 |
| Zykadia .....              | 560 |
| Zymfentra.....             | 172 |
| Zyprexa.....               | 52  |
| Zyprexa Zydis.....         | 52  |
| Zytiga.....                | 560 |
| Zyvox .....                | 375 |

**Prior Authorization Group Description:**

Absorica LD PA

**Drug Name(s)**

Absorica Ld

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Acthar Gel PA

**Drug Name(s)**

Acthar

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of infantile spasm OR
- B. Patient has a diagnosis of nephrotic syndrome AND ONE of the following:
  - i. Patient has failed a conventional agent (i.e., prednisone, tacrolimus) for the requested indication OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to a conventional agent OR
- C. Patient has a diagnosis of multiple sclerosis AND ALL of the following:
  - i. Patient is experiencing an acute exacerbation AND
  - ii. If indicated, there is evidence of a claim that the patient is currently being treated with a disease modifying drug (DMD) within the past 90 days [e.g., Avonex, dimethyl fumarate, glatiramer] to control disease progression OR has an intolerance, FDA labeled contraindication, or hypersensitivity to a DMD AND
  - iii. ONE of the following:
    - 1. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days OR
    - 2. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy OR

Criteria continues: see Other Criteria

**Age Restriction:**

For diagnosis of infantile spasm, patient is less than 2 years of age.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for infantile spasm, 1 month for all other indications

**Other Criteria:**

- D. Patient has a diagnosis of rheumatic disorder (e.g., ankylosing spondylitis, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, rheumatoid arthritis) AND ALL of the following:
  - i. The requested agent will be used as adjunct therapy for short-term administration (to tide the patient over an acute episode or exacerbation) AND

- ii. There is evidence of a claim that the patient is currently being treated with a conventional agent within the past 90 days [e.g., DMARD (methotrexate, leflunomide), biologics (Hadlima)] to control disease progression AND
- iii. ONE of the following:
  - 1. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days
  - OR
  - 2. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy OR
- E. Patient has a diagnosis of systemic lupus erythematosus (SLE) disease AND the patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
- F. Patient has another FDA approved indication AND ONE of the following:
  - i. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy OR
- G. Patient has another indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:
  - i. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy AND
- 2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Actimmune PA

**Drug Name(s)**

Actimmune

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Acyclovir Topical PA

**Drug Name(s)**

Acyclovir

Zovirax

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Adbry PA

**Drug Name(s)**

Adbry

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of moderate-to-severe atopic dermatitis AND BOTH of the following:
  - A. ONE of the following:
    - i. Patient has tried and failed a topical steroid (e.g., triamcinolone) OR
    - ii. Patient has an intolerance or hypersensitivity to a topical steroid OR
    - iii. Patient has an FDA labeled contraindication to a topical steroid AND
  - B. ONE of the following:
    - i. Patient has tried and failed a topical calcineurin inhibitor (e.g., tacrolimus) OR
    - ii. Patient has an intolerance or hypersensitivity to a topical calcineurin inhibitor OR
    - iii. Patient has an FDA labeled contraindication to a topical calcineurin inhibitor AND
2. Patient will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of moderate-to-severe atopic dermatitis AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Agamree PA

**Drug Name(s)**

Agamree

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of Duchenne muscular dystrophy (DMD) confirmed by ONE of the following:
  - A. Presence of abnormal dystrophin OR
  - B. Confirmed mutation of the dystrophin gene

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Duchenne muscular dystrophy (DMD) AND
3. Patient has had improvement, stabilization of the disease, or clinical benefit from baseline (e.g., slowed disease progression, improved strength and timed motor function, improved pulmonary function, reduced the need for scoliosis surgery)

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Aimovig PA

**Drug Name(s)**

Aimovig

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of migraine AND
2. The requested agent is being used for migraine prophylaxis AND
3. Patient has 4 or more migraine headache days per month AND
4. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. The requested agent is being used for migraine prophylaxis AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ajovy PA

**Drug Name(s)**

Ajovy

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of migraine AND
2. The requested agent is being used for migraine prophylaxis AND
3. Patient has 4 or more migraine headache days per month AND
4. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. The requested agent is being used for migraine prophylaxis AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Alcohol Swabs PA

**Drug Name(s)**

Alcohol Swabs

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Alosetron PA

**Drug Name(s)**

Alosetron Hcl

Lotronex

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of irritable bowel syndrome with severe diarrhea (IBS-D) AND
2. Patient's sex is female AND
3. Patient exhibits at least ONE of the following:
  - a. Frequent and severe abdominal pain/discomfort OR
  - b. Frequent bowel urgency or fecal incontinence OR
  - c. Disability or restriction of daily activities due to IBS AND
4. Prescriber has ruled out anatomic or biochemical abnormalities of the gastrointestinal tract

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Alpha-1-Proteinase Inhibitor PA - Aralast/Zemaira

**Drug Name(s)**

Aralast Np

Zemaira

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
2. Patient has a pre-treatment serum alpha-1 antitrypsin (AAT) level less than 11 micromol/L (80 mg/dL by immunodiffusion or 57 mg/dL using nephelometry) AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Alpha-1-Proteinase Inhibitor PA – Glassia

**Drug Name(s)**

Glassia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
2. Patient has a pre-treatment serum alpha-1 antitrypsin (AAT) level less than 11 micromol/L (80 mg/dL by immunodiffusion or 57 mg/dL using nephelometry) AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Alpha-1-Proteinase Inhibitor PA – Prolastin-C

**Drug Name(s)**

Prolastin-C

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
2. Patient has a pre-treatment serum alpha-1 antitrypsin (AAT) level less than 11 micromol/L (80 mg/dL by immunodiffusion or 57 mg/dL using nephelometry) AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD) with clinically evident emphysema AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Alvaiz PA

**Drug Name(s)**

Alvaiz

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP)

AND ONE of the following:

- i. Patient has tried and had an insufficient response to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
- ii. Patient has an intolerance or hypersensitivity to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
- iii. Patient has an FDA labeled contraindication to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
- iv. Patient has had an insufficient response to a splenectomy OR

B. Patient has a diagnosis of hepatitis C associated thrombocytopenia AND ONE of the following:

- i. Patient's platelet count is less than  $75 \times 10^9/L$  AND the intent is to increase platelet counts sufficiently to initiate interferon therapy OR
- ii. Patient is on concomitant therapy with interferon therapy AND is at risk for discontinuing hepatitis C therapy due to thrombocytopenia OR

C. Patient has a diagnosis of severe aplastic anemia (SAA) AND ALL of the following:

- i. Patient has at least 2 of the following blood criteria:
  - 1. Neutrophils less than  $0.5 \times 10^9/L$  OR
  - 2. Platelets less than  $30 \times 10^9/L$  OR
  - 3. Reticulocyte count less than  $60 \times 10^9/L$  AND
- ii. Patient has at least 1 of the following marrow criteria:
  - 1. Severe hypocellularity is less than 25% OR
  - 2. Moderate hypocellularity is 25-50% with hematopoietic cells representing less than 30% of residual cells AND
- iii. Patient has tried and had an insufficient response to BOTH antithymocyte globulin (ATG) AND cyclosporine therapy OR

D. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Initial: 6 months for ITP. Renewal: 12 months for ITP. Other indications, see Other Criteria.

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
    - i. Patient's platelet count is  $50 \times 10^9/L$  or greater OR
    - ii. Patient's platelet count has increased sufficiently to avoid clinically significant bleeding OR
  - B. Patient has a diagnosis of hepatitis C associated thrombocytopenia AND BOTH of the following:
    - i. ONE of the following:
      1. Patient will be initiating hepatitis C therapy with interferon therapy OR
      2. Patient will be maintaining hepatitis C therapy with interferon therapy at the same time as the requested agent AND
    - ii. ONE of the following:
      1. Patient's platelet count is  $90 \times 10^9/L$  or greater OR
      2. Patient's platelet count has increased sufficiently to initiate or maintain interferon therapy for the treatment of hepatitis C OR
  - C. Patient has a diagnosis of severe aplastic anemia (SAA) AND the patient has had clinical benefit with the requested agent OR
  - D. Patient has another indication that is supported in CMS approved compendia AND the patient has had clinical benefit with the requested agent AND
3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Initial: 48 weeks for hepatitis C associated thrombocytopenia, 16 weeks for SAA, 12 months for All other indications

Renewal: 48 weeks for hepatitis C associated thrombocytopenia, 12 months for SAA, 12 months for All other indications

**Prior Authorization Group Description:**

Alyftrek PA

**Drug Name(s)**

Alyftrek

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Patient has at least one F508del mutation or another responsive mutation in the CFTR gene AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Amantadine ER PA – Gocovri

**Drug Name(s)**

Gocovri

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of Parkinson's disease AND
2. ONE of the following:
  - A. The requested agent will be used for the treatment of dyskinesia OR
  - B. The requested agent will be used for the adjunctive treatment in patients experiencing "off" episodes AND
3. The requested agent will be used in combination with levodopa-based therapy

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Anabolic Steroid PA – Danazol

**Drug Name(s)**

Danazol

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Androgen Injectable PA – Aveed

**Drug Name(s)**

Aveed

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient's sex is male with a diagnosis of primary or secondary (hypogonadotropic) hypogonadism AND
2. ONE of the following:
  - A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:
    - i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
    - ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR
  - B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:
    - i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
    - ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND
3. ONE of the following:
  - A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR
  - B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Androgen Injectable PA – Azmiro

**Drug Name(s)**

Azmiro

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient's sex is male with AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

- a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR
- b. Body mass index less than 20 kg/m<sup>2</sup> OR
- c. At least 5% total body cell mass (BCM) loss within 6 months OR
- d. BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is female with metastatic/inoperable breast cancer OR

C. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism OR

D. Patient's sex is male and is an adolescent with delayed puberty AND

2. If the patient's sex is a male, ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

- i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
- ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

- i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
- ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for delayed puberty, 12 months for all other indications

**Other Criteria:**

**Prior Authorization Group Description:**

Androgen Injectable PA - testosterone cypionate

**Drug Name(s)**

Depo-Testosterone

Testosterone Cypionate

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient's sex is male with AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR

b. Body mass index less than 20 kg/m<sup>2</sup> OR

c. At least 5% total body cell mass (BCM) loss within 6 months OR

d. BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is female with metastatic/inoperable breast cancer OR

C. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism OR

D. Patient's sex is male and is an adolescent with delayed puberty AND

2. If the patient's sex is a male, ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR

ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR

ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:**

**Coverage Duration:**

Approval will be 6 months for delayed puberty, 12 months for all other indications

**Other Criteria:**

**Prior Authorization Group Description:**

Androgen Injectable PA - testosterone enanthate

**Drug Name(s)**

Testosterone Enanthate

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient's sex is male with AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

- a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 7.5% within 6 months) OR
- b. Body mass index less than 20 kg/m<sup>2</sup> OR
- c. At least 5% total body cell mass (BCM) loss within 6 months OR
- d. BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is female with metastatic/inoperable breast cancer OR

C. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism OR

D. Patient's sex is male and is an adolescent with delayed puberty AND

2. If the patient's sex is a male, ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

- i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
- ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

- i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
- ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for delayed puberty, 12 months for all other indications

**Other Criteria:**

**Prior Authorization Group Description:**

Androgen Injectable PA – Xyosted

**Drug Name(s)**

Xyosted

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient's sex is male with AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

- a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 5% within 6 months) OR
- b. Body mass index less than 20 kg/m<sup>2</sup> OR
- c. At least 5% total body cell mass (BCM) loss within 6 months OR
- d. BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism AND

2. Patient's sex is male with ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

- i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
- ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

- i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
- ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Androgen Oral PA

**Drug Name(s)**

Methitest

Methyltestosterone

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

- A. Patient's sex is male with cryptorchidism OR
- B. Patient's sex is male with hypogonadism OR
- C. Patient's sex is male and is an adolescent with delayed puberty OR
- D. Patient's sex is female with metastatic/inoperable breast cancer AND

2. If the patient's sex is male, ONE of the following:

- A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:
  - i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
  - ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR
- B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:
  - i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
  - ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

- A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR
- B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for delayed puberty, 12 months for all other indications

**Other Criteria:**



**Prior Authorization Group Description:**

Androgen Topical PA

**Drug Name(s)**

Testim

Testosterone

Testosterone Pump

Testosterone Topical Solution

Vogelxo

Vogelxo Pump

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following diagnoses:

A. Patient has AIDS/HIV-associated wasting syndrome AND BOTH of the following:

i. ONE of the following:

- a. Unexplained involuntary weight loss (greater than 10% baseline body weight within 12 months, or 5% within 6 months) OR
- b. Body mass index less than 20 kg/m<sup>2</sup> OR
- c. At least 5% total body cell mass (BCM) loss within 6 months OR
- d. In men: BCM less than 35% of total body weight and BMI less than 27 kg/m<sup>2</sup> OR
- e. In women: BCM less than 23% of total body weight and BMI less than 27 kg/m<sup>2</sup> AND

ii. All other causes of weight loss have been ruled out OR

B. Patient's sex is male with primary or secondary (hypogonadotropic) hypogonadism AND

2. If the patient's sex is male, ONE of the following:

A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:

- i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
- ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR

B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:

- i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
- ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND

3. ONE of the following:

A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR

B. Prescriber has submitted information in support of therapy with more than one agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Antipsychotics PA

**Drug Name(s)**

Abilify  
Abilify Mycite Maintenance Kit  
Abilify Mycite Starter Kit  
Aripiprazole  
Aripiprazole Odt  
Asenapine Maleate Sl  
Chlorpromazine Hcl  
Clozapine  
Clozapine Odt  
Clozaril  
Fanapt  
Fanapt Pack A  
Fanapt Pack C  
Fluphenazine Decanoate  
Fluphenazine Hcl  
Geodon  
Haldol Decanoate 100  
Haloperidol  
Haloperidol Decanoate  
Haloperidol Lactate  
Invega  
Latuda  
Loxapine  
Lurasidone Hcl  
Lybalvi  
Molindone Hcl  
Olanzapine  
Olanzapine Odt  
Olanzapine/Fluoxetine  
Opipta  
Paliperidone Er  
Perphenazine  
Pimozide  
Quetiapine Fumarate  
Quetiapine Fumarate Er  
Rexulti  
Risperdal  
Risperidone  
Risperidone Odt  
Saphris  
Secuado

Seroquel  
Seroquel Xr  
Symbyax  
Thioridazine Hcl  
Thiothixene  
Trifluoperazine Hcl  
Versacloz  
Ziprasidone Mesylate  
Zyprexa  
Zyprexa Zydis

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - b. Prescriber states the patient is currently being treated with the requested agent OR
  - c. ONE of the following:
    - i. Patient has a diagnosis other than dementia-related psychosis or dementia-related behavioral symptoms OR
    - ii. Patient has dementia-related psychosis or dementia-related behavioral symptoms AND BOTH of the following:
      1. Dementia-related psychosis is determined to be severe or the associated behavior puts the patient or others in danger AND
      2. Prescriber has discussed the risk of increased mortality with the patient and/or the patient's surrogate decision maker

Approval authorizations will apply to the requested medication only.

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Anzupgo PA

**Drug Name(s)**

Anzupgo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of moderate to severe chronic hand eczema (CHE) AND BOTH of the following:
  - A. Patient has hand eczema that has been present for greater than 3 months or has returned at least twice in a year after its initial presentation and subsequent clearance AND
  - B. ONE of the following:
    - i. Patient has tried and had an inadequate response to a topical corticosteroid (e.g., triamcinolone) OR
    - ii. Patient has an intolerance or hypersensitivity to a topical corticosteroid OR
    - iii. Patient has an FDA labeled contraindication to a topical corticosteroid AND
2. Patient will NOT be using the requested agent in combination with other JAK inhibitors, OR potent immunosuppressants (e.g., azathioprine, cyclosporine)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of moderate to severe chronic hand eczema (CHE) AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with other JAK inhibitors, OR potent immunosuppressants (e.g., azathioprine, cyclosporine)

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, allergist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Apomorphine Inj PA

**Drug Name(s)**

Apokyn

Apomorphine Hcl

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent will be used to treat acute, intermittent hypomobility, “off” episodes (“end of dose wearing off” and unpredictable “on/off” episodes) associated with advanced Parkinson’s disease AND
2. The requested agent will be used in combination with agents used for therapy in Parkinson’s disease (e.g., levodopa, dopamine agonist, monoamine oxidase B inhibitor)

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient’s diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Aptensio XR PA

**Drug Name(s)**

Aptensio Xr

Methylphenidate Hcl Er (Aptensio Xr)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Aqneursa PA

**Drug Name(s)**

Aqneursa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of Niemann-Pick disease Type C (NPC) as confirmed by genetic analysis mutation in the NPC1 or NPC2 genes AND
2. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Niemann-Pick disease Type C (NPC) AND
3. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hepatologist, gastroenterologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Arcalyst PA

**Drug Name(s)**

Arcalyst

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has been diagnosed with Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) OR

B. BOTH of the following:

i. Patient has a diagnosis of deficiency of interleukin-1 receptor antagonist AND

ii. The requested agent is being used for maintenance of remission OR

C. BOTH of the following:

i. Patient has a diagnosis of recurrent pericarditis AND

ii. The requested agent is being used to reduce the risk of recurrence AND

2. Patient will NOT be using the requested agent in combination with another biologic agent

**Age Restriction:**

For diagnosis of CAPS including FCAS or MWS, patient is 12 years of age or over.

For diagnosis of recurrent pericarditis and reduction in risk of recurrence, patient is 12 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Arikayce PA

**Drug Name(s)**

Arikayce

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Mycobacterium avium complex (MAC) lung disease AND
2. Patient has not achieved negative sputum cultures despite at least 6 consecutive months of treatment with standard combination antibiotic therapy for MAC lung disease [e.g., standard combination may include a macrolide (clarithromycin, azithromycin), a rifamycin (rifampin, rifabutin), and ethambutol] AND
3. Patient will continue treatment with a combination antibiotic therapy for MAC lung disease with the requested agent [e.g., combination may include a macrolide (clarithromycin, azithromycin), a rifamycin (rifampin, rifabutin), and ethambutol]

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Mycobacterium avium complex (MAC) lung disease AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will continue treatment with a combination antibiotic therapy for MAC lung disease with the requested agent [e.g., combination may include a macrolide (clarithromycin, azithromycin), a rifamycin (rifampin, rifabutin), and ethambutol]

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease, immunologist, pulmonologist, thoracic specialist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Armodafinil PA

**Drug Name(s)**

Armodafinil

Nuvigil

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another target agent (i.e., modafinil)

**Age Restriction:**

Patient is 17 years of age or over

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Atopic Dermatitis PA – Eucrisa

**Drug Name(s)**

Eucrisa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of atopic dermatitis AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
  - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
  - C. Patient has an FDA labeled contraindication to a topical corticosteroid or topical corticosteroid combination preparation

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Atopic Dermatitis PA – Pimecrolimus

**Drug Name(s)**

Elidel

Pimecrolimus

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has a diagnosis of atopic dermatitis or vulvar lichen sclerosus AND ONE of the following:
  - A. Patient has tried and had an inadequate response to a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
  - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
  - C. Patient has an FDA labeled contraindication to a topical corticosteroid or topical corticosteroid combination preparation OR
2. Patient has a diagnosis of facial seborrheic dermatitis associated with HIV infection AND BOTH of the following:
  - A. Patient is currently on an antiretroviral treatment regimen AND
  - B. ONE of the following:
    - i. Patient has tried and had an inadequate response to a topical corticosteroid or topical antifungal treatment (e.g., hydrocortisone, triamcinolone, ketoconazole) OR
    - ii. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical antifungal treatment OR
    - iii. Patient has an FDA labeled contraindication to a topical corticosteroid or topical antifungal treatment OR
3. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Atopic Dermatitis PA – Tacrolimus

**Drug Name(s)**

Tacrolimus

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has a diagnosis of atopic dermatitis AND ONE of the following:
  - A. Patient has tried and had an inadequate response to a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
  - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
  - C. Patient has an FDA labeled contraindication to a topical corticosteroid or topical corticosteroid combination preparation OR
2. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Atovaquone PA

**Drug Name(s)**

Atovaquone

Mepron

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

1. Patient has a diagnosis of mild-to-moderate *Pneumocystis jirovecii* pneumonia OR
2. Patient is using the requested agent for prevention of *Pneumocystis jirovecii* pneumonia AND

ii. ONE of the following:

1. Patient has an intolerance or hypersensitivity to trimethoprim/sulfamethoxazole (TMP/SMX) OR
2. Patient has an FDA labeled contraindication to trimethoprim/sulfamethoxazole (TMP/SMX) OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Attruby PA

**Drug Name(s)**

Attruby

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cardiomyopathy of wild type or variant transthyretin-mediated amyloidosis (ATTR-CM) AND
2. The diagnosis has been confirmed by testing [e.g., stannous pyrophosphate (PYP) scanning, monoclonal antibody studies, biopsy, scintigraphy, genetic testing (TTR genotyping)] AND
3. The requested agent will be used to reduce cardiovascular death and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has clinical manifestations of cardiomyopathy (e.g., dyspnea, fatigue, orthostatic hypotension, syncope, peripheral edema) AND
6. Patient will NOT be using the requested agent in combination with Amvuttra or a tafamidis agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cardiomyopathy of wild type or variant transthyretin-mediated amyloidosis (ATTR-CM) AND
3. The requested agent will be used to reduce cardiovascular death and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has had clinical benefit with the requested agent AND
6. Patient will NOT be using the requested agent in combination with Amvuttra or a tafamidis agent for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Austedo PA

**Drug Name(s)**

Austedo

Austedo Xr

Austedo Xr Patient Titration Kit

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of chorea associated with Huntington's disease AND BOTH of the following:

i. ONE of the following:

1. Patient does NOT have a current diagnosis of depression OR
2. Patient has a current diagnosis of depression and is being treated for depression AND

ii. ONE of the following:

1. Patient does NOT have a diagnosis of passive suicidal ideation and/or behavior OR
2. Patient has a diagnosis of passive suicidal ideation and/or behavior and must NOT be actively suicidal OR

B. Patient has a diagnosis of tardive dyskinesia AND ONE of the following:

- i. Prescriber has reduced the dose of or discontinued any medications known to cause tardive dyskinesia (i.e., dopamine receptor blocking agents) OR
- ii. Prescriber has provided clinical rationale indicating that a reduced dose or discontinuation of any medications known to cause tardive dyskinesia is not appropriate AND

2. Patient will NOT be using the requested agent in combination with a monoamine oxidase inhibitor (MAOI) AND

3. Patient will NOT be using the requested agent in combination with reserpine

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Azstarys PA

**Drug Name(s)**

Azstarys

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Belsomra PA

**Drug Name(s)**

Belsomra

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benign Prostatic Hyperplasia PA – Tadalafil

**Drug Name(s)**

Cialis

Tadalafil 2.5Mg, 5Mg

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used to treat erectile dysfunction ONLY AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of benign prostatic hyperplasia (BPH) AND
2. Patient has tried and had an insufficient response, intolerance or hypersensitivity, or FDA labeled contraindication to TWO alpha blocker agents (e.g., terazosin, doxazosin, tamsulosin)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benlysta SC PA

**Drug Name(s)**

Benlysta SC

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - a. Patient has a diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
    - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
  - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
    - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - a. Patient has diagnosis of active systemic lupus erythematosus (SLE) disease AND the following:
    - i. Patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
  - b. Patient has a diagnosis of active lupus nephritis (LN) AND the following:
    - i. Patient will continue standard LN therapy [corticosteroids (e.g., methylprednisolone, prednisone), immunosuppressives (e.g., azathioprine, mycophenolate)] in combination with the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another biologic agent

**Age Restriction:**

For diagnosis of active systemic lupus erythematosus (SLE) disease, patient is 5 years of age or over. For diagnosis of active lupus nephritis (LN), patient is 5 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA - Chlordiazepoxide

**Drug Name(s)**

Chlordiazepoxide Hcl

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Anxiety disorder AND ONE of the following:

- 1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR
- 2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR
- 3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

b. Alcohol withdrawal OR

c. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Chlordiazepoxide /amitriptyline

**Drug Name(s)**

Chlordiazepoxide/Amitriptyline

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Moderate to severe depression with moderate to severe anxiety AND ONE of the following:

- 1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR
- 2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR
- 3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Clobazam

**Drug Name(s)**

Clobazam

Onfi

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Seizure disorder OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Benzodiazepines PA – Clorazepate

**Drug Name(s)**

Clorazepate Dipotassium

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

- a. Seizure disorder OR
- b. Anxiety disorder AND ONE of the following:
  - 1) Patient has tried and has an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR
  - 2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR
  - 3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR
- c. Alcohol withdrawal OR
- d. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Diazepam

**Drug Name(s)**

Diazepam

Diazepam Intensol

Valium

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

- a. Seizure disorder OR
- b. Anxiety disorder AND ONE of the following:
  - 1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR
  - 2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR
  - 3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR
- c. Skeletal muscle spasms OR
- d. Alcohol withdrawal OR
- e. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Estazolam

**Drug Name(s)**

Estazolam

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. Patient has a diagnosis of insomnia

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Flurazepam

**Drug Name(s)**

Flurazepam Hcl

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. Patient has a diagnosis of insomnia

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Lorazepam

**Drug Name(s)**

Ativan

Lorazepam

Lorazepam Intensol

Loreev Xr

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Anxiety disorder AND ONE of the following:

- 1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR
- 2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR
- 3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Oxazepam

**Drug Name(s)**

Oxazepam

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

a. Anxiety disorder AND ONE of the following:

- 1) Patient has tried and had an inadequate response to a formulary selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) OR
- 2) Patient has an intolerance or hypersensitivity to a formulary SSRI or SNRI OR
- 3) Patient has an FDA labeled contraindication to a formulary SSRI or SNRI OR

b. Alcohol withdrawal OR

c. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Benzodiazepines PA – Sympazan

**Drug Name(s)**

Sympazan

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- b. Prescriber states the patient is currently being treated with the requested agent AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. BOTH of the following:

i. Patient has ONE of the following diagnoses:

- a. Seizure disorder OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Bethkis PA

**Drug Name(s)**

Bethkis

Tobramycin (Bethkis)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Documentation has been provided that indicates the patient has a *Pseudomonas aeruginosa* respiratory infection AND
3. ONE of the following:
  - a. Patient is NOT currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) OR
  - b. Patient is currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) AND ONE of the following:
    - i. Prescriber has confirmed that the other inhaled antibiotic will be discontinued, and that therapy will be continued only with the requested agent OR
    - ii. Prescriber has provided information in support of another inhaled antibiotic therapy used concurrently with or alternating with (i.e., continuous alternating therapy) the requested agent

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Bexarotene Gel PA

**Drug Name(s)**

Bexarotene Gel

Targretin Gel

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. ALL of the following:
    - i. ONE of the following:
      1. BOTH of the following:
        - a. Patient has a diagnosis of stage IA or IB cutaneous T-cell lymphoma (CTCL) with cutaneous lesions AND
        - b. ONE of the following:
          - i. Patient has refractory or persistent disease despite a previous treatment trial with a skin-directed therapy (e.g., topical corticosteroid, topical imiquimod) OR
          - ii. Patient has an intolerance or hypersensitivity to a previous treatment trial with a skin-directed therapy (e.g., topical corticosteroid, topical imiquimod) OR
          - iii. Patient has an FDA labeled contraindication to a previous treatment trial with a skin-directed therapy (e.g., topical corticosteroid, topical imiquimod) OR
        2. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
      - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
      - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. ALL of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
    - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Prior Authorization Group Description:**

Bildyos PA

**Drug Name(s)**

Bildyos

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR
  - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
  - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
  - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
  - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
  - iii. Pt's diagnosis was confirmed by ONE of:
    - 1. A fragility fracture in the hip or spine OR
    - 2. A T-score of -2.5 or lower OR
    - 3. A T-score of -1.0 to -2.5 AND ONE of:
      - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - iv. ONE of:
    - 1. Pt is at high fracture risk as defined by ONE of:
      - a. Pt had a recent fracture (within the past 12 months) OR
      - b. Pt had fractures while on FDA approved osteoporosis therapy OR

- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqcg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Bilprevda PA

**Drug Name(s)**

Bilprevda

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

- iii. ONE of the following:
  - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
  - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Abrilada

**Drug Name(s)**

Abrilada

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Actemra

**Drug Name(s)**

Actemra

Actemra Actpen

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of polyarticular juvenile idiopathic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of ONE preferred agent (Rinvoq tablets) is required for diagnosis of giant cell arteritis

NO preferred agent is required for diagnoses of systemic sclerosis-associated interstitial lung disease (SSc-ILD), cytokine release syndrome, or systemic juvenile idiopathic arthritis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Amjevita

**Drug Name(s)**

Amjevita

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or adult uveitis

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or adult hidradenitis suppurativa

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Bimzelx

**Drug Name(s)**

Bimzelx

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Cosentyx, Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of ankylosing spondylitis

Use of TWO preferred agents (Cosentyx and Rinvoq tablets) is required for diagnosis of non-radiographic axial spondyloarthritis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnosis of hidradenitis suppurativa

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Cimzia

**Drug Name(s)**

Cimzia

Cimzia Starter Kit

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnosis of rheumatoid arthritis



Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnosis of ankylosing spondylitis

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

Only the preferred agent Cosentyx is required for diagnosis of non-radiographic axial spondyloarthritis

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnosis of juvenile idiopathic arthritis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Cosentyx

**Drug Name(s)**

Cosentyx

Cosentyx Sensoready Pen

Cosentyx Unoready

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of ankylosing spondylitis, enthesitis related arthritis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, or psoriatic arthritis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Cyltezo

**Drug Name(s)**

Cyltezo

Cyltezo Starter Package For Crohns Disease/Uc/Hs

Cyltezo Starter Package For Psoriasis

Cyltezo Starter Package For Psoriasis/Uveitis

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or adult uveitis

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or adult hidradenitis suppurativa

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Enbrel

**Drug Name(s)**

Enbrel

Enbrel Mini

Enbrel Sureclick

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of ankylosing spondylitis, psoriatic arthritis, adult plaque psoriasis, polyarticular juvenile idiopathic arthritis, or rheumatoid arthritis

NO preferred agent is required for diagnoses of juvenile psoriatic arthritis or pediatric plaque psoriasis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Entyvio SC

**Drug Name(s)**

Entyvio Pen

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Hadlima

**Drug Name(s)**

Hadlima

Hadlima Pushtouch

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of plaque psoriasis, rheumatoid arthritis, or juvenile idiopathic arthritis

NO prerequisites are required for diagnoses of ankylosing spondylitis, moderate Crohn's disease, severe Crohn's disease, hidradenitis suppurativa, psoriatic arthritis, moderate ulcerative colitis, severe ulcerative colitis, or uveitis

Formulary conventional agents for rheumatoid arthritis or juvenile idiopathic arthritis include leflunomide, methotrexate, or sulfasalazine

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Hulio

**Drug Name(s)**

Adalimumab-Fkjp

Hulio

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Humira

**Drug Name(s)**

Humira

Humira Pen

Humira Pen-Cd/Uc/Hs Starter

Humira Pen-Pediatric Uc Starter Pack

Humira Pen-Ps/Uv Starter

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or adult uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or adult hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or adult ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnoses of adult fistulizing Crohn's disease, pediatric hidradenitis suppurativa, pediatric ulcerative colitis, or pediatric uveitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Hyrimoz

**Drug Name(s)**

Adalimumab-Adaz

Hyrimoz

Hyrimoz Crohn's Disease And Ulcerative Colitis Starter Packk

Hyrimoz Pediatric Crohn's Disease Starter Pack

Hyrimoz Plaque Psoriasis/Uveitis Starter Pack

Hyrimoz Sensoready Pens

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND

4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or adult uveitis

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or adult hidradenitis suppurativa

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease



**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Idacio

**Drug Name(s)**

Adalimumab-Aacf

Adalimumab-Aacf Starter Pack/Cd/Uc/Hs (6 Pen)

Adalimumab-Aacf Starter Pack/Psoriasis/Uveitis (4 Pen)

Idacio

Idacio Starter Package For Crohns Disease

Idacio Starter Package For Plaque Psoriasis

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND

4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or adult uveitis

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or adult hidradenitis suppurativa

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Ilumya

**Drug Name(s)**

Ilumya

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Imuldosa

**Drug Name(s)**

Imuldosa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Kevzara

**Drug Name(s)**

Kevzara

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of juvenile idiopathic arthritis

NO preferred agent is required for diagnosis of polymyalgia rheumatica

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Kineret

**Drug Name(s)**

Kineret

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

NO preferred agent is required for diagnoses of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) or Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Leqselvi

**Drug Name(s)**

Leqselvi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Litfulo

**Drug Name(s)**

Litfulo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Olumiant

**Drug Name(s)**

Olumiant

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

NO preferred agent is required for diagnosis of alopecia areata

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Omvoh

**Drug Name(s)**

Omvoh

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Orencia

**Drug Name(s)**

Orencia

Orencia Clickject

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months



**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of juvenile idiopathic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of ONE preferred agent (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 2 and less than 6 years of age, NO preferred agent is required for diagnosis of psoriatic arthritis

NO preferred agent is required for diagnosis of prophylaxis of acute graft vs host disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Otulfi

**Drug Name(s)**

Otulfi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Pyzchiva

**Drug Name(s)**

Pyzchiva

Ustekin-Ttwe

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Rinvoq Solution

**Drug Name(s)**

Rinvoq Lq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's medication history indicates use of preferred TNF agent(s) OR
    - ii. Patient has an intolerance or hypersensitivity to preferred TNF agent(s) OR
    - iii. Patient has an FDA labeled contraindication to preferred TNF agent(s) OR
    - iv. The request is for an FDA labeled indication that is not covered by preferred TNF agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred TNF (Hadlima or Simlandi) is required for diagnoses of adult psoriatic arthritis or juvenile idiopathic arthritis

NO preferred TNF agent is required for diagnosis of pediatric psoriatic arthritis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Rinvoq Tablet

**Drug Name(s)**

Rinvoq Tablet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. BOTH of the following:
      - a. Patient has an FDA labeled indication other than moderate to severe atopic dermatitis for the requested agent AND
      - b. ONE of the following:
        1. Patient's medication history indicates use of preferred TNF agent(s) OR
        2. Patient has an intolerance or hypersensitivity to preferred TNF agent(s) OR
        3. Patient has an FDA labeled contraindication to preferred TNF agent(s) OR
        4. The request is for an FDA labeled indication that is not covered by preferred TNF agent(s) OR
      - ii. Patient has a diagnosis of moderate to severe atopic dermatitis AND ONE of the following:
        - a. Patient's medication history indicates use of TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication OR
        - b. Patient has an intolerance or hypersensitivity to TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication OR
        - c. Patient has an FDA labeled contraindication to TWO conventional prerequisite agents (i.e., ONE formulary topical corticosteroid AND ONE formulary topical calcineurin inhibitor) for the requested indication AND
  3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Use of ONE preferred TNF (Hadlima or Simlandi) is required for diagnoses of ankylosing spondylitis, rheumatoid arthritis, adult psoriatic arthritis, or juvenile idiopathic arthritis

Use of TWO conventional prerequisite agents are required for diagnosis of moderate to severe atopic dermatitis

NO preferred TNF agents are required for diagnoses of pediatric psoriatic arthritis, non-radiographic axial spondyloarthritis, giant cell arteritis, moderate Crohn's disease, severe Crohn's disease, moderate ulcerative colitis, or severe ulcerative colitis



**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Selarsdi

**Drug Name(s)**

Selarsdi

Ustekin-Aekn

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Siliq

**Drug Name(s)**

Siliq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Simlandi

**Drug Name(s)**

Simlandi

**Indications:**

All FDA-Approved Indications

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnoses of plaque psoriasis, rheumatoid arthritis, or juvenile idiopathic arthritis

NO prerequisites are required for diagnoses of ankylosing spondylitis, moderate Crohn's disease, severe Crohn's disease, hidradenitis suppurativa, psoriatic arthritis, moderate ulcerative colitis, severe ulcerative colitis, or uveitis

Formulary conventional agents for rheumatoid arthritis or juvenile idiopathic arthritis include leflunomide, methotrexate, or sulfasalazine

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Simponi

**Drug Name(s)**

Simponi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnosis of ankylosing spondylitis

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of adult ulcerative colitis

NO preferred agent is required for diagnosis of pediatric ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Skyrizi

**Drug Name(s)**

Skyrizi

Skyrizi Pen

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis



NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Sotyktu

**Drug Name(s)**

Sotyktu

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Stelara

**Drug Name(s)**

Stelara

Ustekinumab

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Steqeyma

**Drug Name(s)**

Steqeyma

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Taltz

**Drug Name(s)**

Taltz

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

Use of TWO preferred agents (Cosentyx, Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of ankylosing spondylitis

Use of TWO preferred agents (Cosentyx and Rinvoq tablets) is required for diagnosis of non-radiographic axial spondyloarthritis



**Prior Authorization Group Description:**

Biologic Immunomodulators PA – Tremfya

**Drug Name(s)**

Tremfya

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's medication history indicates use of another biologic immunomodulator agent for the same FDA labeled indication OR
  - D. Patient's diagnosis does NOT require a conventional prerequisite agent OR
  - E. Patient's medication history indicates use of ONE formulary conventional prerequisite agent for the requested indication OR
  - F. Patient has an intolerance or hypersensitivity to at least ONE formulary conventional prerequisite agent for the requested indication OR
  - G. Patient has an FDA labeled contraindication to at least ONE formulary conventional prerequisite agent for the requested indication AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE conventional prerequisite agent is required for diagnosis of plaque psoriasis

NO prerequisites are required for diagnoses of moderate Crohn's disease, severe Crohn's disease, psoriatic arthritis, moderate ulcerative colitis, or severe ulcerative colitis

Formulary conventional agents (topical or systemic) for plaque psoriasis include acitretin, calcipotriene, methotrexate, tazarotene, or topical corticosteroids

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Tyenne

**Drug Name(s)**

Tyenne

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of polyarticular juvenile idiopathic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of ONE preferred agent (Rinvoq tablets) is required for diagnosis of giant cell arteritis

NO preferred agent is required for diagnoses of cytokine release syndrome or systemic juvenile idiopathic arthritis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Velsipity

**Drug Name(s)**

Velsipity

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Wezlana

**Drug Name(s)**

Wezlana

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Xeljanz Solution

**Drug Name(s)**

Xeljanz Solution

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of juvenile idiopathic arthritis



For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 2 and less than 6 years of age, use of TWO preferred agents (Cosentyx, Rinvoq tablets, or Rinvoq solution) is required for diagnosis of psoriatic arthritis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Xeljanz Tablet

**Drug Name(s)**

Xeljanz Tablet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 2 and less than 6 years of age, use of TWO preferred agents (Cosentyx, Rinvoq tablets, or Rinvoq solution) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Rinvoq solution, or Simlandi) is required for diagnosis of juvenile idiopathic arthritis

Use of TWO preferred agents (Cosentyx, Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of ankylosing spondylitis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Xeljanz XR

**Drug Name(s)**

Xeljanz Xr

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of rheumatoid arthritis

Use of TWO preferred agents (Cosentyx, Hadlima, Rinvoq tablets, or Simlandi) is required for diagnosis of ankylosing spondylitis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Yesintek

**Drug Name(s)**

Yesintek

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
    - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
    - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
    - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Stelara, Steqeyma, or Tremfya) is required for diagnosis of plaque psoriasis

For patients 18 years of age or over, use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

For patients between 6 and less than 18 years of age, use of TWO preferred agents (Cosentyx, Otezla, Otezla XR, Rinvoq tablets, Rinvoq solution, Stelara, Steqeyma, or Tremfya) is required for diagnosis of psoriatic arthritis

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of Crohn's disease

Use of TWO preferred agents (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Yuflyma

**Drug Name(s)**

Adalimumab-Aaty Cd/Uc/Hs Starter

Adalimumab-Aaty Kit

Yuflyma Cd/Uc/Hs Starter

Yuflyma Kit

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:**



**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or adult uveitis

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or adult hidradenitis suppurativa

Use of ONE preferred agent (Simlandi) is required for diagnosis of pediatric hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Yusimry

**Drug Name(s)**

Yusimry

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of ONE preferred agent (Hadlima or Simlandi) is required for diagnoses of juvenile idiopathic arthritis, rheumatoid arthritis, pediatric Crohn's disease, or uveitis

Use of TWO preferred agents (Cosentyx, Hadlima, or Simlandi) is required for diagnoses of ankylosing spondylitis or hidradenitis suppurativa

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of adult Crohn's disease or ulcerative colitis

Use of TWO preferred agents (Cosentyx, Hadlima, Otezla, Otezla XR, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnoses of plaque psoriasis or psoriatic arthritis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Biologic Immunomodulators PA - Zymfentra

**Drug Name(s)**

Zymfentra

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. ONE of the following:
    - i. Patient's diagnosis is indicated for preferred biologic immunomodulator agent(s) AND ONE of the following:
      - a. Patient's medication history indicates use of preferred biologic immunomodulator agent(s) OR
      - b. Patient has an intolerance or hypersensitivity to preferred biologic immunomodulator agent(s) OR
      - c. Patient has an FDA labeled contraindication to preferred biologic immunomodulator agent(s) OR
    - ii. The request is for an FDA labeled indication that is not covered by preferred biologic immunomodulator agent(s) AND
3. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical improvement (slowing of disease progression or decrease in symptom severity and/or frequency) AND
4. Patient will NOT be using the requested agent in combination with another biologic immunomodulator

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of adult Crohn's disease

Use of TWO preferred agents (Hadlima, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) is required for diagnosis of ulcerative colitis

NO preferred agent is required for diagnosis of adult fistulizing Crohn's disease

**Prior Authorization Group Description:**

Bivigam/Flebogamma/Gammagard SD/Gammaplex/Octagam/Privigen PA

**Drug Name(s)**

Bivigam

Gammagard S/D Iga Less Than 1Mcg/MI

Gammaplex

Octagam

Privigen

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

- A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR
- B. B-cell chronic lymphocytic leukemia OR multiple myeloma AND ONE of the following:
  - i. Patient has a history of infections OR
  - ii. Patient has evidence of specific antibody deficiency OR
  - iii. Patient has hypogammaglobulinemia OR
- C. Idiopathic thrombocytopenia purpura AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone), or immunosuppressants (e.g., mycophenolate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- D. Dermatomyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- E. Polymyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- F. Severe rheumatoid arthritis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., tumor necrosis factor antagonists (e.g., Enbrel), DMARDS (e.g., methotrexate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

Criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 6 months for indications in Other Criteria, 12 months for all others

**Other Criteria:**

G. Myasthenia gravis (MG) AND ONE of the following:

- i. Patient is in acute myasthenic crisis OR
- ii. Patient has severe refractory MG (e.g., major functional disability/weakness) AND ONE of the following:
  - a) Patient has failed ONE immunomodulator therapy (i.e., corticosteroid, pyridostigmine, or azathioprine) OR
  - b) Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE immunomodulator therapy OR

H. Multiple sclerosis (MS) AND BOTH of the following:

- i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND
- ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication to TWO MS agents (e.g., Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Plegridy, teriflunomide, Vumerity) OR

I. Acquired von Willebrand hemophilia AND ONE of the following:

- i. Patient has failed ONE conventional therapy (e.g., desmopressin, von Willebrand factor replacement therapy, corticosteroids, FEIBA, or recombinant factor VIIa) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

J. Refractory pemphigus vulgaris AND ONE of the following:

- i. Patient has failed ONE conventional immunosuppressive therapy (e.g., azathioprine, cyclophosphamide, mycophenolate, corticosteroids) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional immunosuppressive therapy OR

2. ONE of the following:

- A. Patient has another FDA labeled indication for the requested agent OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Indications with 6 months approval duration: Acquired von Willebrand hemophilia, Guillain-Barre Syndrome, Lambert-Eaton myasthenia syndrome, Kawasaki disease, CMV induced pneumonitis in solid organ transplant, Toxic shock syndrome due to invasive group A streptococcus, Toxic epidermal necrolysis and Stevens-Johnson syndrome

Drug is also subject to Part B versus Part D review.

**Prior Authorization Group Description:**

Bomyntra PA

**Drug Name(s)**

Bomyntra

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND



- iii. ONE of the following:
  - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
  - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Brekiya PA

**Drug Name(s)**

Brekiya

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:
  - A. The requested agent will be used for the treatment of acute migraine with or without aura  
OR
  - B. The requested agent will be used for the acute treatment of cluster headache episodes  
AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to TWO triptan agents with differing active ingredients (e.g., sumatriptan, rizatriptan) OR
  - B. Patient has an intolerance or hypersensitivity to a triptan agent OR
  - C. Patient has an FDA labeled contraindication to a triptan agent AND
3. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. The requested agent will be used for the treatment of acute migraine with or without aura  
OR
  - B. The requested agent will be used for the acute treatment of cluster headache episodes  
AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Brinsupri PA

**Drug Name(s)**

Brinsupri

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis non-cystic fibrosis bronchiectasis AND
2. Patient has had computed tomography (CT) to confirm the diagnosis of bronchiectasis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis non-cystic fibrosis bronchiectasis AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Budesonide Oral ER PA – Entocort

**Drug Name(s)**

Budesonide Dr (Entocort)

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Budesonide Oral ER PA – Uceris

**Drug Name(s)**

Budesonide Er (Uceris)

Uceris

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Byetta PA

**Drug Name(s)**

Exenatide

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
  - C. ALL of the following:
    - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
    - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Bylvay PA

**Drug Name(s)**

Bylvay

Bylvay (Pellets)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. BOTH of the following:

- i. Patient has a diagnosis of progressive familial intrahepatic cholestasis (PFIC) AND
- ii. The requested agent will be used to treat pruritus OR

B. BOTH of the following:

- i. Patient has a diagnosis of Alagille Syndrome (ALGS) AND
- ii. The requested agent will be used to treat cholestatic pruritus AND

2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Camzyos PA

**Drug Name(s)**

Camzyos

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) AND
2. The requested agent will be used to improve functional capacity and symptoms

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Carglumic PA

**Drug Name(s)**

Carbaglu

Carglumic Acid

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

For generic carglumic acid only - Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)

**Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of ONE of the following:
  - a. Acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) OR
  - b. Chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) OR
  - c. Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, nephrologist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cayston PA

**Drug Name(s)**

Cayston

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Documentation has been provided that indicates the patient has a *Pseudomonas aeruginosa* respiratory infection AND
3. ONE of the following:
  - a. Patient is NOT currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled tobramycin) OR
  - b. Patient is currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled tobramycin) AND ONE of the following:
    - i. Prescriber has confirmed that the other inhaled antibiotic will be discontinued, and that therapy will be continued only with the requested agent OR
    - ii. Prescriber has provided information in support of another inhaled antibiotic therapy used concurrently with or alternating with (i.e., continuous alternating therapy) the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Chenodal PA

**Drug Name(s)**

Chenodal

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of radiolucent stones in a well-opacifying gallbladder AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Chorionic Gonadotropin PA

**Drug Name(s)**

Chorionic Gonadotropin

Novarel

Pregnyl

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used to promote fertility AND requested agent will be used to treat erectile dysfunction ONLY AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of prepubertal cryptorchidism not due to anatomic obstruction OR

B. Patient's sex is male with a diagnosis of hypogonadotropic hypogonadism (hypogonadism secondary to pituitary deficiency) AND BOTH of the following:

i. Patient has a measured current or pretreatment total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR a free serum testosterone level that is below the testing laboratory's lower limit of the normal range AND

ii. Patient has measured luteinizing hormone (LH) AND follicle-stimulating hormone (FSH) levels that are at (low-normal) or below the testing laboratory's normal range OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cibinqo PA

**Drug Name(s)**

Cibinqo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of moderate-to-severe atopic dermatitis AND BOTH of the following:

A. ONE of the following:

- i. Patient has tried and failed a topical steroid (e.g., triamcinolone) OR
- ii. Patient has an intolerance or hypersensitivity to a topical steroid OR
- iii. Patient has an FDA labeled contraindication to a topical steroid AND

B. ONE of the following:

- i. Patient has tried and failed a topical calcineurin inhibitor (e.g., tacrolimus) OR
- ii. Patient has an intolerance or hypersensitivity to a topical calcineurin inhibitor OR
- iii. Patient has an FDA labeled contraindication to a topical calcineurin inhibitor AND

2. Patient will NOT be using the requested agent in combination with other biologic immunomodulator agents, other JAK inhibitors, OR other immunosuppressants

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has a diagnosis of moderate-to-severe atopic dermatitis AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with other biologic immunomodulator agents, other JAK inhibitors, OR other immunosuppressants

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cinacalcet PA

**Drug Name(s)**

Cinacalcet Hcl

Sensipar

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following:

A. A diagnosis of hypercalcemia due to parathyroid carcinoma OR

B. A diagnosis of primary hyperparathyroidism (HPT) AND BOTH of the following:

i. Patient has a pretreatment serum calcium level that is above the testing laboratory's upper limit of normal AND

ii. Patient is unable to undergo parathyroidectomy OR

C. Another indication that is FDA approved or supported in CMS approved compendia for the requested agent not otherwise excluded from Part D [i.e., secondary hyperparathyroidism due to end-stage renal disease (ESRD) on dialysis]

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cinqair PA

**Drug Name(s)**

Cinqair

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of severe asthma with an eosinophilic phenotype AND
2. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent AND
3. Patient will NOT be using the requested agent in combination with Xolair, Dupixent, or with another injectable interleukin 5 (IL-5) inhibitor (e.g., Fasenra, Nucala) for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of severe asthma with an eosinophilic phenotype AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent AND
5. Patient will NOT be using the requested agent in combination with Xolair, Dupixent, or with another injectable interleukin 5 (IL-5) inhibitor (e.g., Fasenra, Nucala) for the requested indication AND
6. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is 18 years of age or over

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cobenfy PA

**Drug Name(s)**

Cobenfy

Cobenfy Starter Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. ALL of the following:
    - i. Prescriber has assessed the patient's liver enzymes and bilirubin prior to starting therapy with the requested agent AND
    - ii. Prescriber has assessed the patient's heart rate prior to starting therapy with the requested agent AND
    - iii. ONE of the following:
      - a. Patient has tried and had an inadequate response to TWO antipsychotic agents (e.g., aripiprazole, haloperidol, loxapine, olanzapine, quetiapine, risperidone) for the requested indication OR
      - b. Patient has an intolerance or hypersensitivity to TWO antipsychotic agents (e.g., aripiprazole, haloperidol, loxapine, olanzapine, quetiapine, risperidone) OR
      - c. Patient has an FDA labeled contraindication to TWO antipsychotic agents (e.g., aripiprazole, haloperidol, loxapine, olanzapine, quetiapine, risperidone) AND
    - iv. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR



C. ALL of the following:

- i. Prescriber has assessed the patient's liver enzymes and bilirubin as clinically indicated during treatment with the requested agent AND
- ii. Prescriber has assessed the patient's heart rate as clinically indicated during treatment with the requested agent AND
- iii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
- iv. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Conexence PA

**Drug Name(s)**

Conexence

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR
  - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
  - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
  - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
  - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
  - iii. Pt's diagnosis was confirmed by ONE of:
    - 1. A fragility fracture in the hip or spine OR
    - 2. A T-score of -2.5 or lower OR
    - 3. A T-score of -1.0 to -2.5 AND ONE of:
      - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - iv. ONE of:
    - 1. Pt is at high fracture risk as defined by ONE of:
      - a. Pt had a recent fracture (within the past 12 months) OR
      - b. Pt had fractures while on FDA approved osteoporosis therapy OR

- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqqg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Fulphila

**Drug Name(s)**

Fulphila

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Fylnetra

**Drug Name(s)**

Fylnetra

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Granix

**Drug Name(s)**

Granix

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Leukine

**Drug Name(s)**

Leukine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**



**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Neulasta

**Drug Name(s)**

Neulasta

Neulasta Onpro Kit

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - i. Patient has an FDA labeled or CMS compendia supported indication for the requested agent that is not indicated for ONE preferred agent OR
  - ii. Patient has tried and had an inadequate response to ONE preferred agent OR
  - iii. Patient has an intolerance or hypersensitivity to ONE preferred agent OR
  - iv. Patient has an FDA labeled contraindication to ONE preferred agent OR
  - v. Prescriber has provided information in support of the use of the non-preferred agent over ONE preferred agent

Preferred agent(s) are Fulphila, Fylnetra, Granix, Nivestym, Nypozi, Nyvepria, Releuko, Stimufend, Udenyca, Zarxio, Ziextenzo

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Neupogen

**Drug Name(s)**

Neupogen

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - i. Patient has an FDA labeled or CMS compendia supported indication for the requested agent that is not indicated for ONE preferred agent OR
  - ii. Patient has tried and had an inadequate response to ONE preferred agent OR
  - iii. Patient has an intolerance or hypersensitivity to ONE preferred agent OR
  - iv. Patient has an FDA labeled contraindication to ONE preferred agent OR
  - v. Prescriber has provided information in support of the use of the non-preferred agent over ONE preferred agent

Preferred agent(s) are Fulphila, Fylnetra, Granix, Nivestym, Nypozi, Nyvepria, Releuko, Stimufend, Udenyca, Zarxio, Ziextenzo

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Nivestym

**Drug Name(s)**

Nivestym

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Nypozi

**Drug Name(s)**

Nypozi

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Nyvepria

**Drug Name(s)**

Nyvepria

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Releuko

**Drug Name(s)**

Releuko

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Stimufend

**Drug Name(s)**

Stimufend

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Udenyca

**Drug Name(s)**

Udenyca

Udenyca Onbody

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**



**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Zarxio

**Drug Name(s)**

Zarxio

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Colony Stimulating Factors PA – Ziextenzo

**Drug Name(s)**

Ziextenzo

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, hematologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Concerta PA

**Drug Name(s)**

Concerta

Methylphenidate Hcl Er (Concerta)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Corlanor PA

**Drug Name(s)**

Corlanor

Ivabradine Hcl

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of following:

A. ALL of the following:

- i. Patient has stable, symptomatic heart failure (e.g., NYHA Class II, III, IV: ACCF/AHA Class C, D) due to dilated cardiomyopathy (DCM) AND
- ii. The requested agent is for a pediatric patient, 6 months of age or over AND
- iii. Patient is in sinus rhythm with an elevated heart rate OR

B. ALL of the following:

- i. Patient has stable, symptomatic chronic heart failure (e.g., NYHA Class II, III, IV: ACCF/AHA Class C, D) AND
- ii. The requested agent is for an adult patient AND
- iii. Patient has a baseline OR current left ventricular ejection fraction of 35% or less AND
- iv. Patient is in sinus rhythm with a resting heart rate of 70 beats or greater per minute prior to initiating therapy with the requested agent AND

v. ONE of the following:

- a. Patient is on a maximally tolerated dose of beta blocker (e.g., bisoprolol, carvedilol, metoprolol) OR
- b. Patient has an intolerance, FDA labeled contraindications, or hypersensitivity to a beta blocker

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cortrophin Gel PA

**Drug Name(s)**

Cortrophin

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of nephrotic syndrome AND ONE of the following:

- i. Patient has failed a conventional agent (i.e., prednisone, tacrolimus) for the requested indication OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to a conventional agent OR

B. Patient has a diagnosis of multiple sclerosis AND ALL of the following:

- i. Patient is experiencing an acute exacerbation AND
- ii. If indicated, there is evidence of a claim that the patient is currently being treated with a disease modifying drug (DMD) within the past 90 days [e.g., Avonex, dimethyl fumarate, glatiramer] to control disease progression OR has an intolerance, FDA labeled contraindication, or hypersensitivity to a DMD AND
- iii. ONE of the following:
  - 1. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days OR
  - 2. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 1 month

**Other Criteria:**

- C. Patient has a diagnosis of rheumatic disorder (e.g., ankylosing spondylitis, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, rheumatoid arthritis) AND ALL of the following:
  - i. The requested agent will be used as adjunct therapy for short-term administration (to tide the patient over an acute episode or exacerbation) AND
  - ii. There is evidence of a claim that the patient is currently being treated with a conventional agent within the past 90 days [e.g., DMARD (methotrexate, leflunomide), biologics (Humira)] to control disease progression AND
  - iii. ONE of the following:

1. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days OR
  2. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy OR
- D. Patient has a diagnosis of systemic lupus erythematosus (SLE) disease AND the patient will continue standard SLE therapy [corticosteroids (e.g., methylprednisolone, prednisone), hydroxychloroquine, immunosuppressives (e.g., azathioprine, methotrexate, oral cyclophosphamide)] in combination with the requested agent OR
- E. Patient has another FDA approved indication AND ONE of the following:
- i. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy OR
- F. Patient has another indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:
- i. Patient has failed corticosteroid therapy (e.g., methylprednisolone) within the last 30 days OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to corticosteroid therapy AND
2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Cotempla PA

**Drug Name(s)**

Cotempla Xr-Odt

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Crenessity PA

**Drug Name(s)**

Crenessity

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency as confirmed by ONE of the following:
  - A. Positive infant screening with secondary tier 2 confirmatory testing OR
  - B. Elevated serum 17-hydroxyprogesterone (17OHP) level above the upper limit of normal (ULN) OR
  - C. Cosyntropin (ACTH) stimulation test OR
  - D. Genetic testing for mutation in the CYP21A2 gene consistent with CAH AND
2. Patient is currently being treated with glucocorticoid replacement therapy (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone) AND
3. Patient will continue glucocorticoid replacement therapy (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone) in combination with the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of classic congenital adrenal hyperplasia (CAH) AND
3. Patient is currently being treated with glucocorticoid replacement therapy (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone) AND
4. Patient will continue glucocorticoid replacement therapy (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone) in combination with the requested agent AND
5. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Cresemba PA

**Drug Name(s)**

Cresemba

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of invasive aspergillosis OR
- B. Patient has a diagnosis of invasive mucormycosis OR
- C. Patient has another indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

- A. Patient has a diagnosis of invasive aspergillosis or invasive mucormycosis and patient has continued indicators of active disease (e.g., biomarkers in serum assay, microbiologic culture, radiographic evidence) OR
- B. BOTH of the following:
  - i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
  - ii. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Crinone PA

**Drug Name(s)**

Crinone

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used to treat infertility AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Crotan PA

**Drug Name(s)**

Crotan

Pruradik Lot 10%

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 2 months

**Other Criteria:**

**Prior Authorization Group Description:**

Crysvita PA

**Drug Name(s)**

Crysvita

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. BOTH of the following:

i. Patient has a diagnosis of X-linked hypophosphatemia (XLH) as confirmed by ONE of the following:

- a. Genetic testing OR
- b. Elevated levels of intact fibroblast growth factor 23 (FGF23) OR
- c. Prescriber has provided information indicating the patient has a positive family history of XLH AND

ii. ONE of the following:

- a. Patient's epiphyseal plate has not fused OR
- b. Patient's epiphyseal plate has fused AND the patient is experiencing symptoms of XLH (e.g., bone pain, fractures, limited mobility) OR

B. Patient has a diagnosis of tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors AND BOTH of the following:

- i. The requested agent is being used to treat FGF23 related hypophosphatemia AND
- ii. The tumor cannot be curatively surgically resected or localized AND

2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of X-linked hypophosphatemia (XLH) OR

B. Patient has a diagnosis of tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors AND

3. Patient has had clinical benefit with the requested agent (e.g., enhanced height velocity, improvement in lower extremity bowing and associated abnormalities, radiographic evidence of epiphyseal healing, improvement in bone pain, enhanced mobility, improvement in osteomalacia, improvement in fracture healing) AND

4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent for the requested indication

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist, endocrinologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cutaquig PA

**Drug Name(s)**

Cutaquig

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR

B. Multiple sclerosis (MS) AND BOTH of the following:

i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND

ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication to TWO MS agents (e.g., Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Plegridy, teriflunomide, Vumerity) OR

2. ONE of the following:

A. Patient has another FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cuvrior PA

**Drug Name(s)**

Cuvrior

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Wilson's disease confirmed by ONE of the following:
  - A. Confirmation of genetic mutation of the ATP7B gene OR
  - B. Patient has TWO of the following:
    - i. Presence of hepatic abnormality (e.g., acute liver failure, cirrhosis, fatty liver)
    - ii. Presence of Kayser-Fleischer rings
    - iii. Serum ceruloplasmin level less than 20 mg/dL
    - iv. Basal urinary copper excretion greater than 40 mcg/24 hours or the testing laboratory's upper limit of normal
    - v. Hepatic parenchymal copper content greater than 40 mcg/g dry weight
    - vi. Presence of neurological symptoms (e.g., dystonia, hypertonia, rigidity with tremors, dysarthria, muscle spasms, dysphasia, polyneuropathy, dysautonomia) AND
2. Patient is decoppered AND
3. Patient has stable Wilson's disease AND
4. Patient is tolerant of penicillamine

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Wilson's disease AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cystadrops PA

**Drug Name(s)**

Cystadrops

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., ophthalmologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Cystaran PA

**Drug Name(s)**

Cystaran

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., ophthalmologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cystinosis Agents PA – Cystagon

**Drug Name(s)**

Cystagon

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of nephropathic cystinosis AND
2. Prescriber has performed a baseline white blood cell (WBC) cystine level test AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of nephropathic cystinosis AND
3. Patient has had clinical benefit with the requested agent (e.g., decrease in WBC cystine levels from baseline) AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Cystinosis Agents PA – Procysbi

**Drug Name(s)**

Procysbi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of nephropathic cystinosis AND
2. Prescriber has performed a baseline white blood cell (WBC) cystine level test AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of nephropathic cystinosis AND
3. Patient has had clinical benefit with the requested agent (e.g., decrease in WBC cystine levels from baseline) AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Dalfampridine PA

**Drug Name(s)**

Ampyra

Dalfampridine Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of multiple sclerosis (MS)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of multiple sclerosis (MS) AND
3. Patient has had improvements or stabilization from baseline in timed walking speed (timed 25-foot walk)

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Daybue PA

**Drug Name(s)**

Daybue

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of Rett syndrome (RTT) with genetic analysis confirming mutation in the MECP2 gene

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Rett syndrome (RTT) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, neurologist, pediatrician) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Dayvigo PA

**Drug Name(s)**

Dayvigo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Deferiprone PA

**Drug Name(s)**

Deferiprone

Ferriprox

Ferriprox Twice-A-Day

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias AND
2. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferasirox) for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent for the requested indication

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Deflazacort PA

**Drug Name(s)**

Deflazacort

Emflaza

Jaythari

Kymbee

Pyquvi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of Duchenne muscular dystrophy (DMD) confirmed by ONE of the following:
  - A. Presence of abnormal dystrophin OR
  - B. Confirmed mutation of the dystrophin gene AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Duchenne muscular dystrophy (DMD) AND
3. Patient has had improvement, stabilization of the disease, or clinical benefit from baseline (e.g., slowed disease progression, improved strength and timed motor function, improved pulmonary function, reduced the need for scoliosis surgery) AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Dichlorphenamide PA

**Drug Name(s)**

Dichlorphenamide

Keveyis

Ormalvi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, or a related variant

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Doptelet Capsule PA

**Drug Name(s)**

Doptelet Cap

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND
2. ONE of the following:
  - A. Patient has tried and had an insufficient response to a corticosteroid, another thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
  - B. Patient has an intolerance or hypersensitivity to a corticosteroid, another thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
  - C. Patient has an FDA labeled contraindication to a corticosteroid, another thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
  - D. Patient has had an insufficient response to a splenectomy AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
  - A. Patient's platelet count is  $50 \times 10^9/L$  or greater OR
  - B. Patient's platelet count has increased sufficiently to avoid clinically significant bleeding AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Doptelet PA

**Drug Name(s)**

Doptelet Tab

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of thrombocytopenia AND ALL of the following:

- i. Patient has chronic liver disease AND
- ii. Patient has a platelet count less than  $50 \times 10^9/L$  AND
- iii. Patient is scheduled to undergo a procedure with an associated risk of bleeding (e.g., gastrointestinal endoscopy, liver biopsy, bronchoscopy, dental procedure) AND
- iv. The length of therapy of the requested agent is within the FDA labeled duration for the requested indication OR

B. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:

- i. Patient has tried and had an insufficient response to a corticosteroid, another thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
- ii. Patient has an intolerance or hypersensitivity to a corticosteroid, another thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
- iii. Patient has an FDA labeled contraindication to a corticosteroid, another thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
- iv. Patient has had an insufficient response to a splenectomy AND

2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Initial (I) 6 mo ITP, Renewal (R) 12 mo ITP. I & R 1 mo thrombocytopenia w/chronic liver disease

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of thrombocytopenia AND ALL of the following:

- i. Patient has chronic liver disease AND
- ii. Patient has a platelet count less than  $50 \times 10^9/L$  AND

- iii. Patient is scheduled to undergo a procedure with an associated risk of bleeding (e.g., gastrointestinal endoscopy, liver biopsy, bronchoscopy, dental procedure) AND
  - iv. The length of therapy of the requested agent is within the FDA labeled duration for the requested indication OR
- B. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
- i. Patient's platelet count is  $50 \times 10^9/L$  or greater OR
  - ii. Patient's platelet count has increased sufficiently to avoid clinically significant bleeding AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Droxidopa PA

**Drug Name(s)**

Droxidopa

Northera

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of neurogenic orthostatic hypotension (nOH) AND
2. Prescriber has performed baseline blood pressure readings while the patient is sitting or supine (lying face up), AND also within three minutes of standing from a supine position AND
3. Patient has a decrease of at least 20 mmHg in systolic blood pressure or 10 mmHg diastolic blood pressure within three minutes after standing AND
4. Patient has persistent and consistent symptoms of neurogenic orthostatic hypotension (nOH) caused by ONE of the following:
  - A. Primary autonomic failure [Parkinson's disease (PD), multiple system atrophy, or pure autonomic failure] OR
  - B. Dopamine beta-hydroxylase deficiency OR
  - C. Non-diabetic autonomic neuropathy AND
5. Prescriber has assessed the severity of the patient's baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like the patient may black out AND
6. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of neurogenic orthostatic hypotension (nOH) AND
3. Patient has had improvements or stabilization with the requested agent as indicated by improvement in severity from baseline symptoms of ONE of the following:
  - A. Dizziness
  - B. Lightheadedness
  - C. Feeling faint
  - D. Feeling like the patient may black out AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 1 month for initial, 3 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Dupixent PA

**Drug Name(s)**

Dupixent

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient (pt) has a diagnosis of moderate-to-severe atopic dermatitis AND ALL of the following:

i. ONE of the following:

a. Pt has tried and failed a topical steroid (e.g., triamcinolone) OR

b. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to a topical steroid AND

ii. For pts 2 years of age or over, ONE of the following:

a. Pt has tried and failed a topical calcineurin inhibitor (e.g., tacrolimus) OR

b. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to a topical calcineurin inhibitor AND

iii. Pt will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication OR

B. Pt has a diagnosis of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma AND BOTH of the following:

i. Pt is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent AND

ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR

C. Pt has a diagnosis of bullous pemphigoid (BP) OR

D. Pt has a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) AND the following:

i. BOTH of the following:

a. ONE of the following:

1. Pt has tried and had an inadequate response to an oral systemic corticosteroid AND an intranasal corticosteroid (e.g., fluticasone) OR

2. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to an oral systemic corticosteroid AND an intranasal corticosteroid AND

b. Pt will continue standard maintenance therapy (e.g., intranasal corticosteroid) in combination with the requested agent OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

For diagnosis (dx) of moderate-to-severe atopic dermatitis, pt is 6 months of age or over. For dx of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma, pt is 6 years of age or over. For dx of CRSwNP OR CSU, pt is 12 years of age or over. For dx of EoE, pt is 1 year of age or over. For dx of PN or BP, pt is 18 years of age or over. For dx of COPD with an eosinophilic phenotype, pt is 18 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist, gastroenterologist, otolaryngologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- E. Pt has a diagnosis of eosinophilic esophagitis (EoE) confirmed by esophageal biopsy OR
- F. Pt has a diagnosis of prurigo nodularis (PN) OR
- G. Pt has a diagnosis of chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype AND BOTH of the following:
  - i. Pt is currently being treated with AND will continue COPD control therapy (e.g., ICS, LABA, LAMA) in combination with the requested agent AND
  - ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
- H. Pt has a diagnosis of chronic spontaneous urticaria (CSU) AND BOTH of the following:
  - i. Pt has had over 6 weeks of hives and itching AND
  - ii. ONE of the following:
    - a. Pt has tried and had an inadequate response to a maximum tolerable H1 antihistamine therapy OR
    - b. Pt has an intolerance, hypersensitivity, or an FDA labeled contraindication to a maximum tolerable H1 antihistamine therapy

Criteria for renewal approval require ALL of the following:

1. Pt has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Pt has a diagnosis of moderate-to-severe atopic dermatitis AND the following:
    - i. Pt will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication OR
  - B. Pt has a diagnosis of moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependent asthma AND BOTH of the following:
    - i. Pt is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent AND
    - ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
  - C. Pt has a diagnosis of bullous pemphigoid (BP) OR

- D. Pt has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND the following:
    - i. Pt will continue standard maintenance therapy (e.g., intranasal corticosteroid) in combination with the requested agent OR
  - E. Pt has a diagnosis of eosinophilic esophagitis (EoE) OR
  - F. Pt has a diagnosis of prurigo nodularis (PN) OR
  - G. Pt has a diagnosis of chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype AND BOTH of the following:
    - i. Pt is currently being treated with AND will continue COPD control therapy (e.g., ICS, LABA, LAMA) in combination with the requested agent AND
    - ii. Pt will NOT be using the requested agent in combination with Xolair or with an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication OR
  - H. Pt has a diagnosis of chronic spontaneous urticaria (CSU) AND
3. Pt has had clinical benefit with the requested agent



**Prior Authorization Group Description:**

Duvyzat PA

**Drug Name(s)**

Duvyzat

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of Duchenne muscular dystrophy (DMD) confirmed by ONE of the following:
  - A. Presence of abnormal dystrophin OR
  - B. Confirmed mutation of the dystrophin gene

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Duchenne muscular dystrophy (DMD) AND
3. Patient has had improvement, stabilization of the disease, or clinical benefit from baseline (e.g., slowed disease progression, improved strength and timed motor function, improved pulmonary function, reduced the need for scoliosis surgery)

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ebglyss PA

**Drug Name(s)**

Ebglyss

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of moderate-to-severe atopic dermatitis AND BOTH of the following:
  - A. ONE of the following:
    - i. Patient has tried and failed a topical steroid (e.g., triamcinolone) OR
    - ii. Patient has an intolerance or hypersensitivity to a topical steroid OR
    - iii. Patient has an FDA labeled contraindication to a topical steroid AND
  - B. ONE of the following:
    - i. Patient has tried and failed a topical calcineurin inhibitor (e.g., tacrolimus) OR
    - ii. Patient has an intolerance or hypersensitivity to a topical calcineurin inhibitor OR
    - iii. Patient has an FDA labeled contraindication to a topical calcineurin inhibitor AND
2. Patient will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of moderate-to-severe atopic dermatitis AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another biologic agent or a JAK inhibitor for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Edaravone PA

**Drug Name(s)**

Edaravone

Radicava

Radicava Ors

Radicava Ors Starter Kit

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of amyotrophic lateral sclerosis (ALS) [also known as Lou Gehrig's disease]  
AND
2. ALL of the following:
  - A. Patient is able to perform most activities of daily living AND
  - B. Patient has had the diagnosis of amyotrophic lateral sclerosis (ALS) for a duration of 2 years or less AND
  - C. Patient has a baseline percent predicted forced vital capacity (FVC) or slow vital capacity (SVC) of 80% or greater AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of amyotrophic lateral sclerosis (ALS) [also known as Lou Gehrig's disease]  
AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Elmiron PA

**Drug Name(s)**

Elmiron

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. The requested agent will be used for the relief of bladder pain or discomfort associated with interstitial cystitis AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent will be used for the relief of bladder pain or discomfort associated with interstitial cystitis AND
3. Patient has had clinical benefit with the requested agent (e.g., decreased bladder pain, decreased frequency or urgency of urination) AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Emgality PA

**Drug Name(s)**

Emgality

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
  - A. Patient has a diagnosis of migraine AND ALL of the following:
    - i. The requested agent is being used for migraine prophylaxis AND
    - ii. Patient has 4 or more migraine headache days per month AND
    - iii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis OR
  - B. Patient has a diagnosis of episodic cluster headache AND BOTH of the following:
    - i. Patient has had at least 5 cluster headache attacks AND
    - ii. Patient has had at least two cluster periods lasting 7 days to one year and separated by pain-free remission periods of 3 months or more

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. ALL of the following:
    - i. Patient has a diagnosis of migraine AND
    - ii. The requested agent is being used for migraine prophylaxis AND
    - iii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis OR
  - B. Patient has a diagnosis of episodic cluster headache AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Empaveli PA

**Drug Name(s)**

Empaveli

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as confirmed by flow cytometry with at least 2 independent flow cytometry reagents on at least 2 cell lineages (e.g., RBCs and WBCs) demonstrating that the patient's peripheral blood cells are deficient in glycosylphosphatidylinositol (GPI) – linked proteins OR

B. ALL of the following:

i. Patient has a diagnosis of complement 3 glomerulopathy (C3G) confirmed by kidney biopsy AND

ii. The requested agent will be used to reduce proteinuria AND

iii. ONE of the following:

a. Patient has a urine protein to creatinine ratio (UPCR) greater than or equal to 0.8 g/g OR

b. Patient has a proteinuria greater than or equal to 1 g/day AND

iv. ONE of the following:

a. Patient has tried and had an inadequate response with a maximally tolerated angiotensin-converting-enzyme inhibitor (ACEI) [e.g., benazepril, lisinopril], or angiotensin II blocker (ARB) [e.g., losartan], or a combination medication containing an ACEI or ARB OR

b. Patient has an intolerance or hypersensitivity to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR

c. Patient has an FDA labeled contraindication to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hematologist, nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. ALL of the following:

- i. Patient has a diagnosis of primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) confirmed by kidney biopsy AND
- ii. The requested agent will be used to reduce proteinuria AND
- iii. ONE of the following:
  - a. Patient has a urine protein-to-creatinine ratio (UPCR) greater than 0.8 g/g OR
  - b. Patient has proteinuria greater than 1 g/day AND
- iv. ONE of the following:
  - a. Patient has tried and had an inadequate response with a maximally tolerated angiotensin-converting-enzyme inhibitor (ACEI) [e.g., benazepril, lisinopril], or angiotensin II blocker (ARB) [e.g., losartan], or a combination medication containing an ACEI or ARB OR
  - b. Patient has an intolerance or hypersensitivity to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR
  - c. Patient has an FDA labeled contraindication to an ACEI or ARB, or a combination medication containing an ACEI or ARB

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
  - A. Patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) OR
  - B. BOTH of the following:
    - i. Patient has a diagnosis of complement 3 glomerulopathy (C3G) AND
    - ii. The requested agent will be used to reduce proteinuria OR
  - C. BOTH of the following:
    - i. Patient has a diagnosis of primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) AND
    - ii. The requested agent will be used to reduce proteinuria AND
- 3. Patient has had clinical benefit with the requested agent

Drug is also subject to Part B versus Part D review.

**Prior Authorization Group Description:**

Emsam PA

**Drug Name(s)**

Emsam

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of major depressive disorder (MDD) OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

- A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- B. Prescriber states the patient is currently being treated with the requested agent OR
- C. BOTH of the following:
  - i. ONE of the following:
    - a. BOTH of the following:
      - i. Patient has a diagnosis of major depressive disorder (MDD) AND
      - ii. ONE of the following:
        - 1. Patient has tried and had an inadequate response to at least two different oral antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), mirtazapine, bupropion) OR
        - 2. Patient has an intolerance or hypersensitivity to at least two different oral antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), mirtazapine, bupropion) OR
        - 3. Patient has an FDA labeled contraindication to at least two different oral antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), mirtazapine, bupropion) OR
      - b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
    - ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:



1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of major depressive disorder (MDD) OR
  - B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Prior Authorization Group Description:**

Enoby PA

**Drug Name(s)**

Enoby

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications

**Off-Label Uses:**

Osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR
  - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
  - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
  - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
  - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
  - iii. Pt's diagnosis was confirmed by ONE of:
    - 1. A fragility fracture in the hip or spine OR
    - 2. A T-score of -2.5 or lower OR
    - 3. A T-score of -1.0 to -2.5 AND ONE of:
      - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
    - iv. ONE of:
      - 1. Pt is at high fracture risk as defined by ONE of:
        - a. Pt had a recent fracture (within the past 12 months) OR

- b. Pt had fractures while on FDA approved osteoporosis therapy OR
- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqcg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Enspryng PA

**Drug Name(s)**

Enspryng

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) AND
2. Patient is anti-aquaporin-4 (AQP4) antibody positive AND
3. Prescriber has screened the patient for hepatitis B viral (HBV) infection and determined to NOT have active hepatitis B viral infection AND
4. Patient does NOT have active or untreated tuberculosis AND
5. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) AND
3. Patient has had clinical benefit with the requested agent (e.g., decreased relapses, improvement or stabilization of vision or paralysis) AND
4. Patient does NOT have active hepatitis B virus (HBV) infection AND
5. Patient does NOT have active or untreated tuberculosis AND
6. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Eohilia PA

**Drug Name(s)**

Eohilia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of eosinophilic esophagitis (EoE) confirmed by esophageal biopsy AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, gastroenterologist, immunologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 3 months

**Other Criteria:**

**Prior Authorization Group Description:**

Epclusa PA

**Drug Name(s)**

Epclusa

Sofosbuvir/Velpatasvir

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of hepatitis C confirmed by serological markers OR
  - B. Patient is a hepatitis C virus (HCV) - uninfected solid organ transplant recipient AND BOTH of the following:
    - i. Patient received an HCV - viremic donor organ AND
    - ii. The requested agent is being used for prophylaxis AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication AND
5. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - C. Patient has an FDA labeled contraindication or hypersensitivity to the preferred agent: Mavyret for supported genotypes OR
  - D. Prescriber has provided information based on FDA approved labeling or AASLD/IDSA guidelines supporting the use of the non-preferred agent for the patient's diagnosis and genotype over the preferred agent: Mavyret for supported genotypes

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Epidiolex PA

**Drug Name(s)**

Epidiolex

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of seizures associated with ONE of the following:

- A. Lennox-Gastaut syndrome OR
- B. Dravet syndrome OR
- C. Tuberous sclerosis complex AND

2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Ergomar PA

**Drug Name(s)**

Ergomar

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. The requested agent will be used to abort or prevent vascular headache (e.g., migraine, migraine variants, or so-called "histaminic cephalalgia") AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to TWO triptan agents with differing active ingredients (e.g., sumatriptan, rizatriptan) OR
  - B. Patient has an intolerance or hypersensitivity to a triptan agent OR
  - C. Patient has an FDA labeled contraindication to a triptan agent AND
3. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent will be used to abort or prevent vascular headache (e.g., migraine, migraine variants, or so-called "histaminic cephalalgia") AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Erythropoietin Stimulating Agents PA – Aranesp

**Drug Name(s)**

Aranesp Albumin Free

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent is being prescribed for ONE of the following:

A. Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy AND ALL of the following:

- i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR less than 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND
- ii. Patient is being concurrently treated with chemotherapy with or without radiation (there must be a minimum of 2 additional months of planned chemotherapy) AND
- iii. The intent of chemotherapy is non-curative OR

B. Anemia associated with chronic kidney disease in a patient NOT on dialysis AND ALL of the following:

- i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR 11 g/dL or less for patients stabilized on therapy (measured within the previous 4 weeks) AND
- ii. The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion AND
- iii. The intent of therapy is to reduce the risk of alloimmunization and/or other RBC transfusion related risks OR

C. Anemia due to myelodysplastic syndrome AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

D. Another indication that is supported in CMS approved compendia for the requested agent AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

2. Patient's transferrin saturation and serum ferritin have been evaluated

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for chemotherapy, 12 months for other indications

**Other Criteria:**

**Prior Authorization Group Description:**

Erythropoietin Stimulating Agents PA - Epogen/Procrit

**Drug Name(s)**

Epogen

Procrit

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent is being prescribed for ONE of the following:

A. To reduce the possibility of allogeneic blood transfusion in a surgery patient AND the patient's hemoglobin level is greater than 10 g/dL but less than or equal to 13 g/dL OR

B. Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR less than 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. Patient is being concurrently treated with chemotherapy with or without radiation (there must be a minimum of 2 additional months of planned chemotherapy) AND

iii. The intent of chemotherapy is non-curative OR

C. Anemia associated with chronic kidney disease in a patient NOT on dialysis AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR 11 g/dL or less for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion AND

iii. The intent of therapy is to reduce the risk of alloimmunization and/or other RBC transfusion related risks OR

D. Anemia due to myelodysplastic syndrome AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

E. Anemia resulting from zidovudine treatment of HIV infection AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

1 month for surgery (reduce transfusion possibility), 6 months for chemo, 12 months for other

**Other Criteria:**

F. Another indication that is supported in CMS approved compendia for the requested agent  
AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR  
less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4  
weeks) AND

2. Patient's transferrin saturation and serum ferritin have been evaluated

Drug is also subject to Part B versus Part D review.

**Prior Authorization Group Description:**

Erythropoietin Stimulating Agents PA – Mircera

**Drug Name(s)**

Mircera

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent is being prescribed for ONE of the following:

A. Anemia associated with chronic kidney disease in a patient NOT on dialysis AND ALL of the following:

- i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR 11 g/dL or less for patients stabilized on therapy (measured within the previous 4 weeks) AND
- ii. The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion AND
- iii. The intent of therapy is to reduce the risk of alloimmunization and/or other RBC transfusion related risks OR

B. Another indication that is supported in CMS approved compendia for the requested agent AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

2. Patient's transferrin saturation and serum ferritin have been evaluated

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Erythropoietin Stimulating Agents PA – Retacrit

**Drug Name(s)**

Retacrit

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent is being prescribed for ONE of the following:

A. To reduce the possibility of allogeneic blood transfusion in a surgery patient AND the patient's hemoglobin level is greater than 10 g/dL but less than or equal to 13 g/dL OR

B. Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR less than 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. Patient is being concurrently treated with chemotherapy with or without radiation (there must be a minimum of 2 additional months of planned chemotherapy) AND

iii. The intent of chemotherapy is non-curative OR

C. Anemia associated with chronic kidney disease in a patient NOT on dialysis AND ALL of the following:

i. Patient's hemoglobin level is less than 10 g/dL for patients initiating ESA therapy OR 11 g/dL or less for patients stabilized on therapy (measured within the previous 4 weeks) AND

ii. The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion AND

iii. The intent of therapy is to reduce the risk of alloimmunization and/or other RBC transfusion related risks OR

D. Anemia resulting from zidovudine treatment of HIV infection AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) OR

E. Another indication that is supported in CMS approved compendia for the requested agent AND the patient's hemoglobin level is less than 12 g/dL for patients initiating ESA therapy OR less than or equal to 12 g/dL for patients stabilized on therapy (measured within the previous 4 weeks) AND

2. Patient's transferrin saturation and serum ferritin have been evaluated

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

1 month for surgery (reduce transfusion possibility), 6 months for chemo, 12 months for other  
**Other Criteria:**

**Prior Authorization Group Description:**

Evenity PA

**Drug Name(s)**

Evenity

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient is postmenopausal with a diagnosis of osteoporosis AND BOTH of the following:

A. Patient's diagnosis was confirmed by ONE of the following:

i. A fragility fracture in the hip or spine OR

ii. A T-score of -2.5 or lower OR

iii. A T-score of -1.0 to -2.5 AND ONE of the following:

a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR

b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR

c. A FRAX 10-year probability of hip fracture of 3% or greater AND

B. ONE of the following:

i. Patient is at a very high fracture risk as defined by ONE of the following:

a. Patient had a recent fracture (within the past 12 months) OR

b. Patient had fractures while on FDA approved osteoporosis therapy OR

c. Patient has had multiple fractures OR

d. Patient had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR

e. Patient has a very low T-score (less than -3.0) OR

f. Patient is at high risk for falls or has a history of injurious falls OR

g. Patient has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR

ii. ONE of the following:

a. Patient has tried and had an inadequate response to a bisphosphonate OR

b. Patient has an intolerance or hypersensitivity to a bisphosphonate OR

c. Patient has an FDA labeled contraindication to a bisphosphonate AND

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

No prior use approve 12 months, Prior use approve remainder of 12 months of total cumulative therapy

**Other Criteria:**

2. ONE of the following:



- A. Patient has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
  - B. Patient has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - C. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) AND
3. Patient will NOT be using the requested agent in combination with a bisphosphonate, denosumab (e.g., Prolia, Xgeva), or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication AND
5. The total cumulative duration of treatment with Evenity (romosozumab-aqqg) has not exceeded 12 months

**Prior Authorization Group Description:**

Evkeeza PA

**Drug Name(s)**

Evkeeza

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
2. Patient's diagnosis was confirmed by ONE of the following:
  - A. Genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes or greater than or equal to 2 such variants at different loci OR
  - B. History of untreated LDL-C greater than 400 mg/dL (greater than 10 mmol/L) AND ONE of the following:
    - i. Patient has cutaneous or tendon xanthomas before the age of 10 years OR
    - ii. Untreated elevated LDL-C levels consistent with heterozygous familial hypercholesterolemia (HeFH) in both parents (or in digenic form, one parent may have normal LDL-C levels and the other may have LDL-C levels consistent with HoFH) AND
3. ONE of the following:
  - A. Patient is currently being treated with a lipid-lowering regimen in the past 90 days (i.e., rosuvastatin in combination with ezetimibe, atorvastatin in combination with ezetimibe, OR PCSK9) OR
  - B. Patient has an intolerance or hypersensitivity to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe, atorvastatin in combination with ezetimibe, OR PCSK9) OR
  - C. Patient has an FDA labeled contraindication to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe, atorvastatin in combination with ezetimibe, OR PCSK9) AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, endocrinologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
3. Patient has had clinical benefit with the requested agent AND
4. ONE of the following:

- A. Patient is currently being treated with a lipid-lowering regimen in the past 90 days (i.e., rosuvastatin in combination with ezetimibe, atorvastatin in combination with ezetimibe, OR PCSK9) OR
  - B. Patient has an intolerance or hypersensitivity to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe, atorvastatin in combination with ezetimibe, OR PCSK9) OR
  - C. Patient has an FDA labeled contraindication to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe, atorvastatin in combination with ezetimibe, OR PCSK9) AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Evrysdi PA

**Drug Name(s)**

Evrysdi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of Spinal Muscular Atrophy (SMA) AND
2. Patient has a deletion or mutation at the survival motor neuron 1 (SMN1) gene on chromosome 5q confirmed by genetic testing

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Spinal Muscular Atrophy (SMA) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Eysuvis PA

**Drug Name(s)**

Eysuvis

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of dry eye disease AND
2. The requested agent will be used for short-term (up to two weeks) treatment AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 1 month

**Other Criteria:**

**Prior Authorization Group Description:**

Fabhalta PA

**Drug Name(s)**

Fabhalta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) OR

B. ALL of the following:

i. Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy AND

ii. The requested agent will be used to reduce proteinuria AND

iii. Patient is at risk of rapid disease progression as shown by ONE of the following:

a. A urine protein to creatinine ratio (UPCR) greater than or equal to 0.44 g/g OR

b. Proteinuria greater than or equal to 0.5 g/day AND

iv. ONE of the following:

a. Patient has tried and had an inadequate response with a maximally tolerated angiotensin-converting-enzyme inhibitor (ACEI) [e.g., benazepril, lisinopril], or angiotensin II blocker (ARB) [e.g., losartan], or a combination medication containing an ACEI or ARB OR

b. Patient has an intolerance or hypersensitivity to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR

c. Patient has an FDA labeled contraindication to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR

C. ALL of the following:

i. Patient has a diagnosis of complement 3 glomerulopathy (C3G) confirmed by kidney biopsy AND

ii. The requested agent will be used to reduce proteinuria AND

iii. ONE of the following:

a. Patient has a urine protein to creatinine ratio (UPCR) greater than or equal to 0.8 g/g OR

b. Patient has a proteinuria greater than or equal to 1 g/day AND

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hematologist, nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- iv. ONE of the following:
  - a. Patient has tried and had an inadequate response with a maximally tolerated angiotensin-converting-enzyme inhibitor (ACEI) [e.g., benazepril, lisinopril], or angiotensin II blocker (ARB) [e.g., losartan], or a combination medication containing an ACEI or ARB OR
  - b. Patient has an intolerance or hypersensitivity to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR
  - c. Patient has an FDA labeled contraindication to an ACEI or ARB, or a combination medication containing an ACEI or ARB

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
  - A. Patient has a diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH) OR
  - B. BOTH of the following:
    - i. Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN) AND
    - ii. The requested agent will be used to reduce proteinuria OR
  - C. BOTH of the following:
    - i. Patient has a diagnosis of complement 3 glomerulopathy (C3G) AND
    - ii. The requested agent will be used to reduce proteinuria AND
- 3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Fasenra PA

**Drug Name(s)**

Fasenra

Fasenra Pen

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of severe asthma with an eosinophilic phenotype AND the following:
    - i. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR
  - B. Patient has a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) AND the following:
    - i. ONE of the following:
      - a. Patient is currently being treated with a maximally tolerated oral corticosteroid OR
      - b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an oral corticosteroid AND
2. Patient will NOT be using the requested agent in combination with Xolair, Dupixent, or with another injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Nucala) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of severe asthma with an eosinophilic phenotype AND the following:
    - i. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR
  - B. Patient has a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) AND the following:
    - i. ONE of the following:
      - a. Patient is currently being treated with maintenance therapy with oral corticosteroid OR
      - b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to oral corticosteroid AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with Xolair, Dupixent, or with another injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Nucala) for the requested indication

**Age Restriction:**



For diagnosis of severe asthma with an eosinophilic phenotype, patient is 6 years of age or over. For diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), patient is 18 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist, otolaryngologist, pulmonologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Fentanyl Oral PA - Fentanyl lozenge

**Drug Name(s)**

Fentanyl Citrate Oral Transmucosal

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. ONE of the following:

a. Patient has a documented diagnosis (i.e., medical records) of chronic cancer pain due to an active malignancy AND BOTH of the following:

i. Prescriber has provided the patient's type of cancer AND

ii. There is evidence of a claim that the patient is currently being treated with a long-acting opioid with the requested agent within the past 90 days OR

b. Patient has a diagnosis that is supported in CMS approved compendia for the requested agent AND

2. Patient will NOT be using the requested agent in combination with any other oral fentanyl agent

**Age Restriction:**

Patient is 16 years of age or over

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Filspari PA

**Drug Name(s)**

Filspari

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy AND
2. The requested agent will be used to slow kidney function decline AND
3. Patient is at risk of disease progression as shown by ONE of the following:
  - A. A urine protein-to-creatinine ratio (UPCR) greater than or equal to 0.44 g/g OR
  - B. Proteinuria greater than or equal to 0.5 g/day AND
4. ONE of the following:
  - A. Patient has tried and had an inadequate response with a maximally tolerated angiotensin-converting-enzyme inhibitor (ACEI) [e.g., benazepril, lisinopril], or angiotensin II blocker (ARB) [e.g., losartan], or a combination medication containing an ACEI or ARB OR
  - B. Patient has an intolerance or hypersensitivity to an ACEI or ARB, or a combination medication containing an ACEI or ARB, that is not expected to occur with the requested agent OR
  - C. Patient has an FDA labeled contraindication to an ACEI or ARB, or a combination medication containing an ACEI or ARB, that is not expected to occur with the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN) AND
3. The requested agent will be used to slow kidney function decline AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Filsuvez PA

**Drug Name(s)**

Filsuvez

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. The requested agent will be used for the treatment of wounds associated with dystrophic or junctional epidermolysis bullosa AND
2. Patient's diagnosis was confirmed by ONE of the following:
  - A. Immunofluorescence mapping (IFM) OR
  - B. Transmission electron microscopy (TEM) OR
  - C. Genetic testing AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent will be used for the treatment of wounds associated with dystrophic or junctional epidermolysis bullosa AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Fintepla PA

**Drug Name(s)**

Fintepla

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of seizures associated with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. ALL of the following:
    - i. An echocardiogram assessment will be obtained before and during treatment with the requested agent, to evaluate for valvular heart disease and pulmonary arterial hypertension AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
    - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Firdapse PA

**Drug Name(s)**

Firdapse

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) confirmed by at least ONE of the following:
  - A. Neurophysiology study (e.g., nerve conduction studies [CMAP], EMG, repetitive stimulation)
  - OR
  - B. Anti-P/Q-type voltage-gated calcium channels (VGCC) antibody testing

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Flucytosine PA

**Drug Name(s)**

Ancobon

Flucytosine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. The requested agent will be used in combination with amphotericin B OR
  - B. Prescriber has provided information in support of therapy without concurrent amphotericin B for the requested indication AND
3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 10 weeks

**Other Criteria:**

**Prior Authorization Group Description:**

Focalin PA

**Drug Name(s)**

Dexmethylphenidate Hcl (Focalin)

Focalin

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Focalin XR PA

**Drug Name(s)**

Dexmethylphenidate Hcl Er (Focalin Xr)

Focalin Xr

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Galafold PA

**Drug Name(s)**

Galafold

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Fabry disease AND
2. The diagnosis was confirmed by mutation of alpha-galactosidase A (alpha-gal A) gene AND
3. Patient has an amenable galactosidase alpha gene (GLA) variant mutation

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Fabry disease AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Gammagard/Gammaked/Gamunex-C PA

**Drug Name(s)**

Gammagard Liquid Erc

Gammagard Liquid

Gammaked

Gamunex-C

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

- A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR
- B. B-cell chronic lymphocytic leukemia OR multiple myeloma AND ONE of the following:
  - i. Patient has a history of infections OR
  - ii. Patient has evidence of specific antibody deficiency OR
  - iii. Patient has hypogammaglobulinemia OR
- C. Idiopathic thrombocytopenia purpura AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone), or immunosuppressants (e.g., mycophenolate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- D. Dermatomyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- E. Polymyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- F. Severe rheumatoid arthritis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., tumor necrosis factor antagonists (e.g., Enbrel), DMARDS (e.g., methotrexate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

Criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 6 months for indications in Other Criteria, 12 months for all others

**Other Criteria:**

G. Myasthenia gravis (MG) AND ONE of the following:

- i. Patient is in acute myasthenic crisis OR
- ii. Patient has severe refractory MG (e.g., major functional disability/weakness) AND ONE of the following:
  - a) Patient has failed ONE immunomodulator therapy (i.e., corticosteroid, pyridostigmine, or azathioprine) OR
  - b) Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE immunomodulator therapy OR

H. Multiple sclerosis (MS) AND BOTH of the following:

- i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND
- ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication to TWO MS agents (e.g., Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Plegridy, teriflunomide, Vumerity) OR

I. Acquired von Willebrand hemophilia AND ONE of the following:

- i. Patient has failed ONE conventional therapy (e.g., desmopressin, von Willebrand factor replacement therapy, corticosteroids, FEIBA, or recombinant factor VIIa) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

J. Refractory pemphigus vulgaris AND ONE of the following:

- i. Patient has failed ONE conventional immunosuppressive therapy (e.g., azathioprine, cyclophosphamide, mycophenolate, corticosteroids) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional immunosuppressive therapy OR

2. ONE of the following:

- A. Patient has another FDA labeled indication for the requested agent OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Indications with 6 months approval duration: Acquired von Willebrand hemophilia, Guillain-Barre Syndrome, Lambert-Eaton myasthenia syndrome, Kawasaki disease, CMV induced pneumonitis in solid organ transplant, Toxic shock syndrome due to invasive group A streptococcus, Toxic epidermal necrolysis and Stevens-Johnson syndrome

Drug is also subject to Part B versus Part D review.

**Prior Authorization Group Description:**

Gattex PA

**Drug Name(s)**

Gattex

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of short bowel syndrome (SBS) AND
2. Patient is dependent on parenteral nutrition OR intravenous (PN/IV) fluids AND
3. ONE of the following:
  - A. Patient is aged 1 year to 17 years AND BOTH of the following:
    - i. A fecal occult blood test has been performed within 6 months prior to initiating treatment with the requested agent AND
    - ii. ONE of the following:
      - a. There was no unexplained blood in the stool OR
      - b. There was unexplained blood in the stool AND a colonoscopy or a sigmoidoscopy was performed OR
  - B. Patient is 18 years of age or over AND BOTH of the following:
    - i. Patient has had a colonoscopy within 6 months prior to initiating treatment with the requested agent AND
    - ii. If polyps were present at this colonoscopy, the polyps were removed AND
4. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of short bowel syndrome (SBS) AND
3. Patient has had clinical benefit with the requested agent [e.g., a reduction from baseline in parenteral nutrition OR intravenous (PN/IV) fluids] AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Gaucher Enzyme Replacement PA – Cerezyme

**Drug Name(s)**

Cerezyme

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) or type 3 (GD3) confirmed by ONE of the following:
  - A. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of glucocerebrosidase (GBA) gene with two disease-causing alleles AND
2. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) or type 3 (GD3) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, hepatologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Gaucher Enzyme Replacement PA – Elelyso

**Drug Name(s)**

Elelyso

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - A. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of glucocerebrosidase (GBA) gene with two disease-causing alleles AND
2. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, hepatologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Gaucher Enzyme Replacement PA – Vpriv

**Drug Name(s)**

Vpriv

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - A. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of glucocerebrosidase (GBA) gene with two disease-causing alleles AND
2. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as a platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, hepatologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Gauze Pads PA

**Drug Name(s)**

Gauze Pads

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Gralise PA

**Drug Name(s)**

Gabapentin Once-Daily

Gralise

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of Postherpetic Neuralgia (PHN) AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to immediate-release gabapentin OR
  - B. Patient has an intolerance or hypersensitivity to immediate-release gabapentin OR
  - C. Patient has an FDA labeled contraindication to immediate-release gabapentin that is not expected to occur with the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Postherpetic Neuralgia (PHN) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Growth Hormone PA – Genotropin

**Drug Name(s)**

Genotropin

Genotropin Miniquick

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of Turner Syndrome OR
- B. Patient has a diagnosis of Prader-Willi Syndrome OR
- C. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
  - i. Deficiencies in 3 or more pituitary axes AND
  - ii. Measured serum IGF-1 (insulin-like growth factor-1) levels are below the age and sex-appropriate reference range when off GH therapy OR
- D. Patient has a diagnosis of growth hormone deficiency (GHD) or short stature AND BOTH of the following:
  - i. ONE of the following:
    - a. Height more than 2 standard deviations (SD) below the mean for age and sex OR
    - b. Height more than 1.5 SD below the midparental height OR
    - c. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
    - d. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over two years AND
  - ii. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) OR
- E. Patient has a diagnosis of small for gestational age (SGA) AND ALL of the following:
  - i. Patient is at least 2 years of age AND
  - ii. Documented birth weight and/or length that is 2 or more standard deviations (SD) below the mean for gestational age AND
  - iii. At 24 months of age, the patient fails to manifest catch-up growth evidenced by a height that remains 2 or more SD below the mean for age and sex AND

2. ONE of the following:

- A. Patient has tried and failed the preferred agent [Omnitrope] OR
- B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Growth Hormone Deficiency, Short Stature OR
  - B. Panhypopituitarism OR
  - C. Prader-Willi Syndrome OR
  - D. Small for Gestational Age OR
  - E. Turner Syndrome AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Patient has a diagnosis of acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one GH stimulation test as an adult OR
  - C. Patient has a diagnosis of idiopathic GHD (adult or childhood onset) AND the patient has failed at least two growth hormone (GH) stimulation tests as an adult AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR

- C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
  4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
  5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

**Prior Authorization Group Description:**

Growth Hormone PA – Humatrope

**Drug Name(s)**

Humatrope

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of Turner Syndrome\* OR
  - B. Patient has a diagnosis of SHOX gene deficiency OR
  - C. Patient has a diagnosis of panhypopituitarism\* AND BOTH of the following:
    - i. Deficiencies in 3 or more pituitary axes AND
    - ii. Measured serum IGF-1 (insulin-like growth factor-1) levels are below the age and sex-appropriate reference range when off GH therapy OR
  - D. Patient has a diagnosis of growth hormone deficiency (GHD)\* or short stature\* AND BOTH of the following:
    - i. ONE of the following:
      - a. Height more than 2 standard deviation (SD) below the mean for age and sex OR
      - b. Height more than 1.5 SD below the midparental height OR
      - c. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
      - d. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over 2 years AND
    - ii. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - E. Patient has a diagnosis of small for gestational age\* AND ALL of the following:
    - i. Patient is at least 2 years of age AND
    - ii. Documented birth weight and/or length that is 2 or more SD below the mean for gestational age AND
    - iii. At 24 months of age, the patient fails to manifest catch-up growth evidenced by a height that remains 2 or more SD below the mean for age and sex AND
2. Patient's diagnosis is indicated in the preferred GH agent AND ONE of the following:
- A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

**NOTE:**

\*Use of the preferred agent [Omnitrope] is required

NO prerequisites are required for the diagnosis of SHOX gene deficiency

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Growth Hormone Deficiency, Short Stature OR
  - B. Panhypopituitarism OR
  - C. Small for Gestational Age OR
  - D. SHOX gene deficiency OR
  - E. Turner Syndrome AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Patient has a diagnosis of acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - C. Patient has a diagnosis of idiopathic GHD (adult or childhood onset) AND the patient has failed at least two GH stimulation tests as an adult AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR
  - C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)



**Prior Authorization Group Description:**

Growth Hormone PA – Ngenla

**Drug Name(s)**

Ngenla

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of growth hormone deficiency (GHD), short stature, or growth failure due to inadequate secretion of endogenous growth hormone AND BOTH of the following:
  - A. ONE of the following:
    - i. Height more than 2 standard deviations (SD) below the mean for age and sex OR
    - ii. Height more than 1.5 SD below the midparental height OR
    - iii. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
    - iv. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over two years AND
  - B. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of growth hormone deficiency (GHD), short stature, or growth failure due to inadequate secretion of endogenous growth hormone AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Growth Hormone PA – Norditropin

**Drug Name(s)**

Norditropin Flexpro

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of Turner Syndrome\* OR
  - B. Patient has a diagnosis of Prader-Willi Syndrome\* OR
  - C. Patient has a diagnosis of Noonan Syndrome OR
  - D. Patient has a diagnosis of panhypopituitarism\* AND BOTH of the following:
    - i. Deficiencies in 3 or more pituitary axes AND
    - ii. Measured serum IGF-1 (insulin-like growth factor-1) levels are below the age and sex-appropriate reference range when off GH therapy OR
  - E. Patient has a diagnosis of growth hormone deficiency (GHD)\* or short stature\* AND BOTH of the following:
    - i. ONE of the following:
      - a. Height more than 2 standard deviations (SD) below the mean for age and sex OR
      - b. Height more than 1.5 SD below the midparental height OR
      - c. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
      - d. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over 2 years AND
    - ii. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - F. Patient has a diagnosis of small for gestational age\* AND ALL of the following:
    - i. Patient is at least 2 years of age AND
    - ii. Documented birth weight and/or length that is 2 or more SD below the mean for gestational age AND
    - iii. At 24 months of age, the patient fails to manifest catch-up growth evidenced by a height that remains 2 or more SD below the mean for age and sex AND
2. Patient's diagnosis is indicated in the preferred GH agent AND ONE of the following:
- A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

**NOTE:**

\*Use of the preferred agent [Omnitrope] is required

NO prerequisites are required for the diagnosis of Noonan Syndrome

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Growth Hormone Deficiency (GHD), Short Stature OR
  - B. Noonan Syndrome OR
  - C. Panhypopituitarism OR
  - D. Small for Gestational Age OR
  - E. Turner Syndrome OR
  - F. Prader-Willi Syndrome AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of childhood GHD with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Patient has a diagnosis of acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - C. Patient has a diagnosis of idiopathic GHD (adult or childhood onset) AND the patient has failed at least two GH stimulation tests as an adult AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR
  - C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

**Prior Authorization Group Description:**

Growth Hormone PA – Nutropin

**Drug Name(s)**

Nutropin Aq Nuspin

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of Turner Syndrome\* OR
- B. Patient has a diagnosis of chronic renal insufficiency AND BOTH of the following:
  - i. Height velocity (HV) is greater than or equal to 1.88 standard deviations (SD) below the mean or less than the third percentile for age and sex AND
  - ii. Other etiologies for growth impairment have been addressed OR
- C. Patient has a diagnosis of panhypopituitarism\* AND BOTH of the following:
  - i. Deficiencies in 3 or more pituitary axes AND
  - ii. Measured serum insulin-like growth factor-1 levels are below the age and sex-appropriate reference range when off GH therapy OR
- D. Patient has a diagnosis of growth hormone deficiency (GHD)\* or short stature\* AND BOTH of the following:
  - i. ONE of the following:
    - a. Height more than 2 SD below the mean for age and sex OR
    - b. Height more than 1.5 SD below the midparental height OR
    - c. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
    - d. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over 2 years AND
  - ii. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) AND

2. Patient's diagnosis is indicated in the preferred GH agent AND ONE of the following:

- A. Patient has tried and failed the preferred agent [Omnitrope] OR
- B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

**NOTE:**

\*Use of the preferred agent [Omnitrope] is required

NO prerequisites are required for the diagnosis of chronic renal insufficiency

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Growth Hormone Deficiency, Short Stature OR
  - B. Chronic renal insufficiency OR
  - C. Panhypopituitarism OR
  - D. Turner Syndrome AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Patient has a diagnosis of acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - C. Patient has a diagnosis of idiopathic GHD (adult or childhood onset) AND the patient has failed at least two growth hormone (GH) stimulation tests as an adult AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR
  - C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND

4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

**Prior Authorization Group Description:**

Growth Hormone PA – Omnitrope

**Drug Name(s)**

Omnitrope

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of Turner Syndrome OR
- B. Patient has a diagnosis of Prader-Willi Syndrome OR
- C. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
  - i. Deficiencies in 3 or more pituitary axes AND
  - ii. Measured serum IGF-1 (insulin-like growth factor-1) levels are below the age and sex-appropriate reference range when off GH therapy OR
- D. Patient has a diagnosis of growth hormone deficiency (GHD) or short stature AND BOTH of the following:
  - i. Patient has ONE of the following:
    - a. Height more than 2 standard deviations (SD) below the mean for age and sex OR
    - b. Height more than 1.5 SD below the midparental height OR
    - c. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
    - d. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over two years AND
  - ii. Failure of at least 2 growth hormone (GH) stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) OR
- E. Patient has a diagnosis of small for gestational age (SGA) AND ALL of the following:
  - i. Patient is at least 2 years of age AND
  - ii. Documented birth weight and/or length that is 2 or more SD below the mean for gestational age AND
  - iii. At 24 months of age, the patient fails to manifest catch-up growth evidenced by a height that remains 2 or more SD below the mean for age and sex

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Children – Criteria for renewal approval require ALL of the following:



1. Patient has been previously approved for the preferred agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Growth Hormone Deficiency, Short Stature OR
  - B. Panhypopituitarism OR
  - C. Prader-Willi Syndrome OR
  - D. Small for Gestational Age (SGA) OR
  - E. Turner Syndrome AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require the following:

1. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - C. Idiopathic GHD (adult or childhood onset) AND the patient has failed at least two growth hormone (GH) stimulation tests as an adult

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the preferred agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR
  - C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

**Prior Authorization Group Description:**

Growth Hormone PA – Serostim

**Drug Name(s)**

Serostim

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. The requested agent is for the treatment of an HIV patient with wasting or cachexia AND
2. BOTH of the following:
  - A. The requested agent will be used in combination with antiretroviral therapy AND
  - B. ONE of the following:
    - i. Patient has had an unintentional weight loss of 10% or more of body weight over 12 months OR
    - ii. Patient has had an unintentional weight loss of greater than 7.5% over 6 months OR
    - iii. Patient has a mid-upper arm circumference less than 10th percentile OR
    - iv. Patient has a body cell mass (BCM) loss of 5% or more over 6 months OR
    - v. Patient's sex is male, has a BCM less than 35% AND a BMI of less than 27 kg/m<sup>2</sup> OR
    - vi. Patient's sex is female, has a BCM less than 23% AND a BMI of less than 27 kg/m<sup>2</sup>

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent is for the treatment of an HIV patient with wasting or cachexia AND
3. BOTH of the following:
  - A. The requested agent will be used in combination with antiretroviral therapy AND
  - B. Patient has had clinical benefit with the requested agent (e.g., weight increase or weight stabilization)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 weeks

**Other Criteria:**

**Prior Authorization Group Description:**

Growth Hormone PA – Skytrofa

**Drug Name(s)**

Skytrofa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of growth hormone deficiency (GHD), short stature, or growth failure due to inadequate secretion of endogenous growth hormone AND BOTH of the following:
  - A. ONE of the following:
    - i. Height more than 2 standard deviations (SD) below the mean for age and sex OR
    - ii. Height more than 1.5 SD below the midparental height OR
    - iii. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
    - iv. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over two years AND
  - B. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of growth hormone deficiency (GHD), short stature, or growth failure due to inadequate secretion of endogenous growth hormone AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Adults – Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Patient has a diagnosis of acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - C. Patient has a diagnosis of idiopathic GHD (adult or childhood onset) AND the patient has failed at least two GH stimulation tests as an adult AND
2. ONE of the following:
- A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Adults – Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR
  - C. Idiopathic GHD (adult or childhood onset) AND
- 3. Patient is being monitored for adverse effects of therapy with the requested agent AND
- 4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
- 5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

**Prior Authorization Group Description:**

Growth Hormone PA – Sogroya

**Drug Name(s)**

Sogroya

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of growth hormone deficiency (GHD), short stature, or growth failure due to inadequate secretion of endogenous growth hormone AND BOTH of the following:
  - A. ONE of the following:
    - i. Height more than 2 standard deviations (SD) below the mean for age and sex OR
    - ii. Height more than 1.5 SD below the midparental height OR
    - iii. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
    - iv. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over two years AND
  - B. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of growth hormone deficiency (GHD), short stature, or growth failure due to inadequate secretion of endogenous growth hormone AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Adults – Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Patient has a diagnosis of acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - C. Patient has a diagnosis of idiopathic GHD (adult or childhood onset) AND the patient has failed at least two GH stimulation tests as an adult AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR
  - C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

**Prior Authorization Group Description:**

Growth Hormone PA – Zomacton

**Drug Name(s)**

Zomacton

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

For Children – Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of Turner Syndrome\* OR
  - B. Patient has a diagnosis of SHOX gene deficiency OR
  - C. Patient has a diagnosis of panhypopituitarism\* AND BOTH of the following:
    - i. Deficiencies in 3 or more pituitary axes AND
    - ii. Measured serum IGF-1 (insulin-like growth factor-1) levels are below the age and sex-appropriate reference range when off GH therapy OR
  - D. Patient has a diagnosis of growth hormone deficiency (GHD)\* or short stature\* AND BOTH of the following:
    - i. ONE of the following:
      - a. Height more than 2 standard deviation (SD) below the mean for age and sex OR
      - b. Height more than 1.5 SD below the midparental height OR
      - c. A decrease in height SD of more than 0.5 over one year in children at least 2 years of age OR
      - d. Height velocity more than 2 SD below the mean over one year or more than 1.5 SD sustained over 2 years AND
    - ii. Failure of at least 2 GH stimulation tests (e.g., peak GH value of less than 10 mcg/L after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - E. Patient has a diagnosis of small for gestational age\* AND ALL of the following:
    - i. Patient is at least 2 years of age AND
    - ii. Documented birth weight and/or length that is 2 or more SD below the mean for gestational age AND
    - iii. At 24 months of age, the patient fails to manifest catch-up growth evidenced by a height that remains 2 or more SD below the mean for age and sex AND
2. Patient's diagnosis is indicated in the preferred GH agent AND ONE of the following:
- A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

**NOTE:**

\*Use of the preferred agent [Omnitrope] is required

NO prerequisites are required for the diagnosis of SHOX gene deficiency

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

For Children – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has been diagnosed with ONE of the following:
  - A. Growth Hormone Deficiency, Short Stature OR
  - B. Panhypopituitarism OR
  - C. Small for Gestational Age OR
  - D. SHOX gene deficiency OR
  - E. Turner Syndrome AND
3. ALL of the following:
  - A. Patient does NOT have closed epiphyses AND
  - B. Patient is being monitored for adverse effects of therapy with the requested agent AND
  - C. Patient's height has increased or height velocity has improved since initiation or last approval of the requested agent

For Adults – Criteria for initial approval require BOTH of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of childhood growth hormone deficiency (GHD) with genetic or organic origin AND ONE of the following:
    - i. Low IGF-1 (insulin-like growth factor-1) level without GH replacement therapy OR
    - ii. Failure of at least one growth hormone (GH) stimulation test as an adult (e.g., peak GH value of 5 mcg/L or lower after stimulation, or otherwise considered abnormal as determined by testing lab) OR
  - B. Patient has a diagnosis of acquired adult GHD secondary to structural lesions or trauma AND ONE of the following:
    - i. Patient has a diagnosis of panhypopituitarism AND BOTH of the following:
      - a. Deficiencies in 3 or more pituitary axes AND
      - b. Low IGF-1 level without GH replacement therapy OR
    - ii. Patient has failed at least one growth hormone (GH) stimulation test as an adult OR
  - C. Patient has a diagnosis of idiopathic GHD (adult or childhood onset) AND the patient has failed at least two GH stimulation tests as an adult AND
2. ONE of the following:
  - A. Patient has tried and failed the preferred agent [Omnitrope] OR
  - B. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent [Omnitrope]

For Adults – Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND



2. Patient has been diagnosed with ONE of the following:
  - A. Childhood growth hormone deficiency (GHD) with genetic or organic origin OR
  - B. Acquired adult GHD secondary to structural lesions or trauma OR
  - C. Idiopathic GHD (adult or childhood onset) AND
3. Patient is being monitored for adverse effects of therapy with the requested agent AND
4. Patient's IGF-1 level has been evaluated to confirm the appropriateness of the current dose AND
5. Patient has had clinical benefit with the requested agent (i.e., body composition, hip-to-waist ratio, cardiovascular health, bone mineral density, serum cholesterol, physical strength, or quality of life)

**Prior Authorization Group Description:**

HAE PA – Andembry

**Drug Name(s)**

Andembry

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiotensin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used for prophylaxis against HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent is being used for prophylaxis against HAE attacks AND

4. Patient has had a decrease in the frequency or severity of acute attacks or has had stabilization of disease from use of the requested agent AND
5. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Prior Authorization Group Description:**

HAE PA – Berinert

**Drug Name(s)**

Berinert

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks AND

5. Patient has had a decrease in the frequency or severity of acute attacks or stabilization of disease from use of the requested agent

**Prior Authorization Group Description:**

HAE PA – Cinryze

**Drug Name(s)**

Cinryze

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Acute HAE attacks

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. ONE of the following:
  - a. The requested agent will be used to treat acute HAE attacks AND the patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks OR
  - b. The requested agent will be used for prophylaxis against HAE attacks AND the patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND ONE of the following:
  - a. The requested agent will be used to treat acute HAE attacks AND the patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks OR
  - b. The requested agent will be used for prophylaxis against HAE attacks AND the patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks AND
3. Patient has had a decrease in the frequency or severity of acute attacks or has had stabilization of disease from use of the requested agent

**Prior Authorization Group Description:**

HAE PA - Dawnzera

**Drug Name(s)**

Dawnzera

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used for prophylaxis against HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent is being used for prophylaxis against HAE attacks AND
4. Patient has had clinical benefit with the requested agent AND



5. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Prior Authorization Group Description:**

HAE PA - Ekterly

**Drug Name(s)**

Ekterly

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks AND

5. Patient has had a decrease in the frequency or severity of acute attacks or stabilization of disease from use of the requested agent

**Prior Authorization Group Description:**

HAE PA – Haegarda

**Drug Name(s)**

Haegarda

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used for prophylaxis against HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent is being used for prophylaxis against HAE attacks AND
4. Patient has had a decrease in the frequency or severity of acute attacks or has had stabilization of disease from use of the requested agent AND

5. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Prior Authorization Group Description:**

HAE PA – Icatibant

**Drug Name(s)**

Firazyr

Icatibant Acetate

Sajazir

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent will be used to treat acute HAE attacks AND

4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks AND
5. Patient has had a decrease in the frequency or severity of acute attacks or stabilization of disease from use of the requested agent

**Prior Authorization Group Description:**

HAE PA – Orladeyo

**Drug Name(s)**

Orladeyo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used for prophylaxis against HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent is being used for prophylaxis against HAE attacks AND
4. Patient has had a decrease in the frequency or severity of acute attacks or has had stabilization of disease from use of the requested agent AND



5. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Prior Authorization Group Description:**

HAE PA – Ruconest

**Drug Name(s)**

Ruconest

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent will be used to treat acute HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for treatment of acute HAE attacks AND

5. Patient has had a decrease in the frequency or severity of acute attacks or stabilization of disease from use of the requested agent

**Prior Authorization Group Description:**

HAE PA – Takhzyro

**Drug Name(s)**

Takhzyro

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hereditary angioedema (HAE) which has been confirmed via two confirmatory tests of C1-INH antigenic level, C1-INH functional level, and C4 level as follows:
  - a. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type I)]: decreased quantities of C4 and C1-INH (antigenic and functional level) OR
  - b. Hereditary angioedema (HAE) due to C1INH deficiency [HAE-C1INH (Type II)]: decreased quantities of C4 and C1-INH function (C1-INH protein level may be normal) OR
  - c. Hereditary angioedema (HAE) with normal C1INH [HAE-nI-C1INH (Type III)]: Normal levels of C4 and C1-INH [antigenic and functional level (at baseline and during an attack)] AND ONE of the following:
    - i. BOTH of the following:
      1. Family history of angioedema AND
      2. ALL other causes of angioedema have been ruled out OR
    - ii. Patient demonstrates a Factor XII mutation, angiopoietin-1 (ANGPT1) mutation, plasminogen (PLG) mutation, kininogen1 mutation, heparan sulfate 3-O-sulfotransferase 6 gene mutation, or myoferlin gene mutation that is associated with the disease AND
2. Medications known to cause angioedema (e.g., ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate AND
3. The requested agent will be used for prophylaxis against HAE attacks AND
4. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hereditary angioedema (HAE) AND
3. The requested agent is being used for prophylaxis against HAE attacks AND
4. Patient has had a decrease in the frequency or severity of acute attacks or has had stabilization of disease from use of the requested agent AND

5. Patient will NOT be using the requested agent in combination with another HAE agent indicated for prophylaxis against HAE attacks

**Prior Authorization Group Description:**

Harvoni PA

**Drug Name(s)**

Harvoni

Ledipasvir/Sofosbuvir

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of hepatitis C confirmed by serological markers AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA dosing for the requested indication AND
5. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - C. Patient has an FDA labeled contraindication or hypersensitivity to the preferred agent: Mavyret for supported genotypes OR
  - D. Prescriber has provided information based on FDA approved labeling or AASLD/IDSA guidelines supporting the use of the non-preferred agent for the patient's diagnosis and genotype over the preferred agent: Mavyret for supported genotypes

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Hetlioz LQ Suspension PA

**Drug Name(s)**

Hetlioz Lq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of Smith-Magenis Syndrome (SMS) confirmed by the presence of ONE of the following genetic mutations:

A. A heterozygous deletion of 17p11.2 OR

B. A heterozygous pathogenic variant involving RAI1 AND

2. The requested agent is being used to treat nighttime sleep disturbances associated with SMS

**Age Restriction:**

Patient is 3 to 15 years of age

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, sleep specialist, psychiatrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

High Risk Medication PA - All Starts

**Drug Name(s)**

Ascomp/Codeine  
Bonjesta  
Butalbital/Acetaminophen/Caffeine/Codeine  
Butalbital/Aspirin/Caffeine/Codeine  
Carbinoxamine Maleate  
Carbinoxamine Maleate Er  
Carbzah  
Clemastine Fumarate  
Clemsza  
Cyproheptadine Hcl  
Diclegis  
Dicyclomine Hcl  
Diphenoxylate/Atropine  
Doxylamine Succinate/Pyridoxine Hcl  
Fioricet/Codeine  
Hydroxyzine Hcl  
Hydroxyzine Pamoate  
Karbinal Er  
Lomotil  
Promethazine Hcl Plain  
Promethazine Hcl  
Promethazine Syrup  
Promethazine Vc  
Promethazine/Phenylephrine  
Promethegan  
Ryvent  
Scopolamine  
Transderm Scop  
Trihexyphenidyl Hcl

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients less than 65 years of age.



Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested high-risk medication AND
2. Prescriber has indicated that the benefits of the requested high-risk medication outweigh the risks for the patient AND
3. Prescriber has indicated that the risks and potential side effects of the requested high-risk medication have been discussed with the patient

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

HoFH PA – Juxtapid

**Drug Name(s)**

Juxtapid

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
2. Patient's diagnosis was confirmed by ONE of the following:
  - A. Genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes or greater than or equal to 2 such variants at different loci OR
  - B. History of untreated LDL-C greater than 400 mg/dL (greater than 10 mmol/L) AND ONE of the following:
    - i. Cutaneous or tendon xanthomas before 10 years of age OR
    - ii. Untreated elevated LDL-C levels consistent with heterozygous familial hypercholesterolemia (HeFH) in both parents (or in digenic form, one parent may have normal LDL-C levels and the other may have LDL-C levels consistent with HoFH) AND
3. ONE of the following:
  - A. Patient is currently being treated with a lipid-lowering regimen in the last 90 days (i.e., rosuvastatin in combination with ezetimibe OR atorvastatin in combination with ezetimibe) OR
  - B. Patient has an intolerance or hypersensitivity to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe OR atorvastatin in combination with ezetimibe) OR
  - C. Patient has an FDA labeled contraindication to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe OR atorvastatin in combination with ezetimibe)

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, endocrinologist, lipidologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
3. Patient has had clinical benefit with the requested agent AND
4. ONE of the following:
  - A. Patient is currently being treated with a lipid-lowering regimen in the last 90 days (i.e., rosuvastatin in combination with ezetimibe OR atorvastatin in combination with ezetimibe) OR

- B. Patient has an intolerance or hypersensitivity to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe OR atorvastatin in combination with ezetimibe) OR
- C. Patient has an FDA labeled contraindication to a lipid-lowering regimen (i.e., rosuvastatin in combination with ezetimibe OR atorvastatin in combination with ezetimibe)

**Prior Authorization Group Description:**

Horizant PA

**Drug Name(s)**

Horizant

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has a diagnosis of Postherpetic Neuralgia (PHN) AND
    - ii. ONE of the following:
      1. Patient has tried and had an inadequate response to immediate-release gabapentin OR
      2. Patient has an intolerance or hypersensitivity to immediate-release gabapentin OR
      3. Patient has an FDA labeled contraindication to immediate-release gabapentin that is not expected to occur with the requested agent OR
  - B. BOTH of the following:
    - i. Patient has a diagnosis of moderate-to-severe primary Restless Legs Syndrome (RLS) AND
    - ii. ONE of the following:
      1. Patient has tried and had an inadequate response to immediate-release pregabalin OR
      2. Patient has an intolerance or hypersensitivity to immediate-release pregabalin OR
      3. Patient has an FDA labeled contraindication to immediate-release pregabalin

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of Postherpetic Neuralgia (PHN) OR
  - B. Patient has a diagnosis of moderate-to-severe primary Restless Legs Syndrome (RLS) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Hyftor PA

**Drug Name(s)**

Hyftor

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of facial angiofibroma associated with tuberous sclerosis complex (TSC) AND
2. Patient's diagnosis has been confirmed (i.e., medical records) by ONE of the following:
  - A. Patient has a pathogenic variant in the TSC1 gene or TSC2 gene confirmed by genetic testing  
OR
  - B. Patient has TWO of any of the following major features of TSC clinical diagnostic criteria:
    - i. hypomelanotic macules (greater than or equal to 3, at least 5 mm diameter)
    - ii. angiofibroma (greater than or equal to 3) or fibrous cephalic plaque
    - iii. ungual fibromas (greater than or equal to 2)
    - iv. shagreen patch
    - v. multiple retinal hamartomas
    - vi. multiple cortical tubers and/or radial migration lines
    - vii. subependymal nodule (greater than or equal to 2)
    - viii. subependymal giant cell astrocytoma
    - ix. cardiac rhabdomyoma
    - x. lymphangiomyomatosis (LAM)\*
    - xi. angiomyolipomas (greater than or equal to 2)\* OR
  - C. BOTH of the following:
    - i. Patient has ONE of any of the following major features of TSC clinical diagnostic criteria:
      1. hypomelanotic macules (greater than or equal to 3, at least 5 mm diameter)
      2. angiofibroma (greater than or equal to 3) or fibrous cephalic plaque
      3. ungual fibromas (greater than or equal to 2)
      4. shagreen patch
      5. multiple retinal hamartomas
      6. multiple cortical tubers and/or radial migration lines
      7. subependymal nodule (greater than or equal to 2)
      8. subependymal giant cell astrocytoma
      9. cardiac rhabdomyoma
      10. lymphangiomyomatosis (LAM)
      11. angiomyolipomas (greater than or equal to 2) AND

Note:

\*A combination of the 2 major clinical features LAM and angiomyolipomas without other features does not meet criteria for a definite diagnosis.

Initial criteria continues: see Other Criteria

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 12 weeks for initial, 12 months for renewal

**Other Criteria:**

ii. Patient has TWO of any of the following minor features of TSC clinical diagnostic criteria:

1. "confetti" skin lesions
2. dental enamel pits (greater than or equal to 3)
3. intraoral fibromas (greater than or equal to 2)
4. retinal achromic patch
5. multiple renal cysts
6. nonrenal hamartomas
7. sclerotic bone lesions AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of facial angiofibroma associated with tuberous sclerosis complex (TSC) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Imiquimod PA

**Drug Name(s)**

Imiquimod Cream 5%

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following diagnoses:

- A. Actinic keratosis OR
- B. Superficial basal cell carcinoma OR
- C. External genital and/or perianal warts/condyloma acuminata OR
- D. Squamous cell carcinoma OR
- E. Basal cell carcinoma OR
- F. Another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

4 months for Actinic keratosis, other diagnoses - see Other Criteria

**Other Criteria:**

2 months for Superficial basal cell carcinoma, Squamous cell carcinoma, or Basal cell carcinoma

4 months for External genital and/or perianal warts/condyloma acuminata

12 months for All other diagnoses

**Prior Authorization Group Description:**

Inbrija PA

**Drug Name(s)**

Inbrija

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent will be used for intermittent treatment of OFF episodes in patients with Parkinson's disease AND
2. The requested agent will be used in combination with carbidopa/levodopa

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Ingrezza PA

**Drug Name(s)**

Ingrezza

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chorea associated with Huntington's disease AND BOTH of the following:

i. ONE of the following:

1. Patient does NOT have a current diagnosis of depression OR
2. Patient has a current diagnosis of depression and is being treated for depression AND

ii. ONE of the following:

1. Patient does NOT have a diagnosis of passive suicidal ideation and/or behavior OR
2. Patient has a diagnosis of passive suicidal ideation and/or behavior and must NOT be actively suicidal OR

B. Patient has a diagnosis of tardive dyskinesia AND ONE of the following:

i. Prescriber has reduced the dose of or discontinued any medications known to cause tardive dyskinesia (i.e., dopamine receptor blocking agents) OR

ii. Prescriber has provided clinical rationale indicating that a reduced dose or discontinuation of any medications known to cause tardive dyskinesia is not appropriate

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Injectable Oncology PA

**Drug Name(s)**

Firmagon

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. ALL of the following:
    - i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND
    - ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - iii. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines

May also be subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Insulin Pen Needle PA

**Drug Name(s)**

Insulin Pen Needle

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Insulin Syringe\_Needle PA

**Drug Name(s)**

Insulin Syringe/Needle

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

This program will be implemented as a dynamic PA.

Criteria for approval require BOTH of the following:

1. The requested medical supply product will be used in the delivery of insulin to the body AND
2. Patient's medication history includes use of insulin within the past 180 days

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Intrarosa PA

**Drug Name(s)**

Intrarosa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Iqirvo PA

**Drug Name(s)**

Iqirvo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Have or has developed decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy)

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of primary biliary cholangitis (PBC) confirmed by at least TWO of the following:
  - A. There is biochemical evidence of cholestasis with an alkaline phosphatase (ALP) elevation OR
  - B. ONE of the following:
    - i. Positive presence of antimitochondrial antibody (AMA) OR
    - ii. Positive presence of other PBC-specific autoantibodies (e.g., sp100, gp210) if AMA is negative OR
  - C. Histologic evidence of nonsuppurative destruction cholangitis and destruction of interlobular bile ducts AND
2. Prescriber has measured the patient's alkaline phosphatase (ALP) level AND total bilirubin level AND
3. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has tried and had an inadequate response to ursodiol (UDCA) AND
    - ii. The requested agent will be used in combination with ursodiol (UDCA) OR
  - B. Patient has an intolerance or hypersensitivity to ursodiol (UDCA) OR
  - C. Patient has an FDA labeled contraindication to ursodiol (UDCA)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of primary biliary cholangitis (PBC) AND
3. ONE of the following:
  - A. The requested agent will be used in combination with ursodiol (UDCA) OR
  - B. Patient has an intolerance or hypersensitivity to ursodiol (UDCA) OR
  - C. Patient has an FDA labeled contraindication to ursodiol (UDCA) AND
4. Patient has had improvements or stabilization with the requested agent as indicated by BOTH of the following:
  - A. Decrease in alkaline phosphatase (ALP) level from baseline AND
  - B. Total bilirubin is less than or equal to the upper limit of normal (ULN)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Iron Chelating Agents PA – Exjade

**Drug Name(s)**

Deferasirox (Exjade)

Exjade

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome AND ONE of the following:

- i. A liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight OR
- ii. A serum ferritin greater than 300 mcg/L OR
- iii. MRI confirmation of iron deposition OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

2. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent for the requested indication

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Iron Chelating Agents PA – Jadenu

**Drug Name(s)**

Deferasirox (Jadenu)

Jadenu

Jadenu Sprinkle

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome AND ONE of the following:

- i. A liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight OR
- ii. A serum ferritin greater than 300 mcg/L OR
- iii. MRI confirmation of iron deposition OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

2. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of chronic iron overload due to a non-transfusion dependent thalassemia syndrome OR

B. Patient has a diagnosis of chronic iron overload due to blood transfusions AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with another iron chelating agent (e.g., deferiprone) for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent for the requested indication

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Isotretinoin PA

**Drug Name(s)**

Absorica

Accutane

Amnesteem

Claravis

Isotretinoin

Zenatane

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Isturisa PA

**Drug Name(s)**

Isturisa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Cushing's syndrome AND
2. The requested agent will be used for the treatment of endogenous hypercortisolemia AND
3. ONE of the following:
  - A. Patient had an inadequate response to surgical resection OR
  - B. Patient is NOT a candidate for surgical resection

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Cushing's syndrome AND
3. The requested agent will be used for the treatment of endogenous hypercortisolemia AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ivermectin Cream PA

**Drug Name(s)**

Ivermectin Cream

Soolantra

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ivermectin Tablet PA

**Drug Name(s)**

Ivermectin Tablet

Stromectol

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 4 months

**Other Criteria:**

**Prior Authorization Group Description:**

Jascayd PA

**Drug Name(s)**

Jascayd

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
    - ii. Patient has no known explanation for interstitial lung disease (ILD) or pulmonary fibrosis (e.g., radiation, drugs, metal dusts, sarcoidosis, or any connective tissue disease known to cause ILD) OR
  - B. Patient has a diagnosis of progressive pulmonary fibrosis (PPF) AND BOTH of the following:
    - i. Patient has TWO of the following occurring within the past year:
      - a. Worsening respiratory symptoms OR
      - b. Physiological evidence of disease progression OR
      - c. Radiological evidence of disease progression AND
    - ii. Alternative explanations of worsening features have been excluded

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) OR
  - B. Patient has a diagnosis of progressive pulmonary fibrosis (PPF) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pathologist, pulmonologist, radiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Jatenzo PA

**Drug Name(s)**

Jatenzo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient's sex is male with a diagnosis of primary or secondary (hypogonadotropic) hypogonadism AND
2. ONE of the following:
  - A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:
    - i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
    - ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR
  - B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:
    - i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
    - ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND
3. ONE of the following:
  - A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR
  - B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Joenja PA

**Drug Name(s)**

Joenja

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS) AND
2. Patient has a variant in either PIK3CD gene or PIK3R1 gene

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Jornay PM PA

**Drug Name(s)**

Jornay Pm

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Jubbonti PA

**Drug Name(s)**

Jubbonti

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR
  - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
  - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
  - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
  - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
  - iii. Pt's diagnosis was confirmed by ONE of:
    - 1. A fragility fracture in the hip or spine OR
    - 2. A T-score of -2.5 or lower OR
    - 3. A T-score of -1.0 to -2.5 AND ONE of:
      - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - iv. ONE of:
    - 1. Pt is at high fracture risk as defined by ONE of:
      - a. Pt had a recent fracture (within the past 12 months) OR
      - b. Pt had fractures while on FDA approved osteoporosis therapy OR

- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqcg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Jynarque PA

**Drug Name(s)**

Jynarque

Tolvaptan (Jynarque)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) confirmed by ONE of the following:
  - A. Ultrasound OR
  - B. MRI or CT scan OR
  - C. Genetic testing AND
2. Patient is at risk of rapid disease progression AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Kalydeco PA

**Drug Name(s)**

Kalydeco

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has ONE of the CFTR gene mutations or a mutation in the CFTR gene that is responsive based on in vitro data, as indicated in the FDA label, confirmed by genetic testing OR
  - B. Patient has another CFTR gene mutation(s) that is responsive to the requested agent, as indicated in the FDA label, confirmed by genetic testing AND
3. Patient is NOT homozygous for the F508del mutation AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Kerendia PA

**Drug Name(s)**

Kerendia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Leuprolide PA

**Drug Name(s)**

Eligard

Leuprolide Acetate

Lupron Depot

Lupron Depot-Ped

Lutrate Depot

Vabrinty

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. Patient is NOT currently being treated with the requested agent AND
    - ii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

L-glutamine PA

**Drug Name(s)**

Endari

L-glutamine

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of sickle cell disease AND
2. Patient is using the requested agent to reduce the acute complications of sickle cell disease AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to maximally tolerated dose of hydroxyurea OR
  - B. Patient has an intolerance or hypersensitivity to hydroxyurea OR
  - C. Patient has an FDA labeled contraindication to hydroxyurea

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of sickle cell disease AND
3. Patient is using the requested agent to reduce the acute complications of sickle cell disease AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine Ointment

**Drug Name(s)**

Lidocaine Ointment

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. The requested agent will be used for ONE of the following:

- A. Anesthesia of accessible mucous membranes of the oropharynx OR
- B. Anesthetic lubricant for intubation OR
- C. Temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites OR
- D. Another indication that is supported in CMS approved compendia for the requested agent

AND ONE of the following:

- i. Patient has tried and had an inadequate response to a conventional therapy [e.g., gabapentin, pregabalin, oral prescription NSAID (non-steroidal anti-inflammatory drug)] for the requested indication OR
- ii. Patient has an intolerance or hypersensitivity to a conventional therapy OR
- iii. Patient has an FDA labeled contraindication to a conventional therapy

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine Patch

**Drug Name(s)**

Lidocaine Patch

Lidocan

Tridacaine Patch

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

- A. Pain associated with postherpetic neuralgia (PHN) OR
  - B. Pain associated with diabetic neuropathy OR
  - C. Neuropathic pain associated with cancer, or cancer treatment OR
  - D. Another diagnosis that is supported in CMS approved compendia for the requested agent
- AND

2. ONE of the following:

- A. Patient has tried and had an inadequate response to a conventional therapy [e.g., gabapentin, pregabalin, oral prescription NSAID (non-steroidal anti-inflammatory drug)] for the requested indication OR
- B. Patient has an intolerance or hypersensitivity to a conventional therapy OR
- C. Patient has an FDA labeled contraindication to a conventional therapy

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine Solution

**Drug Name(s)**

Lidocaine Solution

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. The requested agent will be used for ONE of the following:
  - A. Topical anesthesia of accessible mucous membranes of the oral and nasal cavities OR
  - B. Topical anesthesia of accessible mucous membranes of proximal portions of the digestive tract OR
  - C. Another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA - Lidocaine/prilocaine Cream

**Drug Name(s)**

Lidocaine/Prilocaine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. The requested agent will be used for ONE of the following:
  - A. Local analgesia on normal intact skin OR
  - B. Topical anesthetic for dermal procedures OR
  - C. Adjunctive anesthesia prior to local anesthetic infiltration in adult male genital skin OR
  - D. Anesthesia for minor procedures on female external genitalia OR
  - E. Another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lidocaine Topical PA – ZTlido

**Drug Name(s)**

Ztlido

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has ONE of the following diagnoses:

- A. Pain associated with postherpetic neuralgia (PHN) OR
  - B. Neuropathic pain associated with cancer, or cancer treatment OR
  - C. Another diagnosis that is supported in CMS approved compendia for the requested agent
- AND

2. ONE of the following:

- A. Patient has tried and had an inadequate response to a conventional therapy [e.g., gabapentin, pregabalin, oral prescription NSAID (non-steroidal anti-inflammatory drug)] for the requested indication OR
- B. Patient has an intolerance or hypersensitivity to a conventional therapy OR
- C. Patient has an FDA labeled contraindication to a conventional therapy

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Linezolid PA

**Drug Name(s)**

Linezolid

Zyvox

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND ONE of the following:
  - a. The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient OR
  - b. Patient has a documented infection due to vancomycin-resistant *Enterococcus faecium* OR
  - c. Patient has a diagnosis of pneumonia caused by *Staphylococcus aureus* or *Streptococcus pneumoniae* AND ONE of the following:
    - i. Patient has a documented infection that is resistant to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole, OR that is resistant to vancomycin OR
    - ii. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
    - iii. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
    - iv. Patient has an intolerance or hypersensitivity to vancomycin OR
    - v. Patient has an FDA labeled contraindication to vancomycin OR
  - d. Patient has a documented skin and skin structure infection, including diabetic foot infections, caused by *Staphylococcus aureus*, *Streptococcus pyogenes*, or *Streptococcus agalactiae* AND ONE of the following:
    - i. Patient has a documented infection that is resistant to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole, OR that is resistant to vancomycin at the site of infection OR
    - ii. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
    - iii. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 3 months

**Other Criteria:**

- iv. Patient has an intolerance or hypersensitivity to vancomycin OR
  - v. Patient has an FDA labeled contraindication to vancomycin AND
- 2. Patient will NOT be using the requested agent in combination with Sivextro (tedizolid) for the same infection AND
- 3. The requested dose is within FDA labeled dosing for the requested indication



**Prior Authorization Group Description:**

Liraglutide PA

**Drug Name(s)**

Liraglutide

Victoza

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
  - C. ALL of the following:
    - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
    - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria: Prior Authorization Group Description:**

Livdelzi PA

**Drug Name(s)**

Livdelzi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Have or has developed decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy)

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of primary biliary cholangitis (PBC) confirmed by at least TWO of the following:
  - A. There is biochemical evidence of cholestasis with an alkaline phosphatase (ALP) elevation OR
  - B. ONE of the following:
    - i. Positive presence of antimitochondrial antibody (AMA) OR
    - ii. Positive presence of other PBC-specific autoantibodies (e.g., sp100, gp210) if AMA is negative OR
  - C. Histologic evidence of nonsuppurative destruction cholangitis and destruction of interlobular bile ducts AND
2. Prescriber has measured the patient's alkaline phosphatase (ALP) level AND total bilirubin level AND
3. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has tried and had an inadequate response to ursodiol (UDCA) AND
    - ii. The requested agent will be used in combination with ursodiol (UDCA) OR
  - B. Patient has an intolerance or hypersensitivity to ursodiol (UDCA) OR
  - C. Patient has an FDA labeled contraindication to ursodiol (UDCA)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of primary biliary cholangitis (PBC) AND
3. ONE of the following:
  - A. The requested agent will be used in combination with ursodiol (UDCA) OR
  - B. Patient has an intolerance or hypersensitivity to ursodiol (UDCA) OR
  - C. Patient has an FDA labeled contraindication to ursodiol (UDCA) AND
4. Patient has had improvements or stabilization with the requested agent as indicated by BOTH of the following:
  - A. Decrease in alkaline phosphatase (ALP) level from baseline AND
  - B. Total bilirubin is less than or equal to the upper limit of normal (ULN)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Livmarli PA

**Drug Name(s)**

Livmarli

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of progressive familial intrahepatic cholestasis (PFIC) OR
  - B. Patient has a diagnosis of Alagille Syndrome (ALGS) AND
2. The requested agent will be used to treat cholestatic pruritus AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lumryz PA

**Drug Name(s)**

Lumryz

Lumryz Starter Pack

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of narcolepsy with cataplexy OR
- B. BOTH of the following:
  - i. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness AND
  - ii. ONE of the following:
    - a. Patient is between the ages of 7 and less than 18 years OR
    - b. BOTH of the following:
      - 1. Patient is 18 years of age or over AND
      - 2. ONE of the following:
        - a) Patient has tried and had an inadequate response to modafinil or armodafinil OR
        - b) Patient has an intolerance or hypersensitivity to modafinil or armodafinil OR
        - c) Patient has an FDA labeled contraindication to modafinil or armodafinil OR
- C. Patient has another indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
  - A. Patient has a diagnosis of narcolepsy with cataplexy OR
  - B. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness OR
  - C. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

For diagnosis of narcolepsy with cataplexy, patient is 7 years of age or over. For diagnosis of narcolepsy with excessive daytime sleepiness, patient is 7 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lupkynis PA

**Drug Name(s)**

Lupkynis

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of active lupus nephritis (LN) AND
2. Patient will continue standard LN therapy [i.e. corticosteroids (e.g., methylprednisolone, prednisone) AND mycophenolate] in combination with the requested agent AND
3. Patient will NOT be using the requested agent in combination with cyclophosphamide

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of active lupus nephritis (LN) AND
3. Patient will continue standard LN therapy [i.e. corticosteroids (e.g., methylprednisolone, prednisone) AND mycophenolate] in combination with the requested agent AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with cyclophosphamide

**Age Restriction:**

Patient is 18 years of age or over

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Lynkuet PA

**Drug Name(s)**

Lynkuet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Mavyret PA

**Drug Name(s)**

Mavyret

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of hepatitis C confirmed by serological markers OR

B. Patient is a hepatitis C virus (HCV) - uninfected solid organ transplant recipient AND BOTH of the following:

i. Patient received an HCV - viremic donor organ AND

ii. The requested agent is being used for prophylaxis AND

2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND

3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND

4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Memantine ER PA

**Drug Name(s)**

Memantine Hcl Er

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients greater than or equal to 30 years of age

Criteria for approval require the following:

1. Patient is younger than 30 years of age AND ONE of the following:
  - A. Patient has a diagnosis of moderate to severe dementia of the Alzheimer's type OR
  - B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Memantine PA

**Drug Name(s)**

Memantine Hcl Titration Pak

Memantine Hcl

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

PA does NOT apply to patients greater than or equal to 30 years of age

Criteria for approval require the following:

1. Patient is younger than 30 years of age AND ONE of the following:
  - A. Patient has a diagnosis of moderate to severe dementia of the Alzheimer's type OR
  - B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Methamphetamine PA

**Drug Name(s)**

Methamphetamine Hcl

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used to promote weight loss AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Methylin PA

**Drug Name(s)**

Methylin

Methylphenidate Hcl (Methylin)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Methylphenidate Capsule PA

**Drug Name(s)**

Metadate Cd

Methylphenidate Hcl Cd

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Methylphenidate Chewable PA

**Drug Name(s)**

Methylphenidate Hcl Chewable

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Methylphenidate ER Tablet PA

**Drug Name(s)**

Methylphenidate Hcl Er Tablet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Methylphenidate LA Capsule PA

**Drug Name(s)**

Methylphenidate Hcl Er (La) Capsule

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Methylphenidate Patch PA

**Drug Name(s)**

Daytrana

Methylphenidate Patch

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Miebo PA

**Drug Name(s)**

Miebo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Mifepristone PA

**Drug Name(s)**

Korlym

Mifepristone

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Cushing's syndrome AND
2. ONE of the following:
  - A. Patient has type 2 diabetes mellitus OR
  - B. Patient has glucose intolerance as defined by a 2-hour glucose tolerance test plasma glucose value of 140-199 mg/dL AND
3. ONE of the following:
  - A. Patient had an inadequate response to surgical resection OR
  - B. Patient is NOT a candidate for surgical resection

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Cushing's syndrome AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Migranal PA

**Drug Name(s)**

Dihydroergotamine Mesylate Spray

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. The requested agent will be used for the treatment of acute migraine with or without aura AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to TWO triptan agents with differing active ingredients (e.g., sumatriptan, rizatriptan) OR
  - B. Patient has an intolerance or hypersensitivity to a triptan agent OR
  - C. Patient has an FDA labeled contraindication to a triptan agent AND
3. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent will be used for the treatment of acute migraine with or without aura AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Miplyffa PA

**Drug Name(s)**

Miplyffa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Niemann-Pick disease Type C (NPC) as confirmed by genetic analysis mutation in the NPC1 or NPC2 genes AND
2. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) AND
3. The requested agent will be used in combination with miglustat

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Niemann-Pick disease Type C (NPC) AND
3. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) AND
4. The requested agent will be used in combination with miglustat AND
5. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hepatologist, gastroenterologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Modafinil PA

**Drug Name(s)**

Modafinil

Provigil

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another target agent (i.e., armodafinil)

**Age Restriction:**

Patient is 17 years of age or over

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Mounjaro PA

**Drug Name(s)**

Mounjaro

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
  - C. ALL of the following:
    - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
    - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

MS PA – Avonex

**Drug Name(s)**

Avonex

Avonex Pen

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Bafiertam

**Drug Name(s)**

Bafiertam

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Betaseron

**Drug Name(s)**

Betaseron

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA - Dimethyl Fumarate

**Drug Name(s)**

Dimethyl Fumarate

Dimethyl Fumarate Starterpack

Tecfidera

Tecfidera Starter Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Fingolimod

**Drug Name(s)**

Fingolimod Hcl

Gilenya

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication AND
3. Prescriber will perform an electrocardiogram prior to initiating treatment

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Glatiramer

**Drug Name(s)**

Copaxone

Glatiramer Acetate

Glatopa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Kesimpta

**Drug Name(s)**

Kesimpta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Mavenclad

**Drug Name(s)**

Cladribine Pak

Mavenclad

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) for the requested indication AND
3. The requested dose is within FDA labeled dosing for the requested indication AND
4. The total cumulative duration of treatment with Mavenclad (cladribine) has not exceeded 4 treatment cycles

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

No prior use approve 2 years, Prior use approve remainder of 2 years of total cumulative therapy

**Other Criteria:**



**Prior Authorization Group Description:**

MS PA – Mayzent

**Drug Name(s)**

Mayzent

Mayzent Starter Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Plegridy

**Drug Name(s)**

Plegridy

Plegridy Starter Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Ponvory

**Drug Name(s)**

Ponvory

Ponvory 14-Day Starter Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Rebif

**Drug Name(s)**

Rebif

Rebif Rebidose

Rebif Rebidose Titration Pack

Rebif Titration Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Tascenso

**Drug Name(s)**

Tascenso Odt

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication AND
3. Prescriber has performed an electrocardiogram within 6 months prior to initiating treatment

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Teriflunomide

**Drug Name(s)**

Aubagio

Teriflunomide

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Vumerity

**Drug Name(s)**

Vumerity

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

MS PA – Zeposia

**Drug Name(s)**

Zeposia

Zeposia Starter Kit

Zeposia 7-Day Starter Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication AND
3. ONE of the following:
  - i. The requested diagnosis is NOT moderately to severely active ulcerative colitis (UC) OR
  - ii. The requested diagnosis is moderately to severely active UC AND ONE of the following:
    - a. Patient has tried and had an inadequate response to ONE preferred biologic agent (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) for the treatment of UC OR
    - b. Patient has an intolerance or hypersensitivity to ONE preferred biologic agent (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya) OR
    - c. Patient has an FDA labeled contraindication to ONE preferred biologic agent (Hadlima, Rinvoq tablets, Simlandi, Skyrizi, Stelara, Steqeyma, or Tremfya)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another disease modifying agent (DMA) or a biologic immunomodulator for the requested indication



**Prior Authorization Group Description:**

Mulpleta PA

**Drug Name(s)**

Mulpleta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of thrombocytopenia AND
2. Patient has chronic liver disease AND
3. Patient has a platelet count less than  $50 \times 10^9/L$  AND
4. Patient is scheduled to undergo a procedure with an associated risk of bleeding (e.g., gastrointestinal endoscopy, liver biopsy, bronchoscopy, dental procedure) AND
5. The requested dose is within FDA labeled dosing for the requested indication AND
6. The length of therapy of the requested agent is within the FDA labeled duration for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 1 month

**Other Criteria:**

**Prior Authorization Group Description:**

Myalept PA

**Drug Name(s)**

Myalept

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has leptin deficiency associated with a diagnosis of either congenital generalized lipodystrophy (CGL) or acquired generalized lipodystrophy (AGL) AND
2. Prescriber has provided the patient's baseline levels for HbA1C, triglycerides, and fasting insulin, measured prior to beginning therapy with the requested agent AND
3. Patient also has at least ONE of the complications related to lipodystrophy: diabetes mellitus, hypertriglyceridemia (200 mg/dL or higher), and/or high fasting insulin (30 microunits/mL or higher) AND
4. Patient has tried and had an inadequate response to maximum tolerable dosing of a conventional agent for the additional diagnosis AND
5. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has leptin deficiency associated with a diagnosis of either congenital generalized lipodystrophy (CGL) or acquired generalized lipodystrophy (AGL) AND
3. Patient has had improvement or stabilization with the requested agent as indicated by change from baseline level of at least ONE of the following:
  - A. HbA1C
  - B. Triglycerides
  - C. Fasting insulin AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Conventional agent examples include:

Hypertriglyceridemia: statins, fenofibrates, Omega-3-Acid Ethyl Esters (generic Lovaza)

Diabetes/high fasting insulin: insulin, sulfonylurea/sulfonylurea combination, metformin/metformin combination

**Prior Authorization Group Description:**

Myfembree PA

**Drug Name(s)**

Myfembree

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has a diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) AND
    - ii. Patient's diagnosis of uterine fibroids was confirmed via imaging (e.g., ultrasound) OR
  - B. Patient has a diagnosis of moderate to severe pain associated with endometriosis AND
2. Patient is premenopausal AND
3. Patient will NOT be using the requested agent in combination with another GnRH antagonist agent [e.g., Orilissa (elagolix), Oriahnn (elagolix, estradiol, norethindrone acetate)] for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication AND
5. ONE of the following:
  - A. Patient is initiating therapy with the requested agent OR
  - B. BOTH of the following:
    - i. Patient is continuing therapy with the requested agent and the prescriber has provided information indicating the number of months the patient has been on therapy with the requested agent AND
    - ii. The total duration of treatment with the requested agent has NOT exceeded 24 months per lifetime

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

For no prior Myfembree use:

24 months

For prior Myfembree use:

Remainder of 24 months

**Other Criteria:**

**Prior Authorization Group Description:**

Nemludio PA

**Drug Name(s)**

Nemludio

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient has a diagnosis of prurigo nodularis (PN) OR
- B. Patient has a diagnosis of moderate-to-severe atopic dermatitis (AD) AND ALL of the following:

- i. Patient has tried and had an inadequate response to a topical steroid (e.g., triamcinolone) AND
- ii. Patient has tried and had an inadequate response to a topical calcineurin inhibitor (e.g., tacrolimus) AND
- iii. The requested agent will be used in combination with a topical steroid (e.g., triamcinolone) or a topical calcineurin inhibitor (e.g., tacrolimus) AND

2. Patient will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

- A. Patient has a diagnosis of prurigo nodularis (PN) OR
- B. BOTH of the following:
  - i. Patient has a diagnosis of moderate-to-severe atopic dermatitis (AD) AND
  - ii. ONE of the following:
    - a. The requested agent will be used in combination with a topical steroid (e.g., triamcinolone) or a topical calcineurin inhibitor (e.g., tacrolimus) OR
    - b. BOTH of the following:
      - 1. Patient's disease activity has sufficiently improved AND
      - 2. Combination with a topical steroid (e.g., triamcinolone) or a topical calcineurin inhibitor (e.g., tacrolimus) have been tapered and discontinued AND

3. Patient has had clinical benefit with the requested agent AND

4. Patient will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors)

**Age Restriction:**

For diagnosis of prurigo nodularis (PN), patient is 18 years of age or over. For diagnosis of moderate-to-severe atopic dermatitis (AD), patient is 12 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Nexletol PA

**Drug Name(s)**

Nexletol

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:

- i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR
- ii. Pretreatment LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) OR
- iii. Patient has clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, corneal arcus, tuberous xanthoma, or xanthelasma) OR
- iv. Patient has “definite” or “possible” familial hypercholesterolemia as defined by the Simon Broome criteria OR
- v. Patient has a Dutch Lipid Clinic Network criteria score of greater than 5 OR

B. The requested agent will be used to reduce the risk of myocardial infarction and coronary revascularization AND ONE of the following:

- i. Patient has a diagnosis of established atherosclerotic cardiovascular disease (ASCVD) defined as having ONE of the following:
  - a. Acute coronary syndrome
  - b. History of myocardial infarction
  - c. Stable or unstable angina
  - d. Coronary or other arterial revascularization
  - e. Stroke
  - f. Transient ischemic attack
  - g. Peripheral arterial disease, including aortic aneurysm, presumed to be of atherosclerotic origin OR
- ii. Patient has a diagnosis of high risk for a cardiovascular disease (CVD) event but without established CVD OR

C. Patient has a diagnosis of primary hyperlipidemia, [not associated with HeFH, established cardiovascular disease (CVD), or high risk for CVD event without established CVD] AND

2. ONE of the following:

- A. Patient is on statin therapy OR
- B. Patient has an intolerance to TWO different statins OR
- C. Patient has an FDA labeled contraindication to a statin

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) OR
  - B. The requested agent will be used to reduce the risk of myocardial infarction and coronary revascularization AND ONE of the following:
    - i. Patient has a diagnosis of established atherosclerotic cardiovascular disease (ASCVD) OR
    - ii. Patient has a diagnosis of high risk for a cardiovascular disease (CVD) event but without established CVD OR
  - C. Patient has a diagnosis of primary hyperlipidemia, [not associated with HeFH, established cardiovascular disease (CVD), or high risk for CVD event without established CVD] AND
3. ONE of the following:
  - A. Patient is on statin therapy OR
  - B. Patient has an intolerance to TWO different statins OR
  - C. Patient has an FDA labeled contraindication to a statin AND
4. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Nexlizet PA

**Drug Name(s)**

Nexlizet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:

- i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR
- ii. Pretreatment LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) OR
- iii. Patient has clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, corneal arcus, tuberous xanthoma, or xanthelasma) OR
- iv. Patient has “definite” or “possible” familial hypercholesterolemia as defined by the Simon Broome criteria OR
- v. Patient has a Dutch Lipid Clinic Network criteria score of greater than 5 OR

B. The requested agent will be used to reduce the risk of myocardial infarction and coronary revascularization AND ONE of the following:

- i. Patient has a diagnosis of established atherosclerotic cardiovascular disease (ASCVD) defined as having ONE of the following:
  - a. Acute coronary syndrome
  - b. History of myocardial infarction
  - c. Stable or unstable angina
  - d. Coronary or other arterial revascularization
  - e. Stroke
  - f. Transient ischemic attack
  - g. Peripheral arterial disease, including aortic aneurysm, presumed to be of atherosclerotic origin OR
- ii. Patient has a diagnosis of high risk for a cardiovascular disease (CVD) event but without established CVD OR

C. Patient has a diagnosis of primary hyperlipidemia, [not associated with HeFH, established cardiovascular disease (CVD), or high risk for CVD event without established CVD] AND

2. ONE of the following:

- A. Patient is on statin therapy OR
- B. Patient has an intolerance to TWO different statins OR
- C. Patient has an FDA labeled contraindication to a statin

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**



Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) OR
  - B. The requested agent will be used to reduce the risk of myocardial infarction and coronary revascularization AND ONE of the following:
    - i. Patient has a diagnosis of established atherosclerotic cardiovascular disease (ASCVD) OR
    - ii. Patient has a diagnosis of high risk for a cardiovascular disease (CVD) event but without established CVD OR
  - C. Patient has a diagnosis of primary hyperlipidemia, [not associated with HeFH, established cardiovascular disease (CVD), or high risk for CVD event without established CVD] AND
3. ONE of the following:
  - A. Patient is on statin therapy OR
  - B. Patient has an intolerance to TWO different statins OR
  - C. Patient has an FDA labeled contraindication to a statin AND
4. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Nourianz PA

**Drug Name(s)**

Nourianz

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. The requested agent will be used as adjunctive treatment in patients with Parkinson's disease experiencing "off" episodes AND
2. The requested agent will be used in combination with levodopa/carbidopa agents

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Nucala PA

**Drug Name(s)**

Nucala

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has a diagnosis of severe asthma with an eosinophilic phenotype AND the following:

i. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR

B. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype AND the following:

i. Patient is currently being treated with AND will continue COPD control therapy (e.g., ICS, LABA, LAMA) in combination with the requested agent OR

C. Patient has a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) AND the following:

i. ONE of the following:

a. Patient is currently being treated with a maximally tolerated oral corticosteroid OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an oral corticosteroid OR

D. Patient has a diagnosis of hypereosinophilic syndrome (HES) for 6 months or more without an identifiable non-hematologic secondary cause AND the following:

i. ONE of the following:

a. Patient is currently being treated with a maximally tolerated oral corticosteroid OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an oral corticosteroid OR

E. Patient has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND

2. Patient will NOT be using the requested agent in combination with Xolair, Dupixent, or with another injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra) for the requested indication

**Age Restriction:**

For diagnosis of severe asthma with an eosinophilic phenotype, patient is 6 years of age or over. For diagnosis of EGPA, patient is 18 years of age or over. For diagnosis of HES, patient is 12 years of age or over. For diagnosis of CRSwNP, patient is 18 years of age or over. For diagnosis of COPD and an eosinophilic phenotype, patient is 18 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist, otolaryngologist, pathologist, pulmonologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of severe asthma with an eosinophilic phenotype AND the following:
    - i. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR
  - B. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype AND the following:
    - i. Patient is currently being treated with AND will continue COPD control therapy (e.g., ICS, LABA, LAMA) in combination with the requested agent OR
  - C. Patient has a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) AND the following:
    - i. ONE of the following:
      - a. Patient is currently being treated with maintenance therapy with oral corticosteroid OR
      - b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to oral corticosteroid OR
  - D. Patient has a diagnosis of hypereosinophilic syndrome (HES) for 6 months or more without an identifiable non-hematologic secondary cause AND the following:
    - i. ONE of the following:
      - a. Patient is currently being treated with maintenance therapy with oral corticosteroid OR
      - b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to oral corticosteroid OR
  - E. Patient has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with Xolair, Dupixent, or with another injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra) for the requested indication

**Prior Authorization Group Description:**

Nuedexta PA

**Drug Name(s)**

Nuedexta

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of pseudobulbar affect OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Nuplazid PA

**Drug Name(s)**

Nuplazid

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Nurtec PA

**Drug Name(s)**

Nurtec

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of migraine AND
2. ONE of the following:
  - A. The requested agent is being used for the treatment of acute migraine with or without aura AND BOTH of the following:
    - i. ONE of the following:
      - a. Patient has tried and had an inadequate response to a triptan (e.g., sumatriptan, rizatriptan) agent OR
      - b. Patient has an intolerance, or hypersensitivity to a triptan OR
      - c. Patient has an FDA labeled contraindication to a triptan AND
    - ii. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP) OR
  - B. The requested agent is being used for migraine prophylaxis AND BOTH of the following:
    - i. Patient has 4 or more migraine headache days per month AND
    - ii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. ONE of the following:
  - A. The requested agent is being used for the treatment of acute migraine with or without aura AND BOTH of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP) OR
  - B. The requested agent is being used for migraine prophylaxis AND BOTH of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Nuzyra IV PA

**Drug Name(s)**

Nuzyra IV

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient

**Coverage Duration:**

Approval will be for 14 days

**Other Criteria:**

**Prior Authorization Group Description:**

Nuzyra Tablet PA

**Drug Name(s)**

Nuzyra Tablet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND ONE of the following:

A. The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient OR

B. ONE of the following:

i. Patient has a diagnosis of community-acquired bacterial pneumonia (CABP) caused by *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, or *Chlamydia pneumoniae* AND ONE of the following:

a. Patient has a documented infection that is resistant to TWO of the following: beta-lactams, macrolides, tetracyclines, OR that is resistant to vancomycin at the site of infection OR

b. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, or tetracyclines OR

c. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, or tetracyclines OR

d. Patient has an intolerance or hypersensitivity to vancomycin OR

e. Patient has an FDA labeled contraindication to vancomycin OR

ii. Patient has a diagnosis of acute bacterial skin and skin structure infections (ABSSSI) caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus* group (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, or *Klebsiella pneumoniae* AND ONE of the following:

a. Patient has a documented infection that is resistant to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole, OR that is resistant to vancomycin at the site of infection OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:**

The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient

**Coverage Duration:**

Approval will be for 14 days

**Other Criteria:**

- b. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
  - c. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
  - d. Patient has an intolerance or hypersensitivity to vancomycin OR
  - e. Patient has an FDA labeled contraindication to vancomycin AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Ofev PA

**Drug Name(s)**

Ofev

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
    - ii. Patient has no known explanation for interstitial lung disease (ILD) or pulmonary fibrosis (e.g., radiation, drugs, metal dusts, sarcoidosis, or any connective tissue disease known to cause ILD) OR
  - B. BOTH of the following:
    - i. Patient has a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) AND
    - ii. Patient's diagnosis has been confirmed on high-resolution computed tomography (HRCT) or chest radiography scans OR
  - C. BOTH of the following:
    - i. Patient has a diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype AND
    - ii. Patient's diagnosis has been confirmed on high-resolution computed tomography (HRCT)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of ONE of the following:
  - A. Idiopathic pulmonary fibrosis (IPF) OR
  - B. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) OR
  - C. Chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pathologist, pulmonologist, radiologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ohtuvayre PA

**Drug Name(s)**

Ohtuvayre

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) AND ALL of the following:
  - A. Patient's diagnosis was confirmed by spirometry with a post-bronchodilator FEV1/FVC ratio less than 0.7 AND
  - B. Patient has a post-bronchodilator FEV1 between 30% to 80% predicted AND
  - C. ONE of the following:
    - i. Patient has a Medical Research Council dyspnea (mMRC) score of 2 or greater OR
    - ii. Patient has a COPD Assessment Test (CAT) score greater than or equal to 10 AND
  - D. ONE of the following:
    - i. Patient is currently being treated with a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination with or without an inhaled corticosteroid (ICS) OR
    - ii. Patient has an intolerance or hypersensitivity to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination OR
    - iii. Patient has an FDA labeled contraindication to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) AND
3. ONE of the following:
  - A. Patient is currently being treated with a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination with or without an inhaled corticosteroid (ICS) OR
  - B. Patient has an intolerance or hypersensitivity to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination OR
  - C. Patient has an FDA labeled contraindication to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination AND
4. Patient has had clinical benefit with the requested agent (e.g., decrease in exacerbations and/or dyspnea)

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Omnipod PA

**Drug Name(s)**

Omnipod Kit

Omnipod Pods

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of diabetes mellitus AND
2. Patient is on an insulin regimen of 3 or more injections per day AND
3. ONE of the following:
  - A. Patient is testing glucose levels 4 or more times per day OR
  - B. Patient is using a continuous glucose monitor (CGM)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of diabetes mellitus AND
3. Patient has had clinical benefit with the requested agent (e.g., stable or improved glycemic control)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Onapgo PA

**Drug Name(s)**

Onapgo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of advanced Parkinson's disease AND
2. The requested agent will be used for the treatment of motor fluctuations AND
3. The requested agent will be used in combination with agents used for therapy in Parkinson's disease (e.g., levodopa, dopamine agonist, monoamine oxidase B inhibitor)

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Ophthalmic Immunomodulators PA – Cequa

**Drug Name(s)**

Cequa

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ophthalmic Immunomodulators PA – Verkazia

**Drug Name(s)**

Verkazia

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ophthalmic Immunomodulators PA – Vevye

**Drug Name(s)**

Vevye

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ophthalmic Immunomodulators PA – Xiidra

**Drug Name(s)**

Xiidra

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA - Buprenorphine Pain

**Drug Name(s)**

Belbuca

Buprenorphine

Butrans

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA - Fentanyl Patch

**Drug Name(s)**

Fentanyl Patch

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Opioids ER PA – Hydrocodone

**Drug Name(s)**

Hydrocodone Bitartrate Er

Hysingla Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA – Hydromorphone

**Drug Name(s)**

Hydromorphone Hcl Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA – Morphine

**Drug Name(s)**

Morphine Sulfate Er

Ms Contin

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA – Oxycodone

**Drug Name(s)**

Oxycodone Hcl Er

Oxycontin

Xtampza Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Opioids ER PA – Oxymorphone

**Drug Name(s)**

Oxymorphone Hcl Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA – Tapentadol

**Drug Name(s)**

Nucynta Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opioids ER PA – Tramadol

**Drug Name(s)**

Conzip

Tramadol Hcl Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of cancer-related pain OR
- B. Patient has a diagnosis of pain due to sickle cell disease OR
- C. Patient is undergoing treatment of chronic non-cancer pain AND ONE of the following:
  - i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - ii. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - iii. ALL of the following:
    - a. Prescriber has completed a formal, consultative evaluation including BOTH of the following:
      - 1. Diagnosis AND
      - 2. A medical history which includes previous and current pharmacological and non-pharmacological therapy for the requested diagnosis AND
    - b. The requested agent is NOT prescribed as an as-needed (prn) analgesic AND
    - c. Prescriber has confirmed that a patient-specific pain management plan is on file for the patient AND
    - d. ONE of the following:
      - 1. Patient's medication history includes use of an immediate-acting opioid OR
      - 2. Patient has an intolerance or hypersensitivity to an immediate-acting opioid OR
      - 3. Patient has an FDA labeled contraindication to an immediate-acting opioid AND
    - e. Prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) AND has determined that the opioid dosages and combinations of opioids and other controlled substances within the patient's records do NOT indicate the patient is at high risk for overdose AND
    - f. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Opzelura PA

**Drug Name(s)**

Opzelura

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:
  - A. Patient (pt) has a diagnosis of mild to moderate atopic dermatitis AND ALL of the following:
    - i. The requested agent will be used for short-term and non-continuous chronic treatment AND
    - ii. Pt is NOT immunocompromised AND
    - iii. ONE of the following:
      - a. Pt has tried and failed a topical steroid (e.g., triamcinolone) OR
      - b. Pt has an intolerance or hypersensitivity to a topical steroid OR
      - c. Pt has an FDA labeled contraindication to a topical steroid AND
    - iv. ONE of the following:
      - a. Pt has tried and failed a topical calcineurin inhibitor (e.g., tacrolimus) OR
      - b. Pt has an intolerance or hypersensitivity to a topical calcineurin inhibitor OR
      - c. Pt has an FDA labeled contraindication to a topical calcineurin inhibitor OR
  - B. Pt has a diagnosis of nonsegmental vitiligo AND
2. Pt will NOT be using the requested agent in combination with other biologic immunomodulator agents, other JAK inhibitors, OR potent immunosuppressants (e.g., azathioprine, cyclosporine) AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Pt has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Pt has a diagnosis of mild to moderate atopic dermatitis AND BOTH of the following:
    - i. The requested agent will be used for short-term and non-continuous chronic treatment AND
    - ii. Pt is NOT immunocompromised OR
  - B. Pt has a diagnosis of nonsegmental vitiligo AND
3. Pt has had clinical benefit with the requested agent AND
4. Pt will NOT be using the requested agent in combination with other biologic immunomodulator agents, other JAK inhibitors, OR potent immunosuppressants (e.g., azathioprine, cyclosporine) AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

For diagnosis of mild to moderate atopic dermatitis, patient is 2 years of age or over. For diagnosis of nonsegmental vitiligo, patient is 12 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Atopic dermatitis: 3 months for initial, 12 months for renewal. Other diagnosis -see Other Criteria

**Other Criteria:**

Initial: 6 months for nonsegmental vitiligo, Renewal: 12 months for nonsegmental vitiligo



**Prior Authorization Group Description:**

Oral Immunotherapy Agents PA – Grastek

**Drug Name(s)**

Grastek

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of allergic rhinitis, with or without conjunctivitis AND
2. Patient's diagnosis is confirmed with ONE of the following:
  - A. Positive skin test to ONE of the pollen extracts included in the requested agent OR
  - B. IgE specific antibodies to ONE of the extracts included in the requested agent: Timothy grass or cross-reactive grass AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to an intranasal corticosteroid AND one other standard allergy agent (e.g., oral or intranasal antihistamines, oral or intranasal corticosteroids, leukotriene inhibitors. note: two separate intranasal corticosteroids meet this criteria) OR
  - B. Patient has an intolerance or hypersensitivity to therapy with an intranasal corticosteroid AND one other standard allergy agent OR
  - C. Patient has an FDA labeled contraindication to therapy with an intranasal corticosteroid AND one other standard allergy agent AND
4. Patient will NOT be using the requested agent in combination with a subcutaneous injectable immunotherapy agent AND
5. The requested agent will be started, or has already been started, 3 to 4 months before the expected onset of the applicable pollen season AND
6. The first dose is given in the clinic/hospital under direct supervision from the provider for a period of at least 30 minutes AND
7. Patient has been prescribed epinephrine auto-injector for at home emergency use

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oral Immunotherapy Agents PA – Odactra

**Drug Name(s)**

Odactra

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of allergic rhinitis, with or without conjunctivitis AND
2. Patient's diagnosis is confirmed with ONE of the following:
  - A. Positive skin test to licensed house dust mite allergen extracts OR
  - B. IgE specific antibodies to ONE of the extracts included in the requested agent: Dermatophagoides farinae or Dermatophagoides pteronyssinus AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to an intranasal corticosteroid AND one other standard allergy agent (e.g., oral or intranasal antihistamines, oral or intranasal corticosteroids, leukotriene inhibitors. note: two separate intranasal corticosteroids meet this criteria) OR
  - B. Patient has an intolerance or hypersensitivity to therapy with an intranasal corticosteroid AND one other standard allergy agent OR
  - C. Patient has an FDA labeled contraindication to therapy with an intranasal corticosteroid AND one other standard allergy agent AND
4. Patient will NOT be using the requested agent in combination with a subcutaneous injectable immunotherapy agent AND
5. The first dose is given in the clinic/hospital under direct supervision from the provider for a period of at least 30 minutes AND
6. Patient has been prescribed epinephrine auto-injector for at home emergency use

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Oriahnn PA

**Drug Name(s)**

Oriahnn

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) AND
2. Patient's diagnosis of uterine fibroids was confirmed via imaging (e.g., ultrasound) AND
3. Patient is premenopausal AND
4. Patient will NOT be using the requested agent in combination with another GnRH antagonist agent [e.g., Orilissa (elagolix), Myfembree (relugolix, estradiol hemihydrate, norethindrone acetate)] for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication AND
6. ONE of the following:
  - A. Patient is initiating therapy with the requested agent OR
  - B. BOTH of the following:
    - i. Patient is continuing therapy with the requested agent and the prescriber has provided information indicating the number of months the patient has been on therapy with the requested agent AND
    - ii. The total duration of treatment with the requested agent has NOT exceeded 24 months per lifetime

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

For no prior Oriahnn use: 24 months

For prior Oriahnn use: Remainder of 24 months

**Other Criteria:**

**Prior Authorization Group Description:**

Orilissa PA

**Drug Name(s)**

Orilissa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of moderate to severe pain associated with endometriosis AND
2. ONE of the following:
  - A. Patient has coexisting dyspareunia AND has not received 6 or more months of therapy with the requested agent OR
  - B. Patient has coexisting moderate hepatic impairment (Child-Pugh Class B) AND has not received 6 or more months of therapy with the requested agent OR
  - C. Patient does not have coexisting dyspareunia or moderate hepatic impairment (Child-Pugh Class B), AND has not received 24 or more months of therapy with the requested agent AND
3. Patient will NOT be using the requested agent in combination with another GnRH antagonist agent [e.g., Oriahnn (elagolix, estradiol, norethindrone acetate), Myfembree (relugolix, estradiol hemihydrate, norethindrone acetate)] for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication AND
5. ONE of the following:
  - A. Patient is initiating therapy with the requested agent OR
  - B. BOTH of the following:
    - i. Patient is continuing therapy with the requested agent and the prescriber has provided information indicating the number of months the patient has been on therapy with the requested agent AND
    - ii. The total duration of treatment with the requested agent has NOT exceeded 6 months per lifetime if patient has coexisting dyspareunia or moderate hepatic impairment, or 24 months per lifetime if the patient does NOT have coexisting dyspareunia or moderate hepatic impairment

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

For no prior Orilissa use and for prior Orilissa use, see Other Criteria for approval

**Other Criteria:**

No prior Orilissa use: Approve 6 months for coexisting dyspareunia OR moderate hepatic impairment, Approve 24 months for no coexisting condition

Prior Orilissa use: Approve remainder of 6 months for coexisting dyspareunia OR moderate hepatic impairment, Approve remainder of 24 months for no coexisting condition

**Prior Authorization Group Description:**

Orkambi PA

**Drug Name(s)**

Orkambi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has the presence of the F508del mutation on both alleles (homozygous) of the CFTR gene confirmed by genetic testing OR
  - B. Patient has another CFTR gene mutation(s) that is responsive to the requested agent, as indicated in the FDA label, confirmed by genetic testing AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Osenvelt PA

**Drug Name(s)**

Osenvelt

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

- iii. ONE of the following:
  - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
  - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Osphena PA

**Drug Name(s)**

Osphena

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Ospomyv PA

**Drug Name(s)**

Ospomyv

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR
  - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
  - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
  - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
  - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
  - iii. Pt's diagnosis was confirmed by ONE of:
    - 1. A fragility fracture in the hip or spine OR
    - 2. A T-score of -2.5 or lower OR
    - 3. A T-score of -1.0 to -2.5 AND ONE of:
      - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - iv. ONE of:
    - 1. Pt is at high fracture risk as defined by ONE of:
      - a. Pt had a recent fracture (within the past 12 months) OR
      - b. Pt had fractures while on FDA approved osteoporosis therapy OR

- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqqg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Otezla PA

**Drug Name(s)**

Otezla

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has a diagnosis of plaque psoriasis AND
    - ii. ONE of the following:
      1. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
      2. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
      3. Patient's medication history indicates use of a biologic immunomodulator agent for the same FDA labeled indication OR
      4. Patient has tried and had an inadequate response to at least ONE conventional prerequisite agent for the requested indication OR
      5. Patient has an intolerance or hypersensitivity to at least ONE conventional prerequisite agent for the requested indication OR
      6. Patient has an FDA labeled contraindication to at least ONE conventional prerequisite agent for the requested indication OR
  - B. Patient has a diagnosis of active psoriatic arthritis OR
  - C. Patient has a diagnosis of oral ulcers associated with Behcet's disease (BD)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has ONE of the following diagnoses:
  - A. Plaque psoriasis OR
  - B. Active psoriatic arthritis OR
  - C. Oral ulcers associated with Behcet's disease (BD) AND
3. Patient has had clinical benefit with the requested agent (slowing of disease progression or decrease in symptom severity and/or frequency)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Formulary conventional agent required for diagnosis of plaque psoriasis

Formulary conventional agents for plaque psoriasis include cyclosporine, methotrexate, tazarotene, topical calcitriol, or topical corticosteroids

NO prerequisites are required for diagnoses of active psoriatic arthritis or oral ulcers associated with Behcet's disease (BD)

**Prior Authorization Group Description:**

Otezla Xr PA

**Drug Name(s)**

Otezla Xr

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:
  - A. BOTH of the following:
    - i. Patient has a diagnosis of plaque psoriasis AND
    - ii. ONE of the following:
      1. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
      2. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
      3. Patient's medication history indicates use of a biologic immunomodulator agent for the same FDA labeled indication OR
      4. Patient has tried and had an inadequate response to at least ONE conventional prerequisite agent for the requested indication OR
      5. Patient has an intolerance or hypersensitivity to at least ONE conventional prerequisite agent for the requested indication OR
      6. Patient has an FDA labeled contraindication to at least ONE conventional prerequisite agent for the requested indication OR
  - B. Patient has a diagnosis of active psoriatic arthritis OR
  - C. Patient has a diagnosis of oral ulcers associated with Behcet's disease (BD)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has ONE of the following diagnoses:
  - A. Plaque psoriasis OR
  - B. Active psoriatic arthritis OR
  - C. Oral ulcers associated with Behcet's disease (BD) AND
3. Patient has had clinical benefit with the requested agent (slowing of disease progression or decrease in symptom severity and/or frequency)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Formulary conventional agent required for diagnosis of plaque psoriasis

Formulary conventional agents for plaque psoriasis include cyclosporine, methotrexate, tazarotene, topical calcitriol, or topical corticosteroids

NO prerequisites are required for diagnoses of active psoriatic arthritis or oral ulcers associated with Behcet's disease (BD)

**Prior Authorization Group Description:**

Otrexup PA

**Drug Name(s)**

Otrexup

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to a generic methotrexate injectable agent OR
  - B. Patient has an intolerance or hypersensitivity to a generic methotrexate injectable agent OR
  - C. Patient has an FDA labeled contraindication to a generic methotrexate injectable agent OR
  - D. Prescriber has provided information that the patient has a physical or a mental disability that would prevent the patient from using a generic methotrexate injectable agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Oxervate PA

**Drug Name(s)**

Oxervate

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of neurotrophic keratitis (NK) AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., ophthalmologist, optometrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 8 weeks

**Other Criteria:**

**Prior Authorization Group Description:**

Oxlumo PA

**Drug Name(s)**

Oxlumo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by ONE of the following:
  - A. Genetic testing of the AGXT gene indicates a pathogenic mutation OR
  - B. Liver biopsy demonstrates absent or significantly reduced alanine:glyoxylate aminotransferase (AGT) activity AND
2. The requested agent will be used to lower urinary or plasma oxalate levels AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of primary hyperoxaluria type 1 (PH1) AND
3. The requested agent will be used to lower urinary or plasma oxalate levels AND
4. Patient has had clinical benefit with the requested agent AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, geneticist, nephrologist, urologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Ozempic PA

**Drug Name(s)**

Ozempic

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
  - C. ALL of the following:
    - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
    - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Palforzia PA

**Drug Name(s)**

Palforzia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of peanut allergy AND
2. Patient's diagnosis has been confirmed by ONE of the following:
  - A. A serum peanut-specific IgE level greater than or equal to 0.35 kUA/L OR
  - B. A positive skin-prick test determined by a mean wheal diameter that is at least 3mm larger than the negative control upon skin-prick testing for peanut AND
3. Patient is/was 1-17 years of age at the time of initiating therapy AND
4. Patient has been prescribed epinephrine injection for at home emergency use AND
5. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of peanut allergy AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient has been prescribed epinephrine injection for at home emergency use AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Palynziq PA

**Drug Name(s)**

Palynziq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of phenylketonuria (PKU) AND
2. Patient has a baseline blood Phe level greater than 600 micromol/L (10 mg/dL) AND
3. Patient will NOT be using the requested agent in combination with sapropterin for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of phenylketonuria (PKU) AND
3. ONE of the following:
  - a. Patient's blood Phe levels are being maintained within the acceptable range OR
  - b. Patient has had a decrease in blood Phe level from baseline AND
4. Patient will NOT be using the requested agent in combination with sapropterin for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., metabolic or genetic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 9 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Panretin PA

**Drug Name(s)**

Panretin

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. ALL of the following:
    - i. ONE of the following:
      1. BOTH of the following:
        - a. Patient has a diagnosis of cutaneous lesions associated with AIDS-related Kaposi's sarcoma (KS) AND
        - b. Patient does NOT require systemic anti-Kaposi's sarcoma therapy OR
      2. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., oncologist, dermatologist, infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
    - iii. Patient does NOT have any FDA labeled contraindications to the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Panzyga PA

**Drug Name(s)**

Panzyga

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

- A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR
- B. B-cell chronic lymphocytic leukemia OR multiple myeloma AND ONE of the following:
  - i. Patient has a history of infections OR
  - ii. Patient has evidence of specific antibody deficiency OR
  - iii. Patient has hypogammaglobulinemia OR
- C. Idiopathic thrombocytopenia purpura AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone), or immunosuppressants (e.g., mycophenolate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- D. Dermatomyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- E. Polymyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- F. Severe rheumatoid arthritis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., tumor necrosis factor antagonists (e.g., Enbrel), DMARDS (e.g., methotrexate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 6 months for indications in Other Criteria, 12 months for all others

**Other Criteria:**

G. Myasthenia gravis (MG) AND ONE of the following:

- i. Patient is in acute myasthenic crisis OR
- ii. Patient has severe refractory MG (e.g., major functional disability/weakness) AND ONE of the following:
  - a) Patient has failed ONE immunomodulator therapy (i.e., corticosteroid, pyridostigmine, or azathioprine) OR
  - b) Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE immunomodulator therapy OR

H. Multiple sclerosis (MS) AND BOTH of the following:

- i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND
- ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication to TWO MS agents (e.g., Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Plegridy, teriflunomide, Vumerity) OR

I. Acquired von Willebrand hemophilia AND ONE of the following:

- i. Patient has failed ONE conventional therapy (e.g., desmopressin, von Willebrand factor replacement therapy, corticosteroids, FEIBA, or recombinant factor VIIa) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

J. Refractory pemphigus vulgaris AND ONE of the following:

- i. Patient has failed ONE conventional immunosuppressive therapy (e.g., azathioprine, cyclophosphamide, mycophenolate, corticosteroids) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional immunosuppressive therapy OR

2. ONE of the following:

- A. Patient has another FDA labeled indication for the requested agent OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Indications with 6 months approval duration: Acquired von Willebrand hemophilia, Guillain-Barre Syndrome, Lambert-Eaton myasthenia syndrome, Kawasaki disease, CMV induced pneumonitis in solid organ transplant, Toxic shock syndrome due to invasive group A streptococcus, Toxic epidermal necrolysis and Stevens-Johnson syndrome

Drug is also subject to Part B versus Part D review.



**Prior Authorization Group Description:**

Pegylated Interferon PA

**Drug Name(s)**

Pegasys

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of chronic hepatitis B AND BOTH of the following:

i. The chronic hepatitis B infection has been confirmed by serological markers AND

ii. Patient has NOT been administered the requested agent for more than 48 weeks for the treatment of chronic hepatitis B OR

B. BOTH of the following:

i. Patient has a diagnosis of chronic hepatitis C confirmed by serological markers AND

ii. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling for the patient's diagnosis and genotype OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

12 months for all other diagnoses. For hep B, hep C see Other Criteria

**Other Criteria:**

No prior peginterferon alfa use, approve 48 weeks for hepatitis B infection. Prior peginterferon alfa use, approve remainder of 48 weeks of total therapy for hepatitis B infection

Duration of therapy for hepatitis C: Based on FDA approved labeling

**Prior Authorization Group Description:**

Pirfenidone PA

**Drug Name(s)**

Esbriet

Pirfenidone

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
2. Patient has no known explanation for interstitial lung disease (ILD) or pulmonary fibrosis (e.g., radiation, drugs, metal dusts, sarcoidosis, or any connective tissue disease known to cause ILD)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of idiopathic pulmonary fibrosis (IPF) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., pathologist, pulmonologist, radiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Posaconazole PA

**Drug Name(s)**

Noxafil

Posaconazole

Posaconazole Dr

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of oropharyngeal candidiasis AND ONE of the following:

- i. Patient has tried and had an inadequate response to fluconazole or an alternative antifungal agent OR
- ii. Patient has an intolerance or hypersensitivity to fluconazole or an alternative antifungal agent OR
- iii. Patient has an FDA labeled contraindication to fluconazole or an alternative antifungal agent OR

B. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or Candida AND patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR

C. Patient has a diagnosis of invasive Aspergillus AND ONE of the following:

- i. Patient has tried and had an inadequate response to an alternative antifungal agent OR
- ii. Patient has an intolerance or hypersensitivity to an alternative antifungal agent OR
- iii. Patient has an FDA labeled contraindication to an alternative antifungal agent OR

D. Patient has another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 1 month for oropharyngeal candidiasis, 6 months for all other indications

**Other Criteria:**

Criteria for renewal approval require BOTH of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:

- A. The requested agent is being prescribed for prophylaxis of invasive *Aspergillus* or *Candida* and patient continues to be severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR
- B. Patient has a diagnosis of invasive *Aspergillus* AND patient has continued indicators of active disease (e.g., biomarkers in serum assay, microbiologic cultures, radiographic evidence) OR
- C. BOTH of the following:
  - i. Patient has a diagnosis of oropharyngeal candidiasis AND
  - ii. Patient has had clinical benefit with the requested agent OR
- D. BOTH of the following:
  - i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
  - ii. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Praluent PA

**Drug Name(s)**

Praluent

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has ONE of the following:

- A. A diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:
  - i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR
  - ii. ONE of the following:
    - a. Patient is 18 years of age or older AND has a pretreatment LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) OR
    - b. Patient is between the ages of 8 and less than 18 years of age AND has a pretreatment LDL-C greater than 155 mg/dL (greater than 4.0 mmol/L) OR
  - iii. Clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, corneal arcus, tuberous xanthoma, or xanthelasma) OR
  - iv. "Definite" or "possible" familial hypercholesterolemia as defined by the Simon Broome criteria OR
  - v. A Dutch Lipid Clinic Network criteria score of greater than 5 OR
  - vi. A treated low-density lipoprotein cholesterol (LDL-C) level greater than or equal to 100 mg/dL after treatment with antihyperlipidemic agents but prior to PCSK9 inhibitor therapy OR
- B. A diagnosis of homozygous familial hypercholesterolemia (HoFH) AND ONE of the following:
  - i. Genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes or greater than or equal to 2 such variants at different loci OR
  - ii. History of untreated LDL-C greater than 400 mg/dL (greater than 10 mmol/L) AND ONE of the following:
    - a. Cutaneous or tendon xanthomas before 10 years of age OR
    - b. Untreated elevated LDL-C levels consistent with heterozygous familial hypercholesterolemia (HeFH) in both parents (or in digenic form, one parent may have normal LDL-C levels and the other may have LDL-C levels consistent with HoFH) OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- C. An increased risk of major adverse cardiovascular (CV) events [coronary heart disease death, myocardial infarction (MI), stroke, and unstable angina requiring hospitalization] AND the requested agent will be used to reduce the risk of these events OR
  - D. A diagnosis of hypercholesterolemia [not associated with HeFH, HoFH, or increased risk of major adverse cardiovascular (CV) events] OR
  - E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
- A. Patient has tried and had an inadequate response to a high-intensity statin (i.e., rosuvastatin 20-40 mg or atorvastatin 40-80 mg) OR
  - B. Patient has an intolerance to TWO different statins OR
  - C. Patient has an FDA labeled contraindication to a statin AND
3. Patient will NOT be using the requested agent in combination with another PCSK9 agent AND
4. ONE of the following:
- A. BOTH of the following:
    - i. Patient has a diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND
    - ii. Patient is between 8 and less than 10 years of age OR
  - B. Patient has tried and had an inadequate response to Repatha OR
  - C. Patient has an intolerance or hypersensitivity to Repatha OR
  - D. Patient has an FDA labeled contraindication to Repatha

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent AND
- 4. Patient will NOT be using the requested agent in combination with another PCSK9 agent

**Prior Authorization Group Description:**

Prolia PA

**Drug Name(s)**

Prolia

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR
  - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
  - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
  - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
  - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
  - iii. Pt's diagnosis was confirmed by ONE of:
    - 1. A fragility fracture in the hip or spine OR
    - 2. A T-score of -2.5 or lower OR
    - 3. A T-score of -1.0 to -2.5 AND ONE of:
      - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - iv. ONE of:
    - 1. Pt is at high fracture risk as defined by ONE of:
      - a. Pt had a recent fracture (within the past 12 months) OR
      - b. Pt had fractures while on FDA approved osteoporosis therapy OR



- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqqg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Promacta PA

**Drug Name(s)**

Eltrombopag

Promacta

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

- A. Patient (pt) has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
  - i. Pt has tried and had an insufficient response to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
  - ii. Pt has an intolerance or hypersensitivity to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
  - iii. Pt has an FDA labeled contraindication to a corticosteroid or immunoglobulin (IVIg or anti-D) OR
  - iv. Pt has had an insufficient response to a splenectomy OR
- B. Pt has a diagnosis of hepatitis C associated thrombocytopenia AND ONE of the following:
  - i. Pt's platelet count is less than  $75 \times 10^9/L$  AND the intent is to increase platelet counts sufficiently to initiate interferon therapy OR
  - ii. Pt is on concomitant therapy with interferon therapy AND is at risk for discontinuing hepatitis C therapy due to thrombocytopenia OR
- C. Pt has a diagnosis of severe aplastic anemia (SAA) AND ALL of the following:
  - i. Pt has at least 2 of the following blood criteria:
    - 1. Neutrophils less than  $0.5 \times 10^9/L$  OR
    - 2. Platelets less than  $30 \times 10^9/L$  OR
    - 3. Reticulocyte count less than  $60 \times 10^9/L$  AND
  - ii. Pt has at least 1 of the following marrow criteria:
    - 1. Severe hypocellularity is less than 25% OR
    - 2. Moderate hypocellularity is 25-50% with hematopoietic cells representing less than 30% of residual cells AND
  - iii. ONE of the following:
    - 1. Pt has tried and had an insufficient response to BOTH antithymocyte globulin (ATG) AND cyclosporine therapy OR
    - 2. BOTH of the following:
      - a. Pt will be using the requested agent as first-line treatment (i.e., has not been treated with ATG and/or cyclosporine) AND
      - b. Pt will use the requested agent in combination with standard immunosuppressive therapy (i.e., ATG AND cyclosporine) OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:****Coverage Duration:**

Initial: 6 months for ITP. Renewal: 12 months for ITP. Other indications, see Other Criteria.

**Other Criteria:**

- D. Pt has another indication that is supported in CMS approved compendia for the requested agent AND
- 2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Criteria for renewal approval require ALL of the following:

- 1. Pt has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
  - A. Pt has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
    - i. Pt's platelet count is  $50 \times 10^9/L$  or greater OR
    - ii. Pt's platelet count has increased sufficiently to avoid clinically significant bleeding OR
  - B. Pt has a diagnosis of hepatitis C associated thrombocytopenia AND BOTH of the following:
    - i. ONE of the following:
      - 1. Pt will be initiating hepatitis C therapy with interferon therapy OR
      - 2. Pt will be maintaining hepatitis C therapy with interferon therapy at the same time as the requested agent AND
    - ii. ONE of the following:
      - 1. Pt's platelet count is  $90 \times 10^9/L$  or greater OR
      - 2. Pt's platelet count has increased sufficiently to initiate or maintain interferon therapy for the treatment of hepatitis C OR
  - C. Pt has a diagnosis of severe aplastic anemia (SAA) AND the pt has had clinical benefit with the requested agent OR
  - D. Pt has another indication that is supported in CMS approved compendia and the pt has had clinical benefit with the requested agent AND
- 3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Initial: 48 weeks for hepatitis C associated thrombocytopenia, 6 months for first-line therapy in severe aplastic anemia, 16 weeks for SAA, 12 months for All other indications

Renewal: 48 weeks for hepatitis C associated thrombocytopenia, 12 months for SAA, 12 months for All other indications

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Adempas

**Drug Name(s)**

Adempas

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group 4, as determined by a ventilation-perfusion scan and a confirmatory selective pulmonary angiography AND ALL of the following:

i. ONE of the following:

- a. Patient is NOT a candidate for surgery OR
- b. Patient has had pulmonary endarterectomy AND has persistent or recurrent disease AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units OR

C. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

v. ONE of the following:

- a. The requested agent will be utilized as monotherapy OR
- b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:
  - 1. Patient has unacceptable or deteriorating clinical status despite established pharmacotherapy AND
  - 2. The requested agent is in a different therapeutic class OR
- c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:
  - 1. Patient has unacceptable or deteriorating clinical status despite established pharmacotherapy AND
  - 2. All three agents in the triple therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Ambrisentan

**Drug Name(s)**

Ambrisentan

Letairis

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

- i. Patient's World Health Organization (WHO) functional class is II or greater AND
- ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
- iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
- iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND
- v. ONE of the following:
  - a. The requested agent will be utilized as monotherapy OR
  - b. The requested agent will be used in combination with a phosphodiesterase 5 (PDE5) inhibitor for dual therapy ONLY OR
  - c. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), [except for dual therapy requests for a phosphodiesterase 5 (PDE 5) inhibitor plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:
    - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
    - 2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:
  - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 2. All three agents in the triple therapy are from a different therapeutic class OR
- e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
  - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Bosentan

**Drug Name(s)**

Bosentan

Tracleer

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Elevated liver enzymes accompanied by signs or symptoms of liver dysfunction/injury or a bilirubin level of 2 times the ULN (upper limit of normal) or greater AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1, as determined by right heart catheterization, AND ALL of the following:

- i. Patient's World Health Organization (WHO) functional class is II or greater AND
- ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
- iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
- iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

- a. The requested agent will be utilized as monotherapy OR
- b. The requested agent will be used in combination with a phosphodiesterase 5 (PDE5) inhibitor for dual therapy ONLY OR
- c. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), [except for dual therapy requests for a phosphodiesterase 5 inhibitor (PDE5) plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:
  - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria



**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
2. All three agents in the triple therapy are from a different therapeutic class OR

e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:

1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Opsumit

**Drug Name(s)**

Opsumit

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be used in combination with a phosphodiesterase 5 (PDE5) inhibitor for dual therapy ONLY OR

c. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), [except for dual therapy requests for a phosphodiesterase 5 (PDE 5) inhibitor plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
2. All three agents in the triple therapy are from a different therapeutic class OR

e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:

1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Opsynvi

**Drug Name(s)**

Opsynvi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Concurrently taking another phosphodiesterase 5 (PDE5) inhibitor with the requested agent AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR

b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as dual therapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (triple therapy) AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has an FDA labeled indication for the requested agent AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Orenitram

**Drug Name(s)**

Orenitram

Orenitram Titration Kit

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND

2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

3. All three agents in the triple therapy are from a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- d. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
  - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- e. The requested agent will be utilized for add-on therapy to existing triple therapy (quadruple therapy), AND ALL of the following:
  - 1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 3. All four agents in the quadruple therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Sildenafil

**Drug Name(s)**

Revatio

Sildenafil Citrate

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Concurrently taking another phosphodiesterase 5 (PDE5) inhibitor with the requested agent AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR

b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be used in combination with an endothelin receptor antagonist (ERA) for dual therapy ONLY OR

c. The requested agent will be utilized for add-on therapy to existing monotherapy, [except for dual requests for a phosphodiesterase 5 (PDE5) inhibitor plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**



**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy) AND BOTH of the following:
    - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
    - 2. All three agents in the triple therapy are from a different therapeutic class OR
  - e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
    - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
    - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Tadalafil

**Drug Name(s)**

Adcirca

Alyq

Tadalafil Tablet 20Mg

Tadliq

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Concurrently taking another phosphodiesterase 5 (PDE5) inhibitor with the requested agent AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

- i. Patient's World Health Organization (WHO) functional class is II or greater AND
- ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
- iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
- iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND
- v. ONE of the following:
  - a. The requested agent will be utilized as monotherapy OR
  - b. The requested agent will be used in combination with an endothelin receptor antagonist (ERA) for dual therapy ONLY OR
  - c. The requested agent will be utilized for add-on therapy to existing monotherapy, [except for dual requests for a phosphodiesterase 5 (PDE5) inhibitor plus an endothelin receptor antagonist (ERA)], AND BOTH of the following:
    - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
    - 2. The requested agent is in a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- d. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy) AND BOTH of the following:
  - 1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 2. All three agents in the triple therapy are from a different therapeutic class OR
- e. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
  - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Tyvaso DPI

**Drug Name(s)**

Tyvaso Dpi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND

2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

3. All three agents in the triple therapy are from a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- d. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
  - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- e. The requested agent will be utilized for add-on therapy to existing triple therapy (quadruple therapy), AND ALL of the following:
  - 1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 3. All four agents in the quadruple therapy are from a different therapeutic class OR
- C. Patient has a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO group 3) AND BOTH of the following:
  - i. ONE of the following:
    - a. The diagnosis was confirmed by right heart catheterization AND ALL of the following:
      - 1. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
      - 2. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
      - 3. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units OR
    - b. The diagnosis was confirmed by non-invasive testing (e.g., chest radiography, echocardiography, electrocardiography, computed tomography imaging [CT], brain natriuretic peptide (BNP)/N-terminal pro-BNP [NT-proBNP] measurements) AND
  - ii. Patient will continue standard of care therapy for ILD (e.g., nintedanib)

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent AND

4. ONE of the following:

- A. Patient has a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO group 3) AND the patient will continue standard of care therapy for ILD (e.g., nintedanib) OR
- B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Uptravi

**Drug Name(s)**

Uptravi

Uptravi Titration Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. All three agents in the triple therapy are from a different therapeutic class OR

d. The requested agent will be utilized for add-on therapy to existing triple therapy (quadruple therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
2. All four agents in the quadruple therapy are from a different therapeutic class

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent



**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Ventavis

**Drug Name(s)**

Ventavis

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND

2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

3. All three agents in the triple therapy are from a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- d. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
  - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- e. The requested agent will be utilized for add-on therapy to existing triple therapy (quadruple therapy), AND ALL of the following:
  - 1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 3. All four agents in the quadruple therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

Drug is also subject to Part B versus Part D review.

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Winrevair

**Drug Name(s)**

Winrevair

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

- i. Patient's World Health Organization (WHO) functional class is II or greater AND
- ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
- iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
- iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND
- v. ALL of the following:
  - a. The requested agent will be utilized for add-on therapy AND
  - b. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - c. All agents in the therapy are from a different therapeutic class

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Pulmonary Hypertension PA – Yutrepia

**Drug Name(s)**

Yutrepia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

i. ONE of the following:

- a. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- b. Prescriber states the patient is currently being treated with the requested agent within the past 90 days AND

ii. Patient has an FDA labeled indication for the requested agent OR

B. Patient has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 as determined by right heart catheterization AND ALL of the following:

i. Patient's World Health Organization (WHO) functional class is II or greater AND

ii. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND

iii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND

iv. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units AND

v. ONE of the following:

a. The requested agent will be utilized as monotherapy OR

b. The requested agent will be utilized for add-on therapy to existing monotherapy (dual therapy), AND BOTH of the following:

1. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

2. The requested agent is in a different therapeutic class OR

c. The requested agent will be utilized for add-on therapy to existing dual therapy (triple therapy), AND ALL of the following:

1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND

2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND

3. All three agents in the triple therapy are from a different therapeutic class OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- d. The requested agent will be utilized as part of triple therapy in a treatment naive patient AND BOTH of the following:
  - 1. Patient is classified as WHO functional class IV or has been assessed as high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. The three agents being utilized consist of: ERA plus PDE5i plus prostanoid OR
- e. The requested agent will be utilized for add-on therapy to existing triple therapy (quadruple therapy), AND ALL of the following:
  - 1. Patient is WHO functional class III or IV or has been assessed as intermediate to high risk using another PAH risk stratification tool (e.g., 6-minute walking distance, natriuretic peptide) AND
  - 2. Patient has unacceptable or deteriorating clinical status despite established PAH pharmacotherapy AND
  - 3. All four agents in the quadruple therapy are from a different therapeutic class OR
- C. Patient has a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO group 3) as determined by right heart catheterization AND ALL of the following:
  - i. Patient has a mean pulmonary arterial pressure greater than 20 mmHg AND
  - ii. Patient has a pulmonary capillary wedge pressure less than or equal to 15 mmHg AND
  - iii. Patient has a pulmonary vascular resistance greater than or equal to 2 Wood units

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Pyrimethamine PA

**Drug Name(s)**

Daraprim

Pyrimethamine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Pyrukynd PA

**Drug Name(s)**

Pyrukynd

Pyrukynd Taper Pack

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of hemolytic anemia with pyruvate kinase deficiency (PKD) AND ALL of the following:
  - A. ONE of the following:
    - i. Genetic testing showing a pathogenic PKLR gene mutation OR
    - ii. Patient does NOT have two known pathogenic mutations in the PKLR gene, AND patient has a decrease in pyruvate kinase enzyme activity AND
  - B. Patient is NOT homozygous for the c.1436G to A (p.R479H) variant AND
  - C. Patient has at least 2 variant alleles in the PKLR gene, of which at least 1 is a missense variant AND
  - D. Patient does NOT have two non-missense mutations

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hemolytic anemia with pyruvate kinase deficiency (PKD) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hematologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Qbrexza PA

**Drug Name(s)**

Qbrexza

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of primary axillary hyperhidrosis

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Quillichew PA

**Drug Name(s)**

Quillichew Er

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Quillivant PA

**Drug Name(s)**

Quillivant Xr

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Quinine PA

**Drug Name(s)**

Quinine Sulfate

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following diagnoses:

A. Uncomplicated malaria OR

B. Babesiosis OR

C. An indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 7 days for malaria, 12 months for all other diagnoses

**Other Criteria:**

**Prior Authorization Group Description:**

Qulipta PA

**Drug Name(s)**

Qulipta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of migraine AND
2. The requested agent is being used for migraine prophylaxis AND
3. Patient has 4 migraine or more headache days per month AND
4. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. The requested agent is being used for migraine prophylaxis AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another calcitonin gene-related peptide (CGRP) agent for migraine prophylaxis

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Quviviq PA

**Drug Name(s)**

Quviviq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Rasuvo PA

**Drug Name(s)**

Rasuvo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to a generic methotrexate injectable agent OR
  - B. Patient has an intolerance or hypersensitivity to a generic methotrexate injectable agent OR
  - C. Patient has an FDA labeled contraindication to a generic methotrexate injectable agent OR
  - D. Prescriber has provided information that the patient has a physical or a mental disability that would prevent the patient from using a generic methotrexate injectable agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication for the requested agent AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Rayos PA

**Drug Name(s)**

Prednisone Tab Dr

Rayos

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - a. Patient has tried generic oral immediate-release prednisone AND at least 1 other different generic oral corticosteroid agent (e.g., dexamethasone, methylprednisolone) OR
  - b. Patient has an intolerance or hypersensitivity to generic oral immediate-release prednisone AND at least 1 other different generic oral corticosteroid agent (e.g., dexamethasone, methylprednisolone) OR
  - c. Patient has an FDA labeled contraindication to generic oral immediate-release prednisone AND at least 1 other different generic oral corticosteroid agent (e.g., dexamethasone, methylprednisolone)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 6 months

**Other Criteria:**

**Prior Authorization Group Description:**

Reblozyl PA

**Drug Name(s)**

Reblozyl

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. BOTH of the following:

i. Patient has a diagnosis of Beta thalassemia requiring regular red blood cell (RBC) transfusions AND

ii. Patient's diagnosis was confirmed by BOTH of the following:

a. Hemoglobin analysis by hemoglobin electrophoresis or high-performance liquid chromatography AND

b. Genetic analysis for both Beta thalassemia and Alpha thalassemia mutations  
OR

B. ALL of the following:

i. ONE of the following:

a. Patient has a diagnosis of anemia associated with myelodysplastic syndrome with ring sideroblasts (MDS-RS) OR

b. Patient has a diagnosis of anemia associated with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDC/MPN-RS-T) AND

ii. Patient has very low- to intermediate-risk disease AND

iii. ONE of the following:

a. BOTH of the following:

i. Patient does NOT have a del(5q) abnormality AND

ii. ONE of the following:

1. Patient has ring sideroblasts (RS) greater than or equal to 15%  
OR

2. Patient has RS greater than or equal to 5% AND an SF3B1 mutation OR

b. BOTH of the following:

i. Patient has tried and had an inadequate response to an erythropoiesis stimulating agent (ESA) [e.g., Aranesp (darbepoetin alfa), Epogen/Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx)] AND

ii. Patient has required 2 or more red blood cell (RBC) units over 8 weeks  
OR

C. Patient has a diagnosis of anemia associated with myelodysplastic syndromes (MDS) without previous erythropoiesis stimulating agent use (ESA-naïve) AND BOTH of the following:

i. Patient has very low-to-intermediate-risk disease AND



- ii. Patient has required 2 or more red blood cell (RBC) units over 8 weeks AND
- 2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hematologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Initial approval: 15 wks for Beta thalassemia, 12 mos for all other diagnoses. 12 mos for renewal.

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of Beta thalassemia requiring regular red blood cell (RBC) transfusions OR
  - B. Patient has a diagnosis of anemia associated with myelodysplastic syndrome with ring sideroblasts (MDS-RS) OR
  - C. Patient has a diagnosis of anemia associated with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) OR
  - D. Patient has a diagnosis of anemia associated with myelodysplastic syndromes (MDS) without previous erythropoiesis stimulating agent use (ESA-naive) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Recorlev PA

**Drug Name(s)**

Recorlev

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of endogenous hypercortisolemia with Cushing's syndrome AND
2. ONE of the following:
  - A. Patient had an inadequate response to pituitary surgical resection OR
  - B. Patient is NOT a candidate for pituitary surgical resection

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of endogenous hypercortisolemia with Cushing's syndrome AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Redemplo PA

**Drug Name(s)**

Redemplo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of familial chylomicronemia syndrome (FCS) confirmed by ONE of the following:

A. Genetic confirmation of bi-allelic pathogenic variants in affected genes (e.g., LPL, ApoA5, ApoC2, LMF1, GPIHBP1, or G3PDH1) OR

B. ALL of the following:

i. Fasting triglyceride (TG) levels greater than 880 mg/dL (10 mmol/L) for 3 consecutive measurements AND

ii. Secondary causes of hypertriglyceridemia have been ruled out (e.g., alcohol use, chronic kidney disease, hypothyroidism, uncontrolled diabetes, medications [e.g., atypical antipsychotics, beta-blockers, corticosteroids, oral estrogens]) AND

iii. History of pancreatitis or unexplained recurrent abdominal pain

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has a diagnosis of familial chylomicronemia syndrome (FCS) AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, endocrinologist, geneticist, lipidologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Relexxii PA

**Drug Name(s)**

Methylphenidate Hcl Er (Relexxii)

Relexxii

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Relistor Inj PA

**Drug Name(s)**

Relistor Injection

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following diagnoses:

A. Patient has opioid-induced constipation (OIC) with advanced illness or pain caused by active cancer and is receiving palliative care OR

B. Patient has opioid induced constipation (OIC) and chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment AND

2. Patient has chronic use of an opioid agent in the past 90 days AND

3. ONE of the following:

A. Patient has tried and had an inadequate response to lactulose OR

B. Patient has an intolerance or hypersensitivity to lactulose OR

C. Patient has an FDA labeled contraindication to lactulose

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Relistor Tablet PA

**Drug Name(s)**

Relistor Tablet

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has opioid-induced constipation (OIC) and chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment AND
2. Patient has chronic use of an opioid agent in the past 90 days AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to lactulose OR
  - B. Patient has an intolerance or hypersensitivity to lactulose OR
  - C. Patient has an FDA labeled contraindication to lactulose

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Repatha PA

**Drug Name(s)**

Repatha

Repatha Sureclick

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has ONE of the following:

A. A diagnosis of heterozygous familial hypercholesterolemia (HeFH) AND ONE of the following:

- i. Genetic confirmation of one mutant allele at the LDLR, Apo-B, PCSK9, or 1/LDLRAP1 gene OR
- ii. ONE of the following:
  - a. Patient is 18 years of age or older AND has a pretreatment LDL-C greater than 190 mg/dL (greater than 4.9 mmol/L) OR
  - b. Patient is between the ages of 10 and less than 18 years of age AND has a pretreatment LDL-C greater than 155 mg/dL (greater than 4.0 mmol/L) OR
- iii. Clinical manifestations of HeFH (e.g., cutaneous xanthomas, tendon xanthomas, corneal arcus, tuberous xanthoma, or xanthelasma) OR
- iv. "Definite" or "possible" familial hypercholesterolemia as defined by the Simon Broome criteria OR
- v. A Dutch Lipid Clinic Network criteria score of greater than 5 OR

B. A diagnosis of homozygous familial hypercholesterolemia (HoFH) AND ONE of the following:

- i. Genetic confirmation of bi-allelic pathogenic/likely pathogenic variants on different chromosomes at the LDLR, Apo-B, PCSK9, or LDLRAP1 genes or greater than or equal to 2 such variants at different loci OR
- ii. History of untreated LDL-C 400 mg/dL or greater (10 mmol/L or greater) AND ONE of the following:
  - a. Cutaneous or tendon xanthomas before 20 years of age OR
  - b. Untreated elevated LDL-C levels consistent with heterozygous familial hypercholesterolemia (HeFH) in both parents (or in digenic form, one parent may have normal LDL-C levels and the other may have LDL-C levels consistent with HoFH) OR

Initial criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- C. An increased risk of major adverse cardiovascular (CV) events [CV death, myocardial infarction (MI), stroke, unstable angina requiring hospitalization, or coronary revascularization] AND the requested agent will be used to reduce the risk of these events OR
  - D. A diagnosis of hypercholesterolemia [not associated with HeFH, HoFH, or increased risk of major adverse cardiovascular (CV) events] OR
  - E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
- 2. ONE of the following:
    - A. Patient has tried and had an inadequate response to a high-intensity statin (i.e., rosuvastatin 20-40 mg or atorvastatin 40-80 mg) OR
    - B. Patient has an intolerance to TWO different statins OR
    - C. Patient has an FDA labeled contraindication to a statin AND
  - 3. Patient will NOT be using the requested agent in combination with another PCSK9 agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent AND
- 4. Patient will NOT be using the requested agent in combination with another PCSK9 agent



**Prior Authorization Group Description:**

Revcovi PA

**Drug Name(s)**

Revcovi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) confirmed by ONE of the following:
  - A. Molecular genetic confirmation of mutations in both alleles of the ADA1 gene OR
  - B. Deficiency or absence of ADA in lysed erythrocytes, fibroblasts (cultured from amniotic fluid), or chorionic villus OR
  - C. Positive screening by T cell receptor excision circles (TRECs) OR
  - D. Increase in deoxyadenosine triphosphate (dATP) levels in erythrocyte lysates over the testing laboratory's upper limit of the normal range AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, hematologist, immunologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Reyvow PA

**Drug Name(s)**

Reyvow

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. The requested agent will be used for the treatment of acute migraine with or without aura AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to TWO triptan agents with differing active ingredients (e.g., sumatriptan, rizatriptan) OR
  - B. Patient has an intolerance or hypersensitivity to a triptan agent OR
  - C. Patient has an FDA labeled contraindication to a triptan agent AND
3. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, ergotamine, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent will be used for the treatment of acute migraine with or without aura AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, ergotamine, acute CGRP)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Rezdiffra PA

**Drug Name(s)**

Rezdiffra

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Decompensated cirrhosis AND Moderate to severe hepatic impairment (Child-Pugh Class B or C)

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis AND
2. Patient has stage F2 or F3 fibrosis as confirmed by BOTH of the following (prior to therapy with the requested agent):
  - A. A FIB-4 score consistent with stage F2 or F3 fibrosis adjusted for age AND
  - B. ONE of the following:
    - i. A liver biopsy OR
    - ii. ONE of the following:
      1. Vibration-controlled transient elastography (VCTE, e.g., Fibroscan) OR
      2. Enhanced liver fibrosis (ELF) OR
      3. Magnetic resonance elastography (MRE)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hepatologist, gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Rezurock PA

**Drug Name(s)**

Rezurock

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of chronic graft-versus-host disease (chronic GVHD) AND
2. Patient has failed at least two prior lines of systemic therapy

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of chronic graft-versus-host disease (chronic GVHD) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hematologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Rhapsido PA

**Drug Name(s)**

Rhapsido

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of chronic spontaneous urticaria (CSU) (otherwise known as chronic idiopathic urticaria [CIU]) AND
2. Patient has had over 6 weeks of hives and itching AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to maximum tolerable H1 antihistamine therapy OR
  - B. Patient has an intolerance, hypersensitivity, or FDA labeled contraindication to H1 antihistamine therapy AND
4. Patient will NOT be using the requested agent in combination with Dupixent or Xolair for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of chronic spontaneous urticaria (CSU) (otherwise known as chronic idiopathic urticaria [CIU]) AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with Dupixent or Xolair for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, allergist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ritalin LA PA

**Drug Name(s)**

Methylphenidate Hcl Er (Ritalin LA)

Ritalin La

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ritalin PA

**Drug Name(s)**

Methylphenidate Hcl (Ritalin)

Ritalin

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Rivfloza PA

**Drug Name(s)**

Rivfloza

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by ONE of the following:
  - A. Genetic testing of the AGXT gene indicates a pathogenic mutation OR
  - B. Liver biopsy demonstrates absent or significantly reduced alanine:glyoxylate aminotransferase (AGT) activity AND
2. The requested agent will be used to lower urinary oxalate levels AND
3. Patient has an estimated GFR (eGFR) greater than or equal to 30 mL/min/1.73<sup>2</sup> AND
4. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of primary hyperoxaluria type 1 (PH1) AND
3. The requested agent will be used to lower urinary oxalate levels AND
4. Patient has an estimated GFR (eGFR) greater than or equal to 30 mL/min/1.73<sup>2</sup> AND
5. Patient has had clinical benefit with the requested agent AND
6. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, geneticist, nephrologist, urologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**



**Prior Authorization Group Description:**

Roflumilast PA

**Drug Name(s)**

Daliresp

Roflumilast

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. Patient is currently being treated with a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination with or without an inhaled corticosteroid (ICS) OR
  - B. Patient has an intolerance or hypersensitivity to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination OR
  - C. Patient has an FDA labeled contraindication to a long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Rybelsus PA

**Drug Name(s)**

Rybelsus

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
  - C. ALL of the following:
    - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
    - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Samsca PA

**Drug Name(s)**

Samsca

Tolvaptan (Samsca)

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Any underlying liver disease, including cirrhosis AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. The requested agent was initiated (or re-initiated) in the hospital AND
2. Prior to initiating the requested agent, the patient has or had a diagnosis of clinically significant hypervolemic or euvolemic hyponatremia defined by ONE of the following:
  - A. Serum sodium is less than 125 mEq/L OR
  - B. Serum sodium is 125 mEq/L or greater AND patient has symptomatic hyponatremia that has resisted correction with fluid restriction AND
3. Medications known to cause hyponatremia have been evaluated and discontinued when appropriate AND
4. Patient has NOT already received 30 days of therapy with the requested agent following the most recent hospitalization for initiation of therapy AND
5. The requested dose is within the FDA labeled dosing for the requested indication (Recommended starting dose is 15 mg once daily. Dosage may be increased at intervals greater than or equal to 24 hours to 30 mg once daily, and to a maximum of 60 mg once daily as needed to raise serum sodium. Do not administer for more than 30 days to minimize the risk of liver injury.)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 30 days

**Other Criteria:**

**Prior Authorization Group Description:**

Sapropterin PA

**Drug Name(s)**

Javygtor

Kuvan

Sapropterin Dihydrochloride

Zelvysia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of phenylketonuria (PKU) AND
2. Prescriber has submitted a baseline blood Phe level measured prior to initiation of therapy with the requested agent, which is above the recommended levels indicated for the patient's age range or condition AND
3. Patient will NOT be using the requested agent in combination with Palynziq (pegvaliase-pqpz) for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of phenylketonuria (PKU) AND
3. ONE of the following:
  - a. Patient's blood Phe levels are being maintained within the acceptable range OR
  - b. Patient has had a decrease in blood Phe level from baseline AND
4. Patient will NOT be using the requested agent in combination with Palynziq (pegvaliase-pqpz) for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., metabolic or genetic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Initial: 2 months if dose is 5 to less than 20 mg/kg/day, 1 month if 20 mg/kg/day Renewal: 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Self - Administered Oncology PA

**Drug Name(s)**

Abiraterone Acetate  
Abirtega  
Afinitor  
Afinitor Disperz  
Akeega  
Alecensa  
Alunbrig  
Augtyro  
Avmapki Fakzynja Co-Pack  
Ayvakit  
Balversa  
Besremi  
Bexarotene Capsules  
Bosulif  
Braftovi  
Brukinsa  
Cabometyx  
Calquence  
Caprelsa  
Cometriq  
Copiktra  
Cotellic  
Danziten  
Dasatinib  
Daurismo  
Ensacove  
Erivedge  
Erleada  
Erlotinib Hcl  
Everolimus  
Fotivda  
Fruzaqla  
Gavreto  
Gefitinib  
Gilotrif  
Gleevec  
Gomekli  
Hernexeos  
Hyrnuo  
Ibrance  
Ibtrozi

Iclusig  
Idhifa  
Imatinib Mesylate  
Imbruvica  
Imkeldi  
Inluriyo  
Inlyta  
Inqovi  
Inrebic  
Iressa  
Itovebi  
Iwilfin  
Jakafi  
Jaypirca  
Kisqali  
Kisqali Femara  
Komzifti  
Koselugo  
Krazati  
Lapatinib Ditosylate  
Lazcluze  
Lenalidomide  
Lenvima  
Lonsurf  
Lorbrena  
Lumakras  
Lynparza  
Lytgobi  
Matulane  
Mekinist  
Mektovi  
Modeyso  
Nerlynx  
Nexavar  
Nilotinib  
Ninlaro  
Nubeqa  
Odomzo  
Ogsiveo  
Ojemda  
Ojjaara  
Onureg  
Orgovyx  
Orserdu

Pazopanib Hcl  
Pemazyre  
Phyrago  
Piqray  
Pomalyst  
Qinlock  
Retevmo  
Revlimid  
Revuforj  
Rezlidhia  
Romvimza  
Rozlytrek  
Rubraca  
Rydapt  
Scemblix  
Sorafenib  
Sprycel  
Stivarga  
Sunitinib Malate  
Sutent  
Tabrecta  
Tafinlar  
Tagrisso  
Talzenna  
Targretin Capsule  
Tasigna  
Tazverik  
Tepmetko  
Thalomid  
Tibsovo  
Torpenz  
Tretinoin Capsule  
Truqap  
Tukysa  
Turalio  
Tykerb  
Vanflyta  
Venclexta  
Venclexta Starting Pack  
Verzenio  
Vitrakvi  
Vizimpro  
Vonjo  
Voranigo

Votrient  
Welireg  
Xalkori  
Xospata  
Xpovio  
Xtandi  
Yonsa  
Zejula  
Zelboraf  
Zolinza  
Zydelig  
Zykadia  
Zytiga

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND

2. ONE of the following:

A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR

B. Prescriber states the patient is currently being treated with the requested agent OR

C. ALL of the following:

i. Genetic testing has been completed, if required, for therapy with the requested agent and results indicate the requested agent is appropriate AND

ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND

iii. ONE of the following:

a. The requested agent is FDA labeled or supported by CMS approved compendia as a first-line therapy for the requested indication OR

b. Patient has tried appropriate FDA labeled or CMS approved compendia supported therapy that are indicated as first-line therapy for the requested indication OR

c. Patient has an intolerance or hypersensitivity to the first-line therapy for the requested indication OR

d. Patient has an FDA labeled contraindication to the first-line therapy for the requested indication AND

iv. Patient does NOT have any FDA labeled limitations of use that is not otherwise supported in NCCN guidelines AND

Criteria continues: see Other Criteria

**Age Restriction:**



**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- v. ONE of the following:
  - a. The requested agent is not Bosulif OR
  - b. The requested agent is Bosulif AND ONE of the following:
    - 1. Patient's medication history indicates use of imatinib OR dasatinib for the requested indication (if applicable) OR
    - 2. Patient has an intolerance or hypersensitivity to imatinib OR dasatinib OR
    - 3. Patient has an FDA labeled contraindication to imatinib OR dasatinib OR
    - 4. CMS approved compendia does not support the use of imatinib OR dasatinib for the requested indication OR
    - 5. Prescriber has provided information in support of use of Bosulif over imatinib OR dasatinib for the requested indication AND
- vi. ONE of the following:
  - a. The requested agent is not Ojjaara OR Inrebic OR
  - b. The requested agent is Ojjaara OR Inrebic AND ONE of the following:
    - 1. Patient's medication history indicates use of Jakafi for the requested indication (if applicable) OR
    - 2. Patient has an intolerance or hypersensitivity to Jakafi OR
    - 3. Patient has an FDA labeled contraindication to Jakafi OR
    - 4. CMS approved compendia does not support the use of Jakafi for the requested indication OR
    - 5. Prescriber has provided information in support of use of Ojjaara OR Inrebic over Jakafi for the requested indication

**Prior Authorization Group Description:**

Sephience PA

**Drug Name(s)**

Sephience

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of phenylketonuria (PKU) AND
2. Prescriber has submitted a baseline blood Phe level measured prior to initiation of therapy with the requested agent, which is above the recommended levels indicated for the patient's age range or condition AND
3. Patient will NOT be using the requested agent in combination with Palynziq (pegvaliase-pqpz) or sapropterin for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of phenylketonuria (PKU) AND
3. ONE of the following:
  - a. Patient's blood Phe levels are being maintained within the acceptable range OR
  - b. Patient has had a decrease in blood Phe level from baseline AND
4. Patient will NOT be using the requested agent in combination with Palynziq (pegvaliase-pqpz) or sapropterin for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., metabolic or genetic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Signifor LAR PA

**Drug Name(s)**

Signifor Lar

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Severe hepatic impairment (i.e., Child Pugh C)

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of acromegaly AND ONE of the following:

i. Patient had an inadequate response to surgery as indicated by growth hormone and serum IGF-1 levels that are above the reference ranges for the patient's gender and age  
OR

ii. Patient is NOT a candidate for surgery OR

B. Patient has a diagnosis of Cushing's disease (CD) AND ONE of the following:

i. Patient had an inadequate response to pituitary surgical resection OR

ii. Patient is NOT a candidate for pituitary surgical resection OR

C. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of acromegaly AND ONE of the following:

i. Patient has growth hormone and serum IGF-1 levels that are within normal limits for patient's gender and age reference range OR

ii. Patient has had clinical improvement (e.g., reduction in tumor size, decreased headaches, improved cardiovascular or respiratory symptoms) OR

B. Patient has a diagnosis of Cushing's disease (CD) AND BOTH of the following:

i. Patient has a urinary free cortisol level less than or equal to the upper limit of normal  
AND

ii. Patient has had improvement in at least ONE of the following clinical signs and symptoms:

1. Fasting plasma glucose OR

2. Hemoglobin A1c OR

3. Hypertension OR

4. Weight OR

C. BOTH of the following:

i. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has had clinical benefit with the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Initial: Acromegaly - 6 months, CD - 7 months, All other diagnoses - 12 months, Renewal: 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Signifor PA

**Drug Name(s)**

Signifor

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Severe hepatic impairment (i.e., Child Pugh C)

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of Cushing's disease (CD) AND ONE of the following:

i. Patient had an inadequate response to pituitary surgical resection OR

ii. Patient is NOT a candidate for pituitary surgical resection OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of Cushing's disease (CD) AND BOTH of the following:

i. Patient has a urinary free cortisol level less than or equal to the upper limit of normal AND

ii. Patient has had improvement in at least ONE of the following clinical signs and symptoms:

1. Fasting plasma glucose OR

2. Hemoglobin A1c OR

3. Hypertension OR

4. Weight OR

B. BOTH of the following:

i. Patient has an indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Sivextro PA

**Drug Name(s)**

Sivextro

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following:

A. BOTH of the following:

- i. A documented acute bacterial skin and skin structure infection (ABSSSI) defined as a bacterial infection of the skin with a lesion size area of at least 75 cm<sup>2</sup> (lesion size measured by the area of redness, edema, or induration) AND
- ii. The infection is due to *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus anginosus*, *Streptococcus intermedius*, *Streptococcus constellatus*, or *Enterococcus faecalis* OR

B. Another indication that is supported in CMS approved compendia for the requested agent  
AND

2. ONE of the following:

A. The requested agent is prescribed by an infectious disease specialist or the prescriber has consulted with an infectious disease specialist on treatment of this patient OR

B. The requested agent is NOT prescribed by an infectious disease specialist or the prescriber has NOT consulted with an infectious disease specialist on treatment of this patient AND ONE of the following:

- i. There is documentation of resistance to TWO of the following: beta-lactams, macrolides, clindamycin, tetracycline, or co-trimoxazole at the site of infection OR
- ii. Patient has an intolerance or hypersensitivity to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
- iii. Patient has an FDA labeled contraindication to TWO of the following: beta-lactams, macrolides, clindamycin, tetracyclines, or co-trimoxazole OR
- iv. There is documentation of resistance to vancomycin at the site of infection OR
- v. Patient has an intolerance or hypersensitivity to vancomycin OR
- vi. Patient has an FDA labeled contraindication to vancomycin AND

3. Patient will NOT be using the requested agent in combination with linezolid for the same infection  
AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 days for ABSSSI or 30 days for all other indications

**Other Criteria:**

**Prior Authorization Group Description:**

Skyclarys PA

**Drug Name(s)**

Skyclarys

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of Friedreich's ataxia (FA, FRDA) with genetic analysis confirming mutation in the frataxin (FXN) gene

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Friedreich's ataxia (FA, FRDA) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, geneticist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Sodium Oxybate PA

**Drug Name(s)**

Sodium Oxybate

Xyrem

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. BOTH of the following:

i. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness AND

ii. ONE of the following:

a. Patient is between the ages of 7 and less than 18 years OR

b. BOTH of the following:

1. Patient is 18 years of age or over AND

2. ONE of the following:

a) Patient has tried and had an inadequate response to modafinil or armodafinil OR

b) Patient has an intolerance or hypersensitivity to modafinil or armodafinil OR

c) Patient has an FDA labeled contraindication to modafinil or armodafinil OR

C. Patient has another indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness OR

C. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

For diagnosis of narcolepsy with cataplexy, patient is 7 years of age or over. For diagnosis of narcolepsy with excessive daytime sleepiness, patient is 7 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Sofdra PA

**Drug Name(s)**

Sofdra

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of primary axillary hyperhidrosis

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Somatostatin Analogs PA – Lanreotide

**Drug Name(s)**

Somatuline Depot

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

- i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
- ii. Prescriber states the patient is currently being treated with the requested agent OR

B. ONE of the following:

i. Patient has a diagnosis of acromegaly AND ONE of the following:

- a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
- b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
- c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by growth hormone levels or serum IGF-1 levels that are above the reference range OR

ii. Patient has a diagnosis of gastroenteropancreatic neuroendocrine tumors AND BOTH of the following:

- a. The tumors are well or moderately differentiated AND
- b. ONE of the following:
  - 1. The tumors are unresectable, locally advanced OR
  - 2. Patient has metastatic disease OR

iii. Patient has a diagnosis of carcinoid syndrome OR

iv. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. ONE of the following:
      1. Patient has a diagnosis of acromegaly OR
      2. Patient has a diagnosis of metastatic OR unresectable, locally advanced, well or moderately differentiated gastroenteropancreatic neuroendocrine tumors OR
      3. Patient has a diagnosis of carcinoid syndrome OR
      4. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
    - ii. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Somatostatin Analogs PA – Mycapssa

**Drug Name(s)**

Mycapssa

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

- i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- ii. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR

B. ONE of the following:

i. BOTH of the following:

- a. Patient has a diagnosis of acromegaly AND
- b. Patient has responded to and tolerated treatment with octreotide or lanreotide OR

ii. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of acromegaly OR

B. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

3. Patient has had clinical benefit with the requested agent AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 9 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Somatostatin Analogs PA – Octreotide

**Drug Name(s)**

Octreotide Acetate

Sandostatin

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

- i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- ii. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR

B. ONE of the following:

- i. Patient has a diagnosis of acromegaly AND ONE of the following:
  - a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
  - b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
  - c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by growth hormone levels or serum IGF-1 levels that are above the reference range OR
- ii. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR
- iii. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR
- iv. Patient has a diagnosis of dumping syndrome AND ONE of the following:
  - a. Patient has tried and had an inadequate response to acarbose OR
  - b. Patient has an intolerance or hypersensitivity to acarbose OR
  - c. Patient has an FDA labeled contraindication to acarbose OR
- v. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of acromegaly OR
  - B. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR
  - C. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR
  - D. Patient has a diagnosis of dumping syndrome OR
  - E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication



**Prior Authorization Group Description:**

Somatostatin Analogs PA – Palsonify

**Drug Name(s)**

Palsonify

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of acromegaly AND ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. BOTH of the following:
    - i. ONE of the following:
      - a. Patient is not a candidate for surgical resection OR
      - b. Patient had an inadequate response to surgical resection as indicated by growth hormone levels or serum IGF-1 levels that are above the reference ranges AND
    - ii. ONE of the following:
      - a. Patient has tried and had an inadequate response to octreotide or lanreotide OR
      - b. Patient has an intolerance or hypersensitivity to octreotide or lanreotide OR
      - c. Patient has an FDA labeled contraindication to octreotide or lanreotide AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of acromegaly AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Somatostatin Analogs PA - Sandostatin LAR

**Drug Name(s)**

Octreotide Kit

Sandostatin Lar Depot

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:

A. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND ONE of the following:

- i. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
- ii. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR

B. ONE of the following:

i. Patient has a diagnosis of acromegaly AND ONE of the following:

- a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
- b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
- c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by growth hormone levels or serum IGF-1 levels that are above the reference range OR

ii. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR

iii. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR

iv. Patient has a diagnosis of dumping syndrome AND ONE of the following:

- a. Patient has tried and had an inadequate response to acarbose OR
- b. Patient has an intolerance or hypersensitivity to acarbose OR
- c. Patient has an FDA labeled contraindication to acarbose OR

v. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

2. Patient has responded to and tolerated octreotide for a minimum of 2 weeks prior to starting therapy with the requested agent AND

3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of acromegaly OR
  - B. Patient has severe diarrhea and/or flushing episodes associated with metastatic carcinoid tumors OR
  - C. Patient has profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors OR
  - D. Patient has a diagnosis of dumping syndrome OR
  - E. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Somatostatin Analogs PA – Somavert

**Drug Name(s)**

Somavert

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of acromegaly AND ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent AND provided clinical justification to support that the patient is at risk if therapy is changed OR
  - C. BOTH of the following:
    - i. ONE of the following:
      - a. Patient is not a candidate for surgical resection or pituitary radiation therapy OR
      - b. The requested agent is for adjunctive therapy with pituitary radiation therapy OR
      - c. Patient had an inadequate response to surgery or pituitary radiation therapy as indicated by serum IGF-1 levels that are above the reference range AND
    - ii. ONE of the following:
      - a. Patient has tried and had an inadequate response to octreotide or lanreotide OR
      - b. Patient has an intolerance or hypersensitivity to octreotide or lanreotide OR
      - c. Patient has an FDA labeled contraindication to octreotide or lanreotide AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of acromegaly AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Sovaldi PA

**Drug Name(s)**

Sovaldi

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of hepatitis C confirmed by serological markers AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication AND
5. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - C. Patient has an FDA labeled contraindication or hypersensitivity to the preferred agent: Mavyret for supported genotypes OR
  - D. Prescriber has provided information based on FDA approved labeling or AASLD/IDSA guidelines supporting the use of the non-preferred agent for the patient's diagnosis and genotype over the preferred agent: Mavyret for supported genotypes

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Spevigo SC PA

**Drug Name(s)**

Spevigo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of generalized pustular psoriasis (GPP) AND
2. The requested agent will be used for treatment of GPP when NOT experiencing a flare AND
3. Patient does NOT have active tuberculosis (TB) AND
4. ONE of the following:
  - A. Patient does NOT have latent tuberculosis (TB) OR
  - B. Patient has latent tuberculosis (TB) and the patient has begun or completed therapy for latent TB prior to initiating with the requested agent AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Stoboclo PA

**Drug Name(s)**

Stoboclo

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Osteopenia (osteoporosis prophylaxis)

**Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of:

1. ONE of:

A. Patient's (pt) sex is male or the pt is postmenopausal with a diagnosis of osteoporosis AND BOTH of:

i. Pt's diagnosis was confirmed by ONE of:

1. A fragility fracture in the hip or spine OR
2. A T-score of -2.5 or lower OR
3. A T-score of -1.0 to -2.5 AND ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
  - c. A FRAX 10-year probability of hip fracture of 3% or greater AND

ii. ONE of:

1. Pt is at a very high fracture risk as defined by ONE of:
  - a. Pt had a recent fracture (within the past 12 months) OR
  - b. Pt had fractures while on FDA approved osteoporosis therapy OR
  - c. Pt has had multiple fractures OR
  - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
  - e. Pt has a very low T-score (less than -3.0) OR
  - f. Pt is at high risk for falls or has a history of injurious falls OR
  - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
2. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR
  - b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR

B. Pt is requesting the agent for osteopenia (osteoporosis prophylaxis) AND ALL of:

i. ONE of:

1. Pt's sex is male and the pt is 50 years of age or over OR
2. Pt is postmenopausal AND

- ii. Pt has a T-score between -1.0 to -2.50 AND
- iii. ONE of:
  - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
  - b. 10-year probability of a hip fracture 3% and greater per FRAX OR
  - c. 10-year probability of a major OP-related fracture 20% and greater per FRAX AND
- iv. ONE of:
  - a. Pt's medication history includes use of a bisphosphonate OR

Criteria continues: See Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- C. Pt's sex is a female with a diagnosis of breast cancer who is receiving aromatase inhibitor therapy AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- D. Pt's sex is male with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) AND ONE of:
  - i. Pt's medication history includes use of a bisphosphonate OR
  - ii. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate OR
- E. Pt has a diagnosis of glucocorticoid-induced osteoporosis AND ALL of:
  - i. Pt is either initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or greater of prednisone AND
  - ii. Pt is expected to remain on glucocorticoids for at least 6 months AND
  - iii. Pt's diagnosis was confirmed by ONE of:
    - 1. A fragility fracture in the hip or spine OR
    - 2. A T-score of -2.5 or lower OR
    - 3. A T-score of -1.0 to -2.5 AND ONE of:
      - a. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - iv. ONE of:
    - 1. Pt is at high fracture risk as defined by ONE of:
      - a. Pt had a recent fracture (within the past 12 months) OR
      - b. Pt had fractures while on FDA approved osteoporosis therapy OR



- c. Pt has had multiple fractures OR
- d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
- e. Pt has a very low T-score (less than -2.5) OR
- f. Pt is at high risk for falls or has a history of injurious falls OR
- g. Pt has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR

2. ONE of:

- a. Pt's medication history includes use of a bisphosphonate OR
- b. Pt has an intolerance, FDA labeled contraindication, or hypersensitivity to a bisphosphonate AND

2. ONE of:

- A. Pt has a pretreatment or current calcium level that is NOT below the lower limit of the testing laboratory's normal range OR
- B. Pt has a pretreatment or current calcium level that is below the lower limit of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- C. Prescriber has indicated that the pt is not at risk for hypocalcemia (not including risk associated with the requested agent) AND

3. Pt will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab, romosozumab-aqcg, or parathyroid hormone analog (e.g., abaloparatide, teriparatide) for the requested indication AND

4. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Prior Authorization Group Description:**

Strensiq PA

**Drug Name(s)**

Strensiq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has ONE of the following diagnoses:
  - A. Perinatal or infantile-onset hypophosphatasia OR
  - B. Juvenile-onset hypophosphatasia AND
2. Patient has documentation (i.e., medical records) of clinical manifestations to support the diagnosis of hypophosphatasia at the age of onset prior to age 18 (e.g., vitamin B6-dependent seizures, skeletal abnormalities such as rachitic chest deformity leading to respiratory problems or bowed arms/legs, “failure to thrive”) AND
3. Patient has documentation (i.e., medical records) of radiographic imaging to support the diagnosis of hypophosphatasia at the age of onset prior to age 18 (e.g., infantile rickets, alveolar bone loss, craniosynostosis, fractures) AND
4. Patient has documentation (i.e., medical records) of confirmed mutation(s) in the ALPL gene that encodes the tissue non-specific isoenzyme of alkaline phosphatase (TNSALP) AND
5. Patient has documentation (i.e., medical records) of a measured total serum alkaline phosphatase (ALP) level that is below the normal lab reference range for age and sex AND
6. Patient has documentation (i.e., medical records) of ONE of the following:
  - A. Elevated urine concentration of phosphoethanolamine (PEA) OR
  - B. Elevated serum concentration of pyridoxal 5'-phosphate (PLP) in the absence of vitamin supplements within one week prior to the test OR
  - C. Elevated urinary inorganic pyrophosphate (PPi) AND
7. The requested dose is within FDA labeled dosing (based on the patient’s weight) for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient’s diagnosis (e.g., endocrinologist or geneticist with expertise in metabolic bone diseases) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan’s Prior Authorization criteria AND
2. Patient has ONE of the following diagnoses:
  - A. Perinatal or infantile-onset hypophosphatasia OR

- B. Juvenile-onset hypophosphatasia AND
- 3. There is documentation (i.e., medical records) that the patient has had a decrease from baseline (before treatment with the requested agent) in at least ONE of the following levels:
  - A. Urine concentration of phosphoethanolamine (PEA) OR
  - B. Serum concentration of pyridoxal 5'-phosphate (PLP) in the absence of vitamin supplements within one week prior to the test OR
  - C. Urinary inorganic pyrophosphate (PPI) AND
- 4. Patient has documentation (i.e., medical records) of clinical improvement and/or stabilization with the requested agent (e.g., improvement in respiratory status, growth, pain, radiographic findings, other symptoms associated with the disease) AND
- 5. The requested dose is within FDA labeled dosing (based on the patient's weight) for the requested indication

**Prior Authorization Group Description:**

Substrate Reduction Therapy PA – Cerdelga

**Drug Name(s)**

Cerdelga

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - A. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - B. Confirmation of genetic mutation of the glucocerebrosidase (GBA) gene with two disease-causing alleles AND
2. Patient is a CYP2D6 extensive metabolizer (EMs), intermediate metabolizer (IMs), or poor metabolizer (PMs) established by a genetic test AND
3. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - A. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - B. Thrombocytopenia (defined as platelet count of less than 100,000 per microliter) OR
  - C. Hepatomegaly OR
  - D. Splenomegaly OR
  - E. Growth failure (i.e., growth velocity is below the standard mean for age) OR
  - F. Evidence of bone disease with other causes ruled out

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Gaucher disease type 1 (GD1) AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, hematologist, hepatologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Substrate Reduction Therapy PA – Miglustat

**Drug Name(s)**

Miglustat

Yargesa

Zavesca

**Indications:**

All FDA-Approved Indications, Some Medically-Accepted Indications.

**Off-Label Uses:**

Niemann-Pick disease type C (NPC)

**Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

- i. Patient has a diagnosis of Gaucher disease type 1 (GD1) confirmed by ONE of the following:
  - a. A baseline (prior to therapy for the requested indication) glucocerebrosidase enzyme activity of less than or equal to 15% of mean normal in peripheral blood leukocytes, fibroblasts, or other nucleated cells OR
  - b. Confirmation of genetic mutation of the glucocerebrosidase (GBA) gene with two disease-causing alleles AND
- ii. Prior to any treatment for the intended diagnosis, the patient has had at least ONE of the following clinical presentations:
  - a. Anemia [defined as mean hemoglobin (Hb) level below the testing laboratory's lower limit of the normal range based on age and gender] OR
  - b. Thrombocytopenia (defined as platelet count of less than 100,000 per microliter) OR
  - c. Hepatomegaly OR
  - d. Splenomegaly OR
  - e. Growth failure (i.e., growth velocity is below the standard mean for age) OR
  - f. Evidence of bone disease with other causes ruled out OR

B. ALL of the following:

- i. Patient has a diagnosis of Niemann-Pick disease type C (NPC) as confirmed by genetic analysis mutation in the NPC1 or NPC2 genes AND
- ii. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) AND
- iii. The requested agent will be used in combination with Miplyffa (arimoclomol)

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, gastroenterologist, geneticist, hematologist, hepatologist, neurologist, specialist in metabolic diseases) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following
  - A. Patient has a diagnosis of Gaucher disease type 1 (GD1) OR
  - B. ALL of the following:
    - i. Patient has a diagnosis of Niemann-Pick disease type C (NPC) AND
    - ii. The requested agent will be used for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) AND
    - iii. The requested agent will be used in combination with Miplyffa (arimoclomol) AND
3. Patient has had clinical benefit with the requested agent

**Prior Authorization Group Description:**

Sucraid PA

**Drug Name(s)**

Sucraid

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of congenital sucrase-isomaltase deficiency (CSID) AND
2. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of congenital sucrase-isomaltase deficiency (CSID) AND
3. Patient has had clinical benefit with the requested agent AND
4. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, geneticist, endocrinologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Sunosi PA

**Drug Name(s)**

Sunosi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy OR
  - B. Patient has a diagnosis of excessive daytime sleepiness associated with obstructive sleep apnea (OSA) AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to modafinil or armodafinil OR
  - B. Patient has an intolerance or hypersensitivity to modafinil or armodafinil OR
  - C. Patient has an FDA labeled contraindication to modafinil or armodafinil AND
3. Patient will NOT be using the requested agent in combination with modafinil or armodafinil for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy OR
  - B. Patient has a diagnosis of excessive daytime sleepiness associated with obstructive sleep apnea (OSA) AND
3. Patient will NOT be using the requested agent in combination with modafinil or armodafinil for the requested indication AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is 18 years of age or over

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Symdeko PA

**Drug Name(s)**

Symdeko

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has the presence of the F508del mutation on both alleles (homozygous) of the CFTR gene confirmed by genetic testing OR
  - B. Patient has ONE of the CFTR gene mutations or a mutation in the CFTR gene that is responsive based on in vitro data, as indicated in the FDA label, confirmed by genetic testing OR
  - C. Patient has another CFTR gene mutation(s) that is responsive to the requested agent, as indicated in the FDA label, confirmed by genetic testing AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Symproic PA

**Drug Name(s)**

Symproic

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has opioid-induced constipation (OIC) and chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment AND
2. Patient has chronic use of an opioid agent in the past 90 days AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to lactulose OR
  - B. Patient has an intolerance or hypersensitivity to lactulose OR
  - C. Patient has an FDA labeled contraindication to lactulose

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tarpeyo PA

**Drug Name(s)**

Tarpeyo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy AND
2. The requested agent will be used to reduce the loss of kidney function AND
3. Patient is at risk of disease progression as shown by ONE of the following:
  - A. A urine protein-to-creatinine ratio (UPCR) greater than or equal to 0.44 g/g OR
  - B. Proteinuria greater than or equal to 0.5 g/day AND
4. ONE of the following:
  - A. Patient has tried and had an inadequate response with a maximally tolerated angiotensin-converting-enzyme inhibitor (ACEI) [e.g., benazepril, lisinopril], or angiotensin II blocker (ARB) [e.g., losartan], or a combination medication containing an ACEI or ARB OR
  - B. Patient has an intolerance or hypersensitivity to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR
  - C. Patient has an FDA labeled contraindication to an ACEI or ARB, or a combination medication containing an ACEI or ARB AND
5. Patient has not previously been treated with a course of therapy (10 months) with the requested agent AND
6. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

No prior Tarpeyo use, approve 10 months. Prior use - see Other Criteria.

**Other Criteria:**

Prior Tarpeyo use, approve remainder of 10 months total course of therapy.

**Prior Authorization Group Description:**

Tasimelteon Capsule PA

**Drug Name(s)**

Hetlioz

Tasimelteon

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. BOTH of the following:

- i. Patient has a diagnosis of Non-24-hour sleep-wake disorder AND
- ii. Patient is totally blind (i.e., no light perception) OR

B. BOTH of the following:

- i. Patient has a diagnosis of Smith-Magenis Syndrome (SMS) confirmed by the presence of ONE of the following genetic mutations:

A. A heterozygous deletion of 17p11.2 OR

B. A heterozygous pathogenic variant involving RAI1 AND

- ii. The requested agent is being used to treat nighttime sleep disturbances associated with SMS

**Age Restriction:**

For diagnosis of Non-24-hour sleep-wake disorder, patient is 18 years of age or over. For diagnosis of Smith-Magenis Syndrome (SMS), patient is 16 years of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, sleep specialist, psychiatrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tavalisse PA

**Drug Name(s)**

Tavalisse

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of chronic immune (idiopathic) thrombocytopenia (ITP) AND
2. ONE of the following:
  - A. Patient has tried and had an insufficient response to a corticosteroid, another thrombopoietin receptor agonist (e.g., Promacta), or immunoglobulin (IVIg or anti-D) OR
  - B. Patient has an intolerance or hypersensitivity to a corticosteroid, another thrombopoietin receptor agonist (e.g., Promacta), or immunoglobulin (IVIg or anti-D) OR
  - C. Patient has an FDA labeled contraindication to a corticosteroid, another thrombopoietin receptor agonist (e.g., Promacta), or immunoglobulin (IVIg or anti-D) OR
  - D. Patient has had an insufficient response to a splenectomy AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
  - A. Patient's platelet count is  $50 \times 10^9/L$  or greater OR
  - B. Patient's platelet count has increased sufficiently to avoid clinically significant bleeding AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

**Prior Authorization Group Description:**

Tavneos PA

**Drug Name(s)**

Tavneos

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Severe hepatic impairment (Child-Pugh C)

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and/or microscopic polyangiitis [MPA]) AND
2. Patient will continue standard therapy (e.g., corticosteroids, azathioprine, mycophenolate mofetil) in combination with the requested agent for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., rheumatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Teriparatide PA

**Drug Name(s)**

Bonsity

Forteo

Teriparatide

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has ONE of the following:
  - A. Postmenopausal osteoporosis OR
  - B. Patient's sex is male with primary or hypogonadal osteoporosis OR
  - C. Osteoporosis with sustained systemic glucocorticoid therapy AND
2. Patient's diagnosis was confirmed by ONE of the following:
  - A. A fragility fracture in the hip or spine OR
  - B. A T-score of -2.5 or lower OR
  - C. A T-score of -1.0 to -2.5 AND ONE of the following:
    - i. A fragility fracture of the proximal humerus, pelvis, or distal forearm OR
    - ii. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
    - iii. A FRAX 10-year probability of hip fracture of 3% or greater AND
3. ONE of the following:
  - A. Patient is at high fracture risk as defined by ONE of the following:
    - i. Patient had a recent fracture (within the past 12 months) OR
    - ii. Patient had fractures while on FDA approved osteoporosis therapy OR
    - iii. Patient has had multiple fractures OR
    - iv. Patient had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
    - v. Patient has a very low T-score (less than -2.5) OR
    - vi. Patient is at high risk for falls or has a history of injurious falls OR
    - vii. Patient has a high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 20%, hip fracture greater than 3%) or by other validated fracture risk algorithm OR
  - B. ONE of the following:
    - i. Patient has tried and had an inadequate response to a bisphosphonate OR
    - ii. Patient has an intolerance or hypersensitivity to a bisphosphonate OR
    - iii. Patient has an FDA labeled contraindication to a bisphosphonate AND
4. Patient will NOT be using the requested agent in combination with a bisphosphonate, denosumab (e.g., Prolia, Xgeva), romosozumab-aqqg, or another parathyroid hormone analog (e.g., abaloparatide) for the requested indication AND

Criteria continues: see Other Criteria

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

No prior teriparatide and/or Tymlos use approve 2 years, Prior use - see Other Criteria

**Other Criteria:**

5. The requested dose is within FDA labeled dosing for the requested indication AND

6. ONE of the following:

A. Patient has never received treatment with teriparatide or Tymlos (abaloparatide) OR

B. Patient has been previously treated with teriparatide or Tymlos (abaloparatide) AND ONE of the following:

i. The total cumulative duration of treatment with teriparatide and Tymlos (abaloparatide) has NOT exceeded 2 years OR

ii. Patient has received 2 years or more of treatment with teriparatide, or a combination of teriparatide and Tymlos (abaloparatide), and remains at or has returned to having a high risk for fracture

Prior teriparatide and/or Tymlos use approve remainder of 2 years of total cumulative therapy. Approve 1 year if patient has received 2 years or more teriparatide or a combination of teriparatide and Tymlos (abaloparatide)



**Prior Authorization Group Description:**

Tetrabenazine PA

**Drug Name(s)**

Tetrabenazine

Xenazine

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:
  - A. Patient has a diagnosis of chorea associated with Huntington's disease OR
  - B. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. Patient does NOT have a current diagnosis of depression OR
  - B. Patient has a current diagnosis of depression and is being treated for depression AND
3. ONE of the following:
  - A. Patient does NOT have a diagnosis of suicidal ideation and/or behavior OR
  - B. Patient has a diagnosis of suicidal ideation and/or behavior and must NOT be actively suicidal AND
4. Patient will NOT be using the requested agent in combination with a monoamine oxidase inhibitor (MAOI) AND
5. Patient will NOT be using the requested agent in combination with reserpine

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tlando PA

**Drug Name(s)**

Tlando

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient's sex is male with a diagnosis of primary or secondary (hypogonadotropic) hypogonadism AND
2. ONE of the following:
  - A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:
    - i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
    - ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR
  - B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:
    - i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
    - ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND
3. ONE of the following:
  - A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR
  - B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tobi Podhaler PA

**Drug Name(s)**

Tobi Podhaler

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Documentation has been provided that indicates the patient has a *Pseudomonas aeruginosa* respiratory infection AND
3. ONE of the following:
  - a. Patient is NOT currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) OR
  - b. Patient is currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) AND ONE of the following:
    - i. Prescriber has confirmed that the other inhaled antibiotic will be discontinued, and that therapy will be continued only with the requested agent OR
    - ii. Prescriber has provided information in support of another inhaled antibiotic therapy used concurrently with or alternating with (i.e., continuous alternating therapy) the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tobramycin neb PA

**Drug Name(s)**

Kitabis Pak

Tobi

Tobramycin Neb

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. Documentation has been provided that indicates the patient has a *Pseudomonas aeruginosa* respiratory infection AND
3. ONE of the following:
  - a. Patient is NOT currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) OR
  - b. Patient is currently (within the past 60 days) being treated with another inhaled antibiotic (e.g., inhaled aztreonam) AND ONE of the following:
    - i. Prescriber has confirmed that the other inhaled antibiotic will be discontinued, and that therapy will be continued only with the requested agent OR
    - ii. Prescriber has provided information in support of another inhaled antibiotic therapy used concurrently with or alternating with (i.e., continuous alternating therapy) the requested agent

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Topical Diclofenac 3% Gel PA

**Drug Name(s)**

Diclofenac Sodium Gel 3%

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of actinic keratosis (AK)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 3 months

**Other Criteria:**

**Prior Authorization Group Description:**

Topical Doxepin PA

**Drug Name(s)**

Doxepin Hcl

Prudoxin

Zonalon

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

a. Patient has a diagnosis of moderate pruritus associated with atopic dermatitis AND ONE of the following:

i. Patient has tried and had an inadequate response to a topical corticosteroid (e.g., hydrocortisone, triamcinolone) OR

ii. Patient has an intolerance or hypersensitivity to a topical corticosteroid OR

iii. Patient has an FDA labeled contraindication to a topical corticosteroid OR

b. Patient has a diagnosis of moderate pruritus associated with lichen simplex chronicus AND ONE of the following:

i. Patient has tried and had an inadequate response to a topical corticosteroid (e.g., hydrocortisone, triamcinolone) OR

ii. Patient has an intolerance or hypersensitivity to a topical corticosteroid OR

iii. Patient has an FDA labeled contraindication to a topical corticosteroid

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 8 days

**Other Criteria:**

**Prior Authorization Group Description:**

Topical NSAID PA – Flector

**Drug Name(s)**

Diclofenac Epolamine

Flector

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- a. Patient has an FDA labeled indication for the requested agent OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 3 months for acute pain, 12 months for all other diagnoses

**Other Criteria:**

**Prior Authorization Group Description:**

Topical NSAID PA – Licart

**Drug Name(s)**

Licart

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- a. Patient has an FDA labeled indication for the requested agent OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 3 months for acute pain, 12 months for all other diagnoses

**Other Criteria:**



**Prior Authorization Group Description:**

Topical NSAID PA – Pennsaid

**Drug Name(s)**

Diclofenac Sodium (Pennsaid)

Pennsaid

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

- a. Patient has an FDA labeled indication for the requested agent OR
- b. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

3 months for acute pain, 12 months for all other diagnoses

**Other Criteria:**

**Prior Authorization Group Description:**

Topical Retinoids PA – Adapalene

**Drug Name(s)**

Adapalene

Adapalene Pump

Differin

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for cosmetic purposes

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Topical Retinoids PA – Tazarotene

**Drug Name(s)**

Arazlo

Fabior

Tazarotene

Tazorac

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for cosmetic purposes

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Topical Retinoids PA – Tretinoin

**Drug Name(s)**

Altreno

Atralin

Retin-A

Retin-A Micro

Retin-A Micro Pump

Tretinoin Cream, Gel

Tretinoin Microsphere

Tretinoin Microsphere Pump

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for cosmetic purposes

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Topical Retinoids PA – Trifarotene

**Drug Name(s)**

Aklief

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for cosmetic purposes

**Required Medical Information:**

Criteria for approval require the following:

1. ONE of the following:

A. Patient has an FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Trelstar PA

**Drug Name(s)**

Trelstar Mixject

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. Patient is NOT currently being treated with the requested agent AND
    - ii. Patient does NOT have any FDA labeled contraindications to the requested agent AND
3. The requested dose is within FDA labeled dosing or supported in CMS approved compendia dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Trientine PA

**Drug Name(s)**

Syprine

Trientine Hcl

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of Wilson's disease confirmed by ONE of the following:
  - A. Confirmation of genetic mutation of the ATP7B gene OR
  - B. Patient has TWO or more of the following:
    - i. Presence of hepatic abnormality (e.g., acute liver failure, cirrhosis, fatty liver)
    - ii. Presence of Kayser-Fleischer rings
    - iii. Serum ceruloplasmin level less than 20 mg/dL
    - iv. Basal urinary copper excretion greater than 40 mcg/24 hours or the testing laboratory's upper limit of normal
    - v. Hepatic parenchymal copper content greater than 40 mcg/g dry weight
    - vi. Presence of neurological symptoms (e.g., dystonia, hypertonia, rigidity with tremors, dysarthria, muscle spasms, dysphasia, polyneuropathy, dysautonomia) AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to penicillamine OR
  - B. Patient has an intolerance or hypersensitivity to penicillamine OR
  - C. Patient has an FDA labeled contraindication to penicillamine

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Wilson's disease AND
3. Patient has had clinical benefit with the requested agent as evidenced by ONE of the following:
  - A. Improvement and/or stabilization in hepatic abnormality OR
  - B. Reduction in Kayser-Fleischer rings OR
  - C. Improvement and/or stabilization in neurological symptoms (e.g., dystonia, hypertonia, rigidity with tremors, dysarthria, muscle spasms, dysphasia, polyneuropathy, dysautonomia) OR
  - D. Basal urinary copper excretion greater than 200 mcg/24 hours

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Trikafta PA

**Drug Name(s)**

Trikafta

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cystic fibrosis AND
2. ONE of the following:
  - A. Patient has the presence of the F508del mutation in at least ONE allele (heterozygous OR homozygous) of the CFTR gene confirmed by genetic testing OR
  - B. Patient has ONE of the CFTR gene mutations or a mutation in the CFTR gene that is responsive based on in vitro data, as indicated in the FDA label, confirmed by genetic testing OR
  - C. Patient has another CFTR gene mutation(s) that is responsive to the requested agent, as indicated in the FDA label, confirmed by genetic testing AND
3. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cystic fibrosis AND
3. Patient has had improvement or stabilization with the requested agent [e.g., improvement in FEV1 from baseline, increase in weight/BMI, improvement from baseline Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain score, improvements in respiratory symptoms (cough, sputum production, and difficulty breathing), and/or reduced number of pulmonary exacerbations] AND
4. Patient will NOT be using the requested agent in combination with another CFTR modulator agent for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cystic fibrosis, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Trudhesa PA

**Drug Name(s)**

Trudhesa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. The requested agent will be used for the treatment of acute migraine with or without aura AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to TWO triptan agents with differing active ingredients (e.g., sumatriptan, rizatriptan) OR
  - B. Patient has an intolerance or hypersensitivity to a triptan agent OR
  - C. Patient has an FDA labeled contraindication to a triptan agent AND
3. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. The requested agent will be used for the treatment of acute migraine with or without aura AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., triptan, 5HT-1F, acute CGRP)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Trulicity PA

**Drug Name(s)**

Trulicity

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has an FDA labeled indication for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 180 days OR
  - C. ALL of the following:
    - i. Patient does NOT have any FDA labeled contraindications to the requested agent AND
    - ii. Patient will NOT be using the requested agent in combination with another GLP-1 agonist agent, or an agent containing a GLP-1 agonist AND
    - iii. Patient will NOT be using the requested agent in combination with an agent containing a dipeptidyl peptidase-4 (DPP-4) inhibitor

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tryngolza PA

**Drug Name(s)**

Tryngolza

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has a diagnosis of familial chylomicronemia syndrome (FCS) confirmed by ONE of the following:

A. Genetic confirmation of bi-allelic pathogenic variants in affected genes (e.g., LPL, ApoA5, ApoC2, LMF1, GPIHBP1, or G3PDH1) OR

B. ALL of the following:

i. Fasting triglyceride (TG) levels greater than 880 mg/dL (10 mmol/L) for 3 consecutive measurements AND

ii. Secondary causes of hypertriglyceridemia have been ruled out (e.g., alcohol use, chronic kidney disease, hypothyroidism, uncontrolled diabetes, medications [e.g., atypical antipsychotics, beta-blockers, corticosteroids, oral estrogens]) AND

iii. History of pancreatitis or unexplained recurrent abdominal pain

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has a diagnosis of familial chylomicronemia syndrome (FCS) AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, endocrinologist, geneticist, lipidologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tryptyr PA

**Drug Name(s)**

Tryptyr

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tryvio PA

**Drug Name(s)**

Tryvio

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hypertension AND
2. Patient is still not at blood pressure goal while on TWO other different antihypertensive therapy classes [e.g., angiotensin converting enzyme inhibitor (ACEI) (e.g., lisinopril), angiotensin receptor blocker (ARB) (e.g., losartan), beta blocker (e.g., atenolol), calcium channel blocker (e.g., amlodipine), diuretic (e.g., hydrochlorothiazide), mineralocorticoid receptor antagonist (e.g., spironolactone)] AND
3. The requested agent will be used in combination with other antihypertensive therapies [e.g., angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), beta blocker]

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hypertension AND
3. The requested agent will be used in combination with other antihypertensive therapies [e.g., angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), beta blocker] AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Tymlos PA

**Drug Name(s)**

Tymlos

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient (pt) has ONE of the following:
  - A. Postmenopausal osteoporosis OR
  - B. Pt's sex is male with osteoporosis AND
2. BOTH of the following:
  - A. Pt's diagnosis was confirmed by ONE of the following:
    - i. A fragility fracture in the hip or spine OR
    - ii. A T-score of -2.5 or lower OR
    - iii. A T-score of -1.0 to -2.5 AND ONE of the following:
      - a. A fragility fracture of proximal humerus, pelvis, or distal forearm OR
      - b. A FRAX 10-year probability for major osteoporotic fracture of 20% or greater OR
      - c. A FRAX 10-year probability of hip fracture of 3% or greater AND
  - B. ONE of the following:
    - i. Pt is at a very high fracture risk as defined by ONE of the following:
      - a. Pt had a recent fracture (within the past 12 months) OR
      - b. Pt had fractures while on FDA approved osteoporosis therapy OR
      - c. Pt has had multiple fractures OR
      - d. Pt had fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids) OR
      - e. Pt has a very low T-score (less than -3.0) OR
      - f. Pt is at high risk for falls or has a history of injurious falls OR
      - g. Pt has a very high fracture probability by FRAX (e.g., major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or by other validated fracture risk algorithm OR
    - ii. ONE of the following:
      - a. Pt has tried and had an inadequate response to a bisphosphonate OR
      - b. Pt has an intolerance or hypersensitivity to a bisphosphonate OR
      - c. Pt has an FDA labeled contraindication to a bisphosphonate AND
3. Pt will NOT be using the requested agent in combination with a bisphosphonate, denosumab (e.g., Prolia, Xgeva), romosozumab-aqqg, or another parathyroid hormone analog (e.g., teriparatide) for the requested indication AND
4. The requested dose is within FDA labeled dosing for the requested indication AND
5. The total cumulative duration of treatment with teriparatide and Tymlos (abaloparatide) has not exceeded 2 years

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

No prior Tymlos and/or teriparatide use approve 2 years, Prior use - see Other Criteria

**Other Criteria:**

Prior Tymlos and/or teriparatide use approve remainder of 2 years of total cumulative therapy

**Prior Authorization Group Description:**

Tyrvaya PA

**Drug Name(s)**

Tyrvaya

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:**

**Exclusion Criteria:**

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Ubrelvy PA

**Drug Name(s)**

Ubrelvy

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of migraine AND
2. The requested agent is being used for the treatment of acute migraine with or without aura AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to a triptan (e.g., sumatriptan, rizatriptan) agent OR
  - B. Patient has an intolerance, or hypersensitivity to a triptan OR
  - C. Patient has an FDA labeled contraindication to a triptan AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. The requested agent is being used for the treatment of acute migraine with or without aura AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Undecatrex PA

**Drug Name(s)**

Undecatrex

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient's sex is male with a diagnosis of primary or secondary (hypogonadotropic) hypogonadism AND
2. ONE of the following:
  - A. Patient is NOT currently receiving testosterone replacement therapy AND has ONE of the following pretreatment levels:
    - i. Total serum testosterone level that is below the testing laboratory's lower limit of the normal range or is less than 300 ng/dL OR
    - ii. Free serum testosterone level that is below the testing laboratory's lower limit of the normal range OR
  - B. Patient is currently receiving testosterone replacement therapy AND has ONE of the following current levels:
    - i. Total serum testosterone level that is within the testing laboratory's normal range OR below the testing laboratory's lower limit of the normal range OR is less than 300 ng/dL OR
    - ii. Free serum testosterone level is within the testing laboratory's normal range OR below the testing laboratory's normal range AND
3. ONE of the following:
  - A. Patient will NOT be using the requested agent in combination with another androgen or anabolic steroid OR
  - B. Prescriber has provided information in support of therapy with more than one agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Urea Cycle Disorders PA – Olpruva

**Drug Name(s)**

Olpruva

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS) AND
2. The requested agent will be used as chronic management of UCDs AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Urea Cycle Disorders PA – Pheburane

**Drug Name(s)**

Pheburane

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS) AND
2. The requested agent will be used as chronic management of UCDs AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Urea Cycle Disorders PA – Ravicti

**Drug Name(s)**

Glycerol Phenylbutyrate

Ravicti

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of urea cycle disorder and the requested agent will be used for chronic management AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Urea Cycle Disorders PA - Sodium Phenylbutyrate

**Drug Name(s)**

Buphenyl

Sodium Phenylbutyrate

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of ONE of the following:
  - a. Urea cycle disorder with neonatal-onset involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase OR
  - b. Urea cycle disorder with late-onset and history of hyperammonemic encephalopathy involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, metabolic disorders) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Valchlor PA

**Drug Name(s)**

Valchlor

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. ONE of the following:
      - a. BOTH of the following:
        1. Patient has a diagnosis of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma AND
        2. Patient's medication history indicates use of at least ONE prior skin-directed therapy (e.g., topical corticosteroid) OR
      - b. Patient has an indication that is supported in CMS approved compendia for the requested agent AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has an FDA labeled indication or an indication that is supported in CMS approved compendia for the requested agent AND
3. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, oncologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Age Restriction:**

**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Vanrafia PA

**Drug Name(s)**

Vanrafia

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy AND
2. The requested agent will be used to reduce proteinuria AND
3. Patient is at risk of disease progression as shown by ONE of the following:
  - A. A urine protein-to-creatinine ratio (UPCR) greater than or equal to 0.44 g/g OR
  - B. Proteinuria greater than or equal to 0.5 g/day AND
4. ONE of the following:
  - A. Patient has tried and had an inadequate response with a maximally tolerated angiotensin-converting-enzyme inhibitor (ACEI) [e.g., benazepril, lisinopril], or angiotensin II blocker (ARB) [e.g., losartan], or a combination medication containing an ACEI or ARB OR
  - B. Patient has an intolerance or hypersensitivity to an ACEI or ARB, or a combination medication containing an ACEI or ARB OR
  - C. Patient has an FDA labeled contraindication to an ACEI or ARB, or a combination medication containing an ACEI or ARB

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of primary immunoglobulin A nephropathy (IgAN) AND
3. The requested agent will be used to reduce proteinuria AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Veozah PA

**Drug Name(s)**

Veozah

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has an FDA labeled indication for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

V-Go PA

**Drug Name(s)**

V-Go

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of diabetes mellitus AND
2. Patient is on an insulin regimen of 3 or more injections per day AND
3. ONE of the following:
  - A. Patient is testing glucose levels 4 or more times per day OR
  - B. Patient is using a continuous glucose monitor (CGM)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of diabetes mellitus AND
3. Patient has had clinical benefit with the requested agent (e.g., stable or improved glycemic control)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Viberzi PA

**Drug Name(s)**

Viberzi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of irritable bowel syndrome with diarrhea (IBS-D)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Vijoice PA

**Drug Name(s)**

Vijoice

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS) confirmed by genetic testing indicating a mutation in the PIK3CA gene AND
2. Patient has severe manifestations of PROS AND
3. Patient requires systemic therapy

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS) AND
3. Patient has severe manifestations of PROS AND
4. Patient requires systemic therapy AND
5. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Vivjoa PA

**Drug Name(s)**

Vivjoa

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of vulvovaginal candidiasis (VVC) AND
2. The requested agent will be used to reduce the incidence of recurrent vulvovaginal candidiasis AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to fluconazole OR
  - B. Patient has an intolerance or hypersensitivity to fluconazole OR
  - C. Patient has an FDA labeled contraindication to fluconazole OR
  - D. Patient will be using fluconazole as part of the fluconazole/Vivjoa dosage regimen

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 4 months

**Other Criteria:**

**Prior Authorization Group Description:**

Voriconazole PA

**Drug Name(s)**

Vfend

Vfend Iv

Voriconazole

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of invasive *Aspergillus* OR
- B. Patient has a serious infection caused by *Scedosporium apiospermum* or *Fusarium* species OR
- C. BOTH of the following:
  - i. ONE of the following:
    - 1. Patient has a diagnosis of esophageal candidiasis OR
    - 2. Patient has a diagnosis of candidemia in nonneutropenic patient OR
    - 3. Patient has a diagnosis of other deep tissue *Candida* infections AND
  - ii. ONE of the following:
    - 1. Patient has tried and had an inadequate response to fluconazole or an alternative antifungal agent OR
    - 2. Patient has an intolerance or hypersensitivity to fluconazole or an alternative antifungal agent OR
    - 3. Patient has an FDA labeled contraindication to fluconazole or an alternative antifungal agent OR
- D. Patient has a diagnosis of blastomycosis AND ONE of the following:
  - i. Patient has tried and had an inadequate response to itraconazole OR
  - ii. Patient has an intolerance or hypersensitivity to itraconazole OR
  - iii. Patient has an FDA labeled contraindication to itraconazole OR
- E. The requested agent is being prescribed for prophylaxis of invasive *Aspergillus* or *Candida* AND patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR
- F. Patient has another indication that is supported in CMS approved compendia for the requested agent

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be 1 month for esophageal candidiasis, 6 months for all other indications

**Other Criteria:**

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. Patient has a diagnosis of invasive Aspergillus, a serious infection caused by *Scedosporium apiospermum* or *Fusarium* species, esophageal candidiasis, candidemia in nonneutropenic patient, other deep tissue *Candida* infections, or blastomycosis and patient has continued indicators of active disease (e.g., biomarkers in serum assay, microbiologic cultures, radiographic evidence) OR

B. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or *Candida* and patient continues to be severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient, or hematologic malignancy with prolonged neutropenia from chemotherapy, or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient, or long term use of high dose corticosteroids (greater than 1 mg/kg/day of prednisone or equivalent) OR

C. BOTH of the following:

i. Patient has another indication that is supported in CMS approved compendia for the requested agent AND

ii. Patient has had clinical benefit with the requested agent



**Prior Authorization Group Description:**

Vosevi PA

**Drug Name(s)**

Vosevi

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of hepatitis C confirmed by serological markers AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication AND
5. If genotype 1, the patient's subtype has been identified and provided

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Vowst PA

**Drug Name(s)**

Vowst

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ALL of the following:

1. The requested agent will be used to prevent the recurrence of Clostridioides difficile infection (CDI) AND
2. Patient has had a confirmed diagnosis of recurrent CDI as defined by greater than or equal to 3 episodes of CDI in a 12 month period AND
3. Patient has completed a standard of care antibiotic regimen (e.g., vancomycin, fidaxomicin) for recurrent CDI at least 2 to 4 days before initiating treatment with the requested agent AND
4. Patient will NOT be using the requested agent in combination with any antibiotic regimen for any indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease, gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Voxzogo PA

**Drug Name(s)**

Voxzogo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of achondroplasia AND
2. The requested agent will be used to increase linear growth AND
3. Patient has open epiphyses

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of achondroplasia AND
3. The requested agent will be used to increase linear growth AND
4. Patient has open epiphyses AND
5. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Voydeya PA

**Drug Name(s)**

Voydeya

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) AND
2. The requested agent will be used for the treatment of extravascular hemolysis (EVH) AND
3. The requested agent will be used in combination with Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) AND
3. The requested agent will be used for the treatment of extravascular hemolysis (EVH) AND
4. The requested agent will be used in combination with Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz) AND
5. Patient has had clinical benefit with the requested agent [e.g., decreased requirement for packed red blood cell transfusions, stabilization/improvement of hemoglobin]

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., hematologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Vtama PA

**Drug Name(s)**

Vtama

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of plaque psoriasis AND BOTH of the following:

i. ONE of the following:

- a. Patient has tried and failed a topical corticosteroid (e.g., triamcinolone) OR
- b. Patient has an intolerance or hypersensitivity to a topical corticosteroid OR
- c. Patient has an FDA labeled contraindication to a topical corticosteroid AND

ii. ONE of the following:

- a. Patient has tried and failed a topical vitamin D analog (e.g., calcipotriene) OR tazarotene OR
- b. Patient has an intolerance or hypersensitivity to a topical vitamin D analog OR tazarotene OR
- c. Patient has an FDA labeled contraindication to a topical vitamin D analog OR tazarotene OR

B. Patient has a diagnosis of atopic dermatitis AND BOTH of the following:

i. ONE of the following:

- a. Patient has tried and failed a topical corticosteroid (e.g., triamcinolone) OR
- b. Patient has an intolerance or hypersensitivity to a topical corticosteroid OR
- c. Patient has an FDA labeled contraindication to a topical corticosteroid AND

ii. ONE of the following:

- a. Patient has tried and failed a topical calcineurin inhibitor (e.g., tacrolimus) OR
- b. Patient has an intolerance or hypersensitivity to a topical calcineurin inhibitor OR
- c. Patient has an FDA labeled contraindication to a topical calcineurin inhibitor

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

- A. Patient has a diagnosis of plaque psoriasis OR
- B. Patient has a diagnosis of atopic dermatitis AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Vykat XR PA

**Drug Name(s)**

Vykat XR

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of Prader-Willi syndrome (PWS) AND
2. Patient's diagnosis has been confirmed by genetic testing confirming mutation on chromosome 15 AND
3. The requested agent will be used for the treatment of hyperphagia

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of Prader-Willi syndrome (PWS) AND
3. The requested agent will be used for the treatment of hyperphagia AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Vyndamax PA

**Drug Name(s)**

Vyndamax

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) AND
2. The diagnosis has been confirmed by testing [e.g., stannous pyrophosphate (PYP) scanning, monoclonal antibody studies, biopsy, scintigraphy, genetic testing (TTR genotyping)] AND
3. The requested agent will be used to reduce cardiovascular mortality and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has clinical manifestations of cardiomyopathy (e.g., dyspnea, fatigue, orthostatic hypotension, syncope, peripheral edema) AND
6. Patient will NOT be using the requested agent in combination with another tafamidis agent, Amvuttra, or Attruby for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) AND
3. The requested agent will be used to reduce cardiovascular mortality and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has had clinical benefit with the requested agent AND
6. Patient will NOT be using the requested agent in combination with another tafamidis agent, Amvuttra, or Attruby for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Vyndaqel PA

**Drug Name(s)**

Vyndaqel

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) AND
2. The diagnosis has been confirmed by testing [e.g., stannous pyrophosphate (PYP) scanning, monoclonal antibody studies, biopsy, scintigraphy, genetic testing (TTR genotyping)] AND
3. The requested agent will be used to reduce cardiovascular mortality and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has clinical manifestations of cardiomyopathy (e.g., dyspnea, fatigue, orthostatic hypotension, syncope, peripheral edema) AND
6. Patient will NOT be using the requested agent in combination with another tafamidis agent, Amvuttra, or Attruby for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) AND
3. The requested agent will be used to reduce cardiovascular mortality and cardiovascular-related hospitalization AND
4. Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure AND
5. Patient has had clinical benefit with the requested agent AND
6. Patient will NOT be using the requested agent in combination with another tafamidis agent, Amvuttra, or Attruby for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Vyvgart Hytrulo PA

**Drug Name(s)**

Vyvgart Hytrulo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has ONE of the following:

A. ALL of the following:

- i. Diagnosis of generalized myasthenia gravis (gMG) AND
- ii. A positive serological test for anti-AChR antibodies AND
- iii. A Myasthenia Gravis Foundation of America (MGFA) clinical classification class of II-IV prior to treatment with the requested agent AND
- iv. A Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score of greater than or equal to 5 prior to treatment with the requested agent OR

B. Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)

Criteria for renewal approval require BOTH of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. ONE of the following:

A. BOTH of the following:

- i. Diagnosis of generalized myasthenia gravis (gMG) AND
- ii. Patient has had clinical benefit with the requested agent [e.g., stabilization/improvement of Myasthenia Gravis-Activities of Daily Living score (MG-ADL) or Quantitative MG score (QMG)] OR

B. BOTH of the following:

- i. Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) AND
- ii. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Wainua PA

**Drug Name(s)**

Wainua

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis AND
2. The diagnosis has been confirmed by biopsy or genetic testing AND
3. Patient has clinical manifestations of polyneuropathy (e.g., neuropathic pain, altered sensation, numbness, tingling, impaired balance, motor disability) AND
4. Patient will NOT be using the requested agent in combination with Amvuttra (vutrisiran), Onpattro (patisiran), or Tegsedi (inotersen) for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with Amvuttra (vutrisiran), Onpattro (patisiran), or Tegsedi (inotersen) for the requested indication AND
5. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., geneticist, neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Wakix PA

**Drug Name(s)**

Wakix

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. BOTH of the following:

i. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy  
AND

ii. ONE of the following:

a. Patient is between the ages of 6 and less than 18 years OR

b. BOTH of the following:

1. Patient is 18 years of age or over AND

2. ONE of the following:

a) Patient has tried and had an inadequate response to  
modafinil or armodafinil OR

b) Patient has an intolerance or hypersensitivity to modafinil or  
armodafinil OR

c) Patient has an FDA labeled contraindication to modafinil or  
armodafinil

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization  
criteria AND

2. ONE of the following:

A. Patient has a diagnosis of narcolepsy with cataplexy OR

B. Patient has a diagnosis of excessive daytime sleepiness associated with narcolepsy AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

For diagnosis of narcolepsy with cataplexy, patient is 18 years of age or over. For diagnosis of excessive  
daytime sleepiness associated with narcolepsy, patient is 6 years of age or over.

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Wayrilz PA

**Drug Name(s)**

Wayrilz

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND
2. ONE of the following:
  - A. Patient has tried and had an insufficient response to a corticosteroid, thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
  - B. Patient has an intolerance or hypersensitivity to a corticosteroid, thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
  - C. Patient has an FDA labeled contraindication to a corticosteroid, thrombopoietin receptor agonist (e.g., eltrombopag), or immunoglobulin (IVIg or anti-D) OR
  - D. Patient has had an insufficient response to a splenectomy AND
3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of persistent or chronic immune (idiopathic) thrombocytopenia (ITP) AND ONE of the following:
  - A. Patient's platelet count is  $50 \times 10^9/L$  or greater OR
  - B. Patient's platelet count has increased sufficiently to avoid clinically significant bleeding AND
3. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Wegovy PA

**Drug Name(s)**

Wegovy

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. ONE of the following:

A. ALL of the following:

- i. The requested agent will be used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) AND
- ii. Patient has documentation (i.e., medical records) of a diagnosis of established cardiovascular disease [e.g., myocardial infarction, stroke, any revascularization procedure, transient ischemic attack, unstable angina, amputation, symptomatic or asymptomatic coronary artery disease] AND
- iii. Patient has documentation (i.e., medical records) that they are either obese or overweight (i.e., BMI 27 kg/m<sup>2</sup> or greater) OR

B. ALL of the following:

- i. Patient has a diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) formerly known as nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis AND
- ii. Patient has stage F2 or F3 fibrosis as confirmed by ONE of the following (prior to therapy with the requested agent)
  - 1. A liver biopsy OR
  - 2. Patient has at least TWO of the following:
    - a. A FIB-4 score consistent with stage F2 or F3 fibrosis adjusted for age
    - b. Vibration-controlled transient elastography (VCTE, e.g., Fibroscan)
    - c. Enhanced liver fibrosis (ELF)
    - d. Magnetic resonance elastography (MRE) AND
- iii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., hepatologist, gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND

2. Patient will NOT be using the requested agent in combination with another glucagon-like peptide-1 (GLP-1) agonist agent, or an agent containing a GLP-1 agonist

**Age Restriction:**

Patient is 18 years of age or over

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. BOTH of the following:
    - i. The requested agent will be used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) AND
    - ii. Patient has documentation (i.e., medical records) of a diagnosis of established cardiovascular disease [e.g., myocardial infarction, stroke, any revascularization procedure, transient ischemic attack, unstable angina, amputation, symptomatic or asymptomatic coronary artery disease] OR
  - B. BOTH of the following:
    - i. Patient has a diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) formerly known as nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., hepatologist, gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND
3. Patient has had clinical benefit with the requested agent AND
4. Patient will NOT be using the requested agent in combination with another glucagon-like peptide-1 (GLP-1) agonist agent, or an agent containing a GLP-1 agonist

**Prior Authorization Group Description:**

Winlevi PA

**Drug Name(s)**

Winlevi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for cosmetic purposes

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of acne vulgaris

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Wyost PA

**Drug Name(s)**

Wyost

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

- i. The requested agent will be used for the prevention of skeletal-related events AND
- ii. ONE of the following:

- 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
- 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

- i. The requested agent will be used for the prevention of skeletal-related events AND
- ii. Patient has bone metastases AND
- iii. ONE of the following:

- 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
- 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
- 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

- C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:
  - i. The requested agent will be used for the prevention of skeletal-related events AND
  - ii. Patient has bone metastases AND

- iii. ONE of the following:
  - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
  - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Xdemvy PA

**Drug Name(s)**

Xdemvy

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require the following:

1. Patient has a diagnosis of Demodex blepharitis AND BOTH of the following:
  - A. Patient has ONE of the following signs of Demodex infestation:
    - i. Collarettes (cylindrical dandruff at the eyelash base) OR
    - ii. Lid margin erythema or edema OR
    - iii. Conjunctival injection OR
    - iv. Eyelash misdirection/irregularity AND
  - B. Patient has ONE of the following symptoms of Demodex infestation:
    - i. Blurred/fluctuating vision OR
    - ii. Discharge or crusting on lashes OR
    - iii. Dryness OR
    - iv. Foreign body sensation OR
    - v. Itching OR
    - vi. Pain/burning OR
    - vii. Watering/tearing

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., infectious disease, ophthalmologist, optometrist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 6 weeks

**Other Criteria:**

**Prior Authorization Group Description:**

Xembify PA

**Drug Name(s)**

Xembify

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR

B. Multiple sclerosis (MS) AND BOTH of the following:

i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND

ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication to TWO MS agents (e.g., Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Plegridy, teriflunomide, Vumerity) OR

2. ONE of the following:

A. Patient has another FDA labeled indication for the requested agent OR

B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Drug is also subject to Part B versus Part D review.

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Xermelo PA

**Drug Name(s)**

Xermelo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of carcinoid syndrome diarrhea AND
2. Patient has tried and had an inadequate response to treatment with a somatostatin analog (e.g., octreotide) AND
3. The requested agent will be used in combination with a somatostatin analog (e.g., octreotide)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of carcinoid syndrome diarrhea AND
3. Patient has had clinical benefit with the requested agent (e.g., reduction in the average number of daily bowel movements) AND
4. The requested agent will be used in combination with a somatostatin analog (e.g., octreotide)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Xgeva PA

**Drug Name(s)**

Xgeva

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

- iii. ONE of the following:
  - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
  - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Xifaxan 200 MG Tablet PA

**Drug Name(s)**

Xifaxan 200Mg

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of traveler's diarrhea (TD) AND
2. Patient's traveler's diarrhea is caused by noninvasive strains of Escherichia coli

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Xifaxan 550 MG Tablet PA

**Drug Name(s)**

Xifaxan 550Mg

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require the following:

1. Patient has ONE of the following:

- a. A diagnosis of irritable bowel syndrome with diarrhea (IBS-D) OR
- b. A diagnosis of hepatic encephalopathy [reduction in risk of overt hepatic encephalopathy (HE) recurrence]

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Xolair PA

**Drug Name(s)**

Xolair

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of moderate to severe persistent asthma AND ALL of the following:

i. ONE of the following:

a. Patient is 6 to less than 12 years of age AND BOTH of the following:

1. Patient's pretreatment IgE level is 30 IU/mL to 1300 IU/mL AND

2. Patient's weight is 20 kg to 150 kg OR

b. Patient is 12 years of age or over AND BOTH of the following:

1. Patient's pretreatment IgE level is 30 IU/mL to 700 IU/mL AND

2. Patient's weight is 30 kg to 150 kg AND

ii. Allergic asthma has been confirmed by a positive skin test or in vitro reactivity test to a perennial aeroallergen AND

iii. ONE of the following:

a. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an asthma control therapy OR

B. Patient has a diagnosis of chronic idiopathic urticaria (CSU) AND BOTH of the following:

i. Patient has had over 6 weeks of hives and itching AND

ii. ONE of the following:

a. Patient has tried and had an inadequate response to maximum tolerable H1 antihistamine therapy OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to H1 antihistamine therapy OR

C. Patient has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND BOTH of the following:

i. ONE of the following:

a. Patient has tried and had an inadequate response to an intranasal corticosteroid OR

b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an intranasal corticosteroid AND

ii. ONE of the following:

a. The requested agent will be used in combination with an intranasal corticosteroid OR

- b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an intranasal corticosteroid OR

Initial criteria continues: see Other Criteria

**Age Restriction:**

For diagnosis of moderate to severe persistent asthma, patient is 6 years of age or over. For diagnosis of chronic idiopathic urticaria (CSU), patient is 12 years of age or over. For diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), patient is 18 years of age or over. For diagnosis of IgE-mediated food allergy, patient is 1 year of age or over.

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, hematologist, immunologist, oncologist, otolaryngologist, pulmonologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be 6 months for initial, 12 months for renewal

**Other Criteria:**

- D. Patient has a diagnosis of IgE-mediated food allergy AND ALL of the following:
  - i. Patient is using the requested agent for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods AND
  - ii. IgE-mediated food allergy has been confirmed by an allergy diagnostic test (e.g., skin prick test, serum specific IgE test, oral food challenge) AND
  - iii. Patient will avoid known food allergens while treated with the requested agent AND
  - iv. The requested agent will NOT be used for the emergency treatment of allergic reactions, including anaphylaxis AND
- 2. Patient will NOT be using the requested agent in combination with Dupixent or an injectable Interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
  - A. Patient has a diagnosis of moderate to severe persistent asthma AND BOTH of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. ONE of the following:
      - a. Patient is currently being treated with AND will continue asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline) in combination with the requested agent OR
      - b. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to an asthma control therapy OR
  - B. Patient has a diagnosis of chronic idiopathic urticaria (CSU) AND the following:
    - a. Patient has had clinical benefit with the requested agent OR

- C. Patient has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND the following:
  - a. Patient has had clinical benefit with the requested agent OR
- D. Patient has a diagnosis of IgE-mediated food allergy AND ALL of the following:
  - a. Patient is using the requested agent for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods AND
  - b. Patient has had clinical benefit with the requested agent AND
  - c. Patient will avoid known food allergens while treated with the requested agent AND
  - d. The requested agent will NOT be used for the emergency treatment of allergic reactions, including anaphylaxis AND
- 3. Patient will NOT be using the requested agent in combination with Dupixent or an injectable interleukin 5 (IL-5) inhibitor (e.g., Cinqair, Fasenra, Nucala) for the requested indication AND
- 4. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Xolremdi PA

**Drug Name(s)**

Xolremdi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome AND
2. BOTH of the following:
  - a. Patient has a genetic analysis confirming mutation in the CXC chemokine receptor 4 (CXCR4) gene AND
  - b. Patient has a confirmed absolute neutrophil count (ANC) OR total white blood cell (WBC) less than or equal to 400 cells/microliter (prior to therapy with the requested agent AND during no clinical evidence of infection) AND
3. The requested agent will be used to increase the number of circulating mature neutrophils and lymphocytes

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome AND
3. The requested agent will be used to increase the number of circulating mature neutrophils and lymphocytes AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, geneticist, hematologist, immunologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Xtrenbo PA

**Drug Name(s)**

Xtrenbo

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. ONE of the following:

A. Patient has a diagnosis of multiple myeloma AND BOTH of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

B. Patient has a diagnosis of prostate cancer AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

iii. ONE of the following:

1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR

2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR

3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

C. Patient has a solid tumor cancer diagnosis (e.g., thyroid, non-small cell lung, kidney cancer, or breast cancer) AND ALL of the following:

i. The requested agent will be used for the prevention of skeletal-related events AND

ii. Patient has bone metastases AND

- iii. ONE of the following:
  - 1. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - 2. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - 3. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- D. Patient has a diagnosis of giant cell tumor of bone AND ONE of the following:
  - i. Patient has a pretreatment or current calcium level that is NOT below the limits of the testing laboratory's normal range OR
  - ii. Patient has a pretreatment or current calcium level that is below the limits of the testing laboratory's normal range AND it will be corrected prior to use of the requested agent OR
  - iii. Prescriber has indicated that the patient is not at risk for hypocalcemia (not including risk associated with the requested agent) OR
- E. Patient has a diagnosis of hypercalcemia of malignancy AND
- 2. Patient will NOT be using the requested agent in combination with another form of denosumab AND
- 3. The requested dose is within FDA labeled dosing for the requested indication

**Prior Authorization Group Description:**

Xywav PA

**Drug Name(s)**

Xywav

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

- A. Patient has a diagnosis of narcolepsy with cataplexy OR
- B. BOTH of the following:
  - i. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness AND
  - ii. ONE of the following:
    - a. Patient is between the ages of 7 and less than 18 years OR
    - b. BOTH of the following:
      - 1. Patient is 18 years of age or over AND
      - 2. ONE of the following:
        - a) Patient has tried and had an inadequate response to modafinil or armodafinil OR
        - b) Patient has an intolerance or hypersensitivity to modafinil or armodafinil OR
        - c) Patient has an FDA labeled contraindication to modafinil or armodafinil OR
- C. Patient has a diagnosis of idiopathic hypersomnia OR
- D. Patient has another indication that is supported in CMS approved compendia for the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. ONE of the following:
  - A. Patient has a diagnosis of narcolepsy with cataplexy OR
  - B. Patient has a diagnosis of narcolepsy with excessive daytime sleepiness OR
  - C. Patient has a diagnosis of idiopathic hypersomnia OR
  - D. Patient has another indication that is supported in CMS approved compendia for the requested agent AND
- 3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

For diagnosis of narcolepsy with cataplexy, patient is 7 years of age or over. For diagnosis of narcolepsy with excessive daytime sleepiness, patient is 7 years of age or over. For diagnosis of idiopathic hypersomnia, patient is 18 years of age or over.



**Prescriber Restrictions:**

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Yimmugo PA

**Drug Name(s)**

Yimmugo

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has ONE of the following diagnoses:

- A. Primary immunodeficiency [e.g., congenital agammaglobulinemia, common variable immunodeficiency (CVID), severe combined immunodeficiency, Wiskott-Aldrich Syndrome, X-linked agammaglobulinemia (XLA), humoral immunodeficiency, IgG subclass deficiency with or without IgA deficiency] OR
- B. B-cell chronic lymphocytic leukemia OR multiple myeloma AND ONE of the following:
  - i. Patient has a history of infections OR
  - ii. Patient has evidence of specific antibody deficiency OR
  - iii. Patient has hypogammaglobulinemia OR
- C. Idiopathic thrombocytopenia purpura AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone), or immunosuppressants (e.g., mycophenolate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- D. Dermatomyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- E. Polymyositis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., corticosteroids (e.g., methylprednisolone) or immunosuppressants (e.g., azathioprine)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR
- F. Severe rheumatoid arthritis AND ONE of the following:
  - i. Patient has failed ONE conventional therapy [e.g., tumor necrosis factor antagonists (e.g., Enbrel), DMARDS (e.g., methotrexate)] OR
  - ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

Criteria continues: see Other Criteria

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 6 months for indications in Other Criteria, 12 months for all others

**Other Criteria:**

G. Myasthenia gravis (MG) AND ONE of the following:

- i. Patient is in acute myasthenic crisis OR
- ii. Patient has severe refractory MG (e.g., major functional disability/weakness) AND ONE of the following:
  - a) Patient has failed ONE immunomodulator therapy (i.e., corticosteroid, pyridostigmine, or azathioprine) OR
  - b) Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE immunomodulator therapy OR

H. Multiple sclerosis (MS) AND BOTH of the following:

- i. Patient has a diagnosis of relapsing remitting MS (RRMS) AND
- ii. Patient has had an insufficient response, documented failure, or FDA labeled contraindication to TWO MS agents (e.g., Avonex, Betaseron, dimethyl fumarate, fingolimod, glatiramer, Glatopa, Kesimpta, Plegridy, teriflunomide, Vumerity) OR

I. Acquired von Willebrand hemophilia AND ONE of the following:

- i. Patient has failed ONE conventional therapy (e.g., desmopressin, von Willebrand factor replacement therapy, corticosteroids, FEIBA, or recombinant factor VIIa) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional therapy OR

J. Refractory pemphigus vulgaris AND ONE of the following:

- i. Patient has failed ONE conventional immunosuppressive therapy (e.g., azathioprine, cyclophosphamide, mycophenolate, corticosteroids) OR
- ii. Patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ONE conventional immunosuppressive therapy OR

2. ONE of the following:

- A. Patient has another FDA labeled indication for the requested agent OR
- B. Patient has an indication that is supported in CMS approved compendia for the requested agent

Indications with 6 months approval duration: Acquired von Willebrand hemophilia, Guillain-Barre Syndrome, Lambert-Eaton myasthenia syndrome, Kawasaki disease, CMV induced pneumonitis in solid organ transplant, Toxic shock syndrome due to invasive group A streptococcus, Toxic epidermal necrolysis and Stevens-Johnson syndrome

Drug is also subject to Part B versus Part D review.

**Prior Authorization Group Description:**

Yorvipath PA

**Drug Name(s)**

Yorvipath

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of hypoparathyroidism AND
2. Patient does NOT have acute post-surgical hypoparathyroidism AND
3. Patient does NOT have a baseline (prior to therapy with the requested agent) vitamin D level below the testing laboratory's lower limit of normal AND
4. Patient has baseline (prior to therapy with the requested agent) albumin-corrected serum calcium of at least 7.8 mg/dL

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of hypoparathyroidism AND
3. Patient does NOT have acute post-surgical hypoparathyroidism AND
4. Patient has had clinical benefit with the requested agent

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, nephrologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Zavzpret PA

**Drug Name(s)**

Zavzpret

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of migraine AND
2. The requested agent is being used for the treatment of acute migraine with or without aura AND
3. ONE of the following:
  - A. Patient has tried and had an inadequate response to a triptan (e.g., sumatriptan, rizatriptan) agent OR
  - B. Patient has an intolerance, or hypersensitivity to a triptan OR
  - C. Patient has an FDA labeled contraindication to a triptan AND
4. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP)

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of migraine AND
3. The requested agent is being used for the treatment of acute migraine with or without aura AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another acute migraine agent (e.g., 5HT-1F, ergotamine, acute CGRP)

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Zelsuvmi PA

**Drug Name(s)**

Zelsuvmi

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require BOTH of the following:

1. Patient has a diagnosis of molluscum contagiosum (MC) AND
2. The requested dose is within FDA labeled dosing for the requested indication

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 weeks

**Other Criteria:**

**Prior Authorization Group Description:**

Zepatier PA

**Drug Name(s)**

Zepatier

**Indications:**

All Medically-Accepted Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for approval require ALL of the following:

1. Patient has a diagnosis of hepatitis C confirmed by serological markers AND
2. Prescriber has screened the patient for current or prior hepatitis B viral (HBV) infection and if positive, will monitor the patient for HBV flare-up or reactivation during and after treatment with the requested agent AND
3. The requested agent will be used in a treatment regimen and length of therapy that is supported in FDA approved labeling or AASLD/IDSA guidelines for the patient's diagnosis and genotype AND
4. The requested dose is within FDA labeled dosing or supported in AASLD/IDSA guideline dosing for the requested indication AND
5. If genotype 1, the patient's subtype has been identified and provided AND
6. If genotype 1a, the prescriber has tested the patient for the presence of virus with NS5A resistance-associated polymorphisms AND
7. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 90 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent within the past 90 days OR
  - C. Patient has an FDA labeled contraindication or hypersensitivity to the preferred agent: Mavyret for supported genotypes OR
  - D. Prescriber has provided information based on FDA approved labeling or AASLD/IDSA guidelines supporting the use of the non-preferred agent for the patient's diagnosis and genotype over the preferred agent: Mavyret for supported genotypes

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist or infectious disease) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Duration of therapy: Based on FDA approved labeling or AASLD/IDSA guideline supported

**Other Criteria:**

**Prior Authorization Group Description:**

Zepbound PA

**Drug Name(s)**

Zepbound

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

Requested agent will be used for weight loss alone AND FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of moderate to severe obstructive sleep apnea (OSA) AND
2. Patient has had a polysomnography (PSG) or home sleep apnea test (HSAT) AND
3. Patient has an apnea hypopnea index (AHI) greater than or equal to 15 events/hour from baseline (prior to initiation of pharmacotherapy) AND
4. Patient has documentation (i.e., medical records) that they are obese (i.e., BMI 30 kg/m<sup>2</sup> or greater) AND
5. Patient does NOT have any of the following:
  - A. A diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas greater than or equal to 50% OR
  - B. A diagnosis of Cheyne Stokes Respiration OR
  - C. A diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia AND
6. Patient will NOT be using the requested agent in combination with another glucagon-like peptide-1 (GLP-1) agonist agent, or an agent containing a GLP-1 agonist

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of moderate to severe obstructive sleep apnea (OSA) AND
3. Patient does NOT have any of the following:
  - A. A diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas greater than or equal to 50% OR
  - B. A diagnosis of Cheyne Stokes Respiration OR
  - C. A diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia AND
4. Patient has had clinical benefit with the requested agent AND
5. Patient will NOT be using the requested agent in combination with another glucagon-like peptide-1 (GLP-1) agonist agent, or an agent containing a GLP-1 agonist

**Age Restriction:**

Patient is 18 years of age or over

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Zilbrysq PA

**Drug Name(s)**

Zilbrysq

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. Patient has ALL of the following:

- A. Diagnosis of generalized myasthenia gravis (gMG) AND
- B. A positive serological test for anti-AChR antibodies AND
- C. A Myasthenia Gravis Foundation of America (MGFA) clinical classification class of II-IV prior to treatment with the requested agent AND
- D. A Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score of greater than or equal to 6 prior to treatment with the requested agent

Criteria for renewal approval require ALL of the following:

- 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
- 2. Patient has a diagnosis of generalized myasthenia gravis (gMG) AND
- 3. Patient has had clinical benefit with the requested agent [e.g., stabilization/improvement of Myasthenia Gravis-Activities of Daily Living score (MG-ADL) or Quantitative MG score (QMG)]

**Age Restriction:****Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Zokinvy PA

**Drug Name(s)**

Zokinvy

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:**

FDA labeled contraindications to the requested agent

**Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following:

A. BOTH of the following:

- i. Patient has a diagnosis of Hutchinson-Gilford progeria syndrome (HGPS) AND
- ii. Genetic testing has confirmed a pathogenic variant in the LMNA gene that results in production of progerin OR

B. Patient has a diagnosis of processing-deficient progeroid laminopathy AND ONE of the following:

- i. Genetic testing has confirmed heterozygous LMNA mutation with progerin-like protein accumulation OR
- ii. Genetic testing has confirmed homozygous or compound heterozygous ZMPSTE24 mutations

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND

2. Patient has a diagnosis of ONE of the following:

- A. Hutchinson-Gilford progeria syndrome (HGPS) OR
- B. Processing-deficient progeroid laminopathies with either: heterozygous LMNA mutation with progerin-like protein accumulation OR homozygous or compound heterozygous ZMPSTE24 mutations AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, geneticist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Zoryve 0.05% Cream PA

**Drug Name(s)**

Zoryve Cream 0.05%

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of mild to moderate atopic dermatitis AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
  - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
  - C. Patient has an FDA labeled contraindication to a topical corticosteroid or topical corticosteroid combination preparation

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of mild to moderate atopic dermatitis AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Zoryve 0.15% Cream PA

**Drug Name(s)**

Zoryve Cream 0.15%

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of mild to moderate atopic dermatitis AND
2. ONE of the following:
  - A. Patient has tried and had an inadequate response to a topical corticosteroid or topical corticosteroid combination preparation (e.g., hydrocortisone, triamcinolone) OR
  - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid or topical corticosteroid combination preparation OR
  - C. Patient has an FDA labeled contraindication to a topical corticosteroid or topical corticosteroid combination preparation

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of mild to moderate atopic dermatitis AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Zoryve 0.3% Cream PA

**Drug Name(s)**

Zoryve Cream 0.3%

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require ALL of the following:

1. Patient has a diagnosis of plaque psoriasis AND
2. ONE of the following:
  - A. Patient has tried and failed a topical corticosteroid (e.g., triamcinolone) OR
  - B. Patient has an intolerance or hypersensitivity to a topical corticosteroid OR
  - C. Patient has an FDA labeled contraindication to a topical corticosteroid AND
3. ONE of the following:
  - A. Patient has tried and failed a topical vitamin D analog (e.g., calcipotriene) OR tazarotene OR
  - B. Patient has an intolerance or hypersensitivity to a topical vitamin D analog OR tazarotene OR
  - C. Patient has an FDA labeled contraindication to a topical vitamin D analog OR tazarotene

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of plaque psoriasis AND
3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Zoryve Foam PA

**Drug Name(s)**

Zoryve Foam

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require the following:

1. ONE of the following
  - A. BOTH of the following:
    - i. Patient has a diagnosis of seborrheic dermatitis AND
    - ii. ONE of the following:
      - a. Patient has tried and failed ONE topical antifungal (e.g., ketoconazole) OR ONE topical corticosteroid (e.g., betamethasone) OR
      - b. Patient has an intolerance or hypersensitivity to a topical antifungal OR a topical corticosteroid OR
      - c. Patient has an FDA labeled contraindication to a topical antifungal OR a topical corticosteroid OR
  - B. BOTH of the following:
    - i. Patient has a diagnosis of plaque psoriasis of the scalp and body AND
    - ii. BOTH of the following:
      - a. ONE of the following:
        - i. Patient has tried and failed a topical corticosteroid (e.g., betamethasone) OR
        - ii. Patient has an intolerance or hypersensitivity to a topical corticosteroid OR
        - iii. Patient has an FDA labeled contraindication to a topical corticosteroid AND
      - b. ONE of the following:
        - i. Patient has tried and failed a topical vitamin D analog (e.g., calcipotriene) OR tazarotene OR
        - ii. Patient has an intolerance or hypersensitivity to a topical vitamin D analog OR tazarotene OR
        - iii. Patient has an FDA labeled contraindication to a topical vitamin D analog OR tazarotene

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. ONE of the following:
  - A. Patient has a diagnosis of seborrheic dermatitis OR
  - B. Patient has a diagnosis of plaque psoriasis of the scalp and body AND

3. Patient has had clinical benefit with the requested agent

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:**

Prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**

**Prior Authorization Group Description:**

Ztalmy PA

**Drug Name(s)**

Ztalmy

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for initial approval require BOTH of the following:

1. Patient has a diagnosis of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) AND
2. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. Patient's diagnosis has been confirmed with genetic testing indicating variant in CDKL5 gene AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

Criteria for renewal approval require ALL of the following:

1. Patient has been previously approved for the requested agent through the plan's Prior Authorization criteria AND
2. Patient has a diagnosis of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) AND
3. ONE of the following:
  - A. There is evidence of a claim that the patient is currently being treated with the requested agent within the past 180 days OR
  - B. Prescriber states the patient is currently being treated with the requested agent OR
  - C. BOTH of the following:
    - i. Patient has had clinical benefit with the requested agent AND
    - ii. Prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**Age Restriction:**

Patient is within the FDA labeled age for the requested agent

**Prescriber Restrictions:****Coverage Duration:**

Approval will be for 12 months

**Other Criteria:**



**Prior Authorization Group Description:**

Zyclara PA

**Drug Name(s)**

Imiquimod Cream 3.75% (Zyclara)

Imiquimod Pump

Zyclara

Zyclara Pump

**Indications:**

All FDA-Approved Indications.

**Off-Label Uses:****Exclusion Criteria:****Required Medical Information:**

Criteria for approval require ONE of the following:

1. Patient has a diagnosis of actinic keratosis OR
2. Patient has a diagnosis of external genital and/or perianal warts/condyloma acuminata AND the requested agent is Zyclara/imiquimod 3.75%

**Age Restriction:****Prescriber Restrictions:****Coverage Duration:**

External genital and/or perianal warts/condyloma acuminata: 8 weeks

Actinic keratosis: 6 weeks

**Other Criteria:**